_unit_id,_created_at,_id,_started_at,_tainted,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,exp_decision,relation,sent_id,orig_sentence,term1,term2
788659430,9/15/2015 10:25:09,1738656148,9/15/2015 10:24:56,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,143,219,,,146,227,ALS,RILUZOLE,ALS riluzole,143-219,219-143,ALS RILUZOLE,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:31:53,1738657615,9/15/2015 10:31:37,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,143,219,,,146,227,ALS,RILUZOLE,ALS,143,219,RILUZOLE,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:33:31,1738658066,9/15/2015 10:33:10,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,143,219,,,146,227,ALS,RILUZOLE,riluzole ALS treatment of ALS,81-143-235-245-248,219-228-231-235-248,RILUZOLE in the treatment ALS,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:37:08,1738658937,9/15/2015 10:37:02,false,neodev,1,33644825,USA,IL,Chicago,65.60.20.67,143,219,,,146,227,ALS,RILUZOLE,in patients with ALS may be of,126-129-138-143-147-151-154,197-208-216-219-228-231-235,biological effects of RILUZOLE in the treatment,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:40:53,1738660028,9/15/2015 10:40:36,false,prodege,1,9169061,CAN,ON,Kitchener,99.235.192.130,143,219,,,146,227,ALS,RILUZOLE,ALS,143,219,RILUZOLE,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:43:47,1738660724,9/15/2015 10:43:35,false,clixsense,1,21490235,GBR,N7,Woking,86.30.254.232,143,219,,,146,227,ALS,RILUZOLE,ALS,143,219,RILUZOLE,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:51:28,1738662562,9/15/2015 10:49:36,false,points4rewards,1,28703583,USA,,,184.53.32.113,143,219,,,146,227,ALS,RILUZOLE,the ability of riluzole to retard ALS,70-78-81-90-93-143-66,126-129-138-143-219,in patients with ALS RILUZOLE,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:54:24,1738663195,9/15/2015 10:54:04,false,neodev,1,33758777,USA,,,38.95.108.251,143,219,,,146,227,ALS,RILUZOLE,ALS,143,219,RILUZOLE,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:56:38,1738663746,9/15/2015 10:56:25,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,143,219,,,146,227,ALS,RILUZOLE,ALS,143,219,RILUZOLE,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659430,9/15/2015 10:59:36,1738664322,9/15/2015 10:58:49,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,143,219,,,146,227,ALS,RILUZOLE,riluzole to retard the rate of neuronal loss in patients with ALS,81-90-93-100-104-109-112-121-126-129-143-138,197-208-216-219-228-231-235-248-252-245,biological effects of RILUZOLE in the treatment of ALS (4).,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4).,143,219,143,219,146,227,-1,RO-may_treat,820078,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of riluzole in the treatment of ALS (4),ALS,riluzole
788659431,9/15/2015 14:20:03,1738732165,9/15/2015 14:19:39,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,167,189,,,173,198,ZOSTER,ACYCLOVIR,herpes ZOSTER,160-167,189,ACYCLOVIR,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 14:48:03,1738740106,9/15/2015 14:47:45,false,coinworker,1,20231698,USA,OR,,172.56.33.130,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella herpes ZOSTER Varicella: acyclovir famciclovir,149-160-167-177-189-200,160-167-177-189-200-213-229,herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 15:01:28,1738743847,9/15/2015 15:01:10,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella herpes ZOSTER Varicella:,149-160-167-177,160-167-177-189-200-213-229,herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 15:28:01,1738754715,9/15/2015 15:27:38,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella herpes ZOSTER Varicella:,149-160-167-177,189-200-213-229,ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 15:31:06,1738755657,9/15/2015 15:30:14,false,clixsense,1,32053717,GBR,,,51.174.76.80,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella zoster virus Herpesviridae droplet contact Varicella herpes ZOSTER Varicella: acyclovir famciclovir,94-104-111-117-139-149-160-167-177-189-200-131,94-104-111-117-131-149-160-167-177-189-200-213-229-139,Varicella zoster virus Herpesviridae droplet contact Varicella herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 15:39:43,1738758335,9/15/2015 15:39:02,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella herpes ZOSTER,149-160-167,177-189-200,Varicella: ACYCLOVIR famciclovir,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 15:43:20,1738759333,9/15/2015 15:43:00,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,167,189,,,173,198,ZOSTER,ACYCLOVIR,ZOSTER,167,189,ACYCLOVIR,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 15:59:17,1738765243,9/15/2015 15:58:49,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella herpes ZOSTER,149-160-167,177-189-200-213,Varicella: ACYCLOVIR famciclovir valacyclovir,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 16:00:12,1738765725,9/15/2015 15:59:43,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella herpes ZOSTER,149-160-167,160-167-177-189-200-213-229,herpes zoster Varicella: ACYCLOVIR famciclovir valacyclovir Zoster:,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659431,9/15/2015 16:01:12,1738766171,9/15/2015 16:00:00,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,167,189,,,173,198,ZOSTER,ACYCLOVIR,Varicella herpes ZOSTER,160-167-149,189,ACYCLOVIR,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection.,167,189,167,189,173,198,-1,RO-may_prevent,820292,droplet contact   German measles  congenital rubella    None MMR vaccine Antibody detection   Varicella-zoster virus Herpesviridae droplet contact   Varicella  herpes zoster    Varicella:  acyclovir  famciclovir  valacyclovir    Zoster:  acyclovir  famciclovir      Varicella vaccine  varicella-zoster immuneglobulin      Cell culture  antigen and nucleic acid detection,zoster,acyclovir
788659432,9/15/2015 11:32:29,1738678106,9/15/2015 11:32:08,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,HEPATITIS B INFECTIONS,79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 11:55:36,1738688317,9/15/2015 11:55:11,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,HEPATITIS B INFECTIONS,79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 12:33:35,1738701023,9/15/2015 12:32:41,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,new definite HEPATITIS B INFECTIONS was 1.0% per year,66-70-79-89-91-102-106-111-115,13-21-33-36-46-49-53,"workers susceptible to HEPATITIS B, the incidence","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 13:42:27,1738722722,9/15/2015 13:41:46,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,incidence of new definite HEPATITIS B INFECTIONS was 1.0%,53-63-66-70-79-89-91-102-106,6-13-21-33-36-46,"health workers susceptible to HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 14:00:39,1738726801,9/15/2015 14:00:18,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,HEPATITIS B INFECTIONS,79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 14:03:41,1738727661,9/15/2015 14:03:18,false,vivatic,1,15201808,GBR,,,87.112.19.240,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,HEPATITIS B INFECTIONS,79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 14:06:50,1738728477,9/15/2015 14:05:54,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,new definite HEPATITIS B INFECTIONS,66-70-79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 14:12:10,1738729753,9/15/2015 14:10:29,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,HEPATITIS B INFECTIONS,79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 14:12:37,1738729879,9/15/2015 14:12:19,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,HEPATITIS B INFECTIONS,79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659432,9/15/2015 14:34:31,1738736150,9/15/2015 14:34:20,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,79,36,,,101,47,HEPATITIS B INFECTIONS,HEPATITIS B,HEPATITIS B INFECTIONS,79-89-91,36-46,"HEPATITIS B,","Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017.",79 89 91,36 46,79,36,101,47,-1,RO-may_prevent,820161,"Among health workers susceptible to hepatitis B, the incidence of new definite hepatitis B infections was 1.0% per year in 362 health workers (804 person-years of follow-up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person-years of observation) with limited blood contact (p = 0.017",hepatitis B infections,hepatitis B
788659433,9/15/2015 10:25:21,1738656193,9/15/2015 10:25:10,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,177,132,,,181,144,WORM,ANTHELMINTIC,anthelmintic WORM,177-132,132-177,ANTHELMINTIC worm,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:32:13,1738657725,9/15/2015 10:31:54,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,177,132,,,181,144,WORM,ANTHELMINTIC,WORM,177,132,ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:33:53,1738658141,9/15/2015 10:33:31,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,177,132,,,181,144,WORM,ANTHELMINTIC,anthelmintic reduce WORM,170-177-132,132-170-177,ANTHELMINTIC reduce worm,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:41:13,1738660109,9/15/2015 10:40:53,false,prodege,1,9169061,CAN,ON,Kitchener,99.235.192.130,177,132,,,181,144,WORM,ANTHELMINTIC,WORM,177,132,ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:44:01,1738660776,9/15/2015 10:43:48,false,clixsense,1,21490235,GBR,N7,Woking,86.30.254.232,177,132,,,181,144,WORM,ANTHELMINTIC,WORM,177,132,ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:52:45,1738662804,9/15/2015 10:51:33,false,points4rewards,1,28703583,USA,,,184.53.32.113,177,132,,,181,144,WORM,ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) WORM,0-2-9-12-23-33-177,72-75-78-88-91-132,to be resistant to ivermectin ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:54:44,1738663264,9/15/2015 10:54:26,false,neodev,1,33758777,USA,,,38.95.108.251,177,132,,,181,144,WORM,ANTHELMINTIC,WORM,177,132,ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:57:52,1738663958,9/15/2015 10:56:41,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,177,132,,,181,144,WORM,ANTHELMINTIC,WORM,177,132,ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 10:59:21,1738664261,9/15/2015 10:58:52,false,neodev,1,11382239,AUS,2,Strathfield,60.241.129.81,177,132,,,181,144,WORM,ANTHELMINTIC,WORM,177,132,ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659433,9/15/2015 11:00:12,1738664488,9/15/2015 10:59:37,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,177,132,,,181,144,WORM,ANTHELMINTIC,ivermectin (IVM) with 0.4 mg kg 1 WORM burdens.,91-102-108-113-117-120-177-182-123,91-102-108-113-117-122-125-128-132,ivermectin (IVM) with 0.4 mg - of the ANTHELMINTIC,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens.,177,132,177,132,181,144,-1,RO-may_prevent,820375,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg-1 of the anthelmintic failing to significantly reduce worm burdens,worm,anthelmintic
788659434,9/15/2015 09:20:46,1738638302,9/15/2015 09:20:33,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,54,86,,,58,93,PAIN,ASPIRIN,"PAIN,",54,86,ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 09:39:16,1738643644,9/15/2015 09:38:17,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,54,86,,,58,93,PAIN,ASPIRIN,"43 (63%) on iloprost treatment had complete relief of PAIN, compared with 18 (28%) on aspirin.",3-9-12-21-31-35-44-51-54-60-69-74-77-83-86-0,0-3-9-12-21-31-35-44-51-54-60-74-77-83-86-69,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on ASPIRIN.","43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 09:40:11,1738643997,9/15/2015 09:39:56,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,54,86,,,58,93,PAIN,ASPIRIN,"relief of PAIN,",44-54-51,86,ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 09:53:39,1738647628,9/15/2015 09:53:19,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,54,86,,,58,93,PAIN,ASPIRIN,"PAIN,",54,86,ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 10:02:19,1738649785,9/15/2015 10:02:04,false,neodev,1,20306047,GBR,,,80.41.0.252,54,86,,,58,93,PAIN,ASPIRIN,"PAIN,",54,86,ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 10:06:33,1738650993,9/15/2015 10:06:21,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,54,86,,,58,93,PAIN,ASPIRIN,"PAIN,",54,86,ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 10:24:26,1738655949,9/15/2015 10:24:13,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,54,86,,,58,93,PAIN,ASPIRIN,"PAIN, aspirin.",54-86,86-54,"pain, ASPIRIN.","43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 10:25:32,1738656225,9/15/2015 10:23:42,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,54,86,,,58,93,PAIN,ASPIRIN,"relief of PAIN,",44-51-54,86,ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 10:31:00,1738657463,9/15/2015 10:30:40,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,54,86,,,58,93,PAIN,ASPIRIN,"PAIN,",54,86,ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659434,9/15/2015 10:32:32,1738657829,9/15/2015 10:32:14,false,neodev,1,33238512,CAN,AB,Calgary,136.159.234.238,54,86,,,58,93,PAIN,ASPIRIN,"complete relief of PAIN, compared with 18",35-44-51-54-60-69-74,74-77-83-86,18 (28%) on ASPIRIN.,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin.",54,86,54,86,58,93,-1,RO-may_prevent,820197,"43 (63%) on iloprost treatment had complete relief of pain, compared with 18 (28%) on aspirin",pain,aspirin
788659435,9/15/2015 10:25:44,1738656285,9/15/2015 10:25:23,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,levodopa PARKINSON'S DISEASE,311-323-277,277-311-323,LEVODOPA Parkinson's disease,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 10:32:36,1738657860,9/15/2015 10:32:13,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,311-323,277-286-294,LEVODOPA induced complications,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 10:34:23,1738658283,9/15/2015 10:33:54,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,levodopa induced complications in PARKINSON'S DISEASE,140-149-157-311-323-171,277-286-294-308-311-323,LEVODOPA induced complications in Parkinson's disease,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 10:44:22,1738660849,9/15/2015 10:44:02,false,clixsense,1,21490235,GBR,N7,Woking,86.30.254.232,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE Pergolide,311-323-332,277,LEVODOPA,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 10:54:09,1738663151,9/15/2015 10:52:50,false,points4rewards,1,28703583,USA,,,184.53.32.113,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE levodopa induced motor complications,311-323-367-376-384-390,277-570-582,LEVODOPA Parkinson's disease,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 10:55:08,1738663351,9/15/2015 10:54:47,false,neodev,1,33758777,USA,,,38.95.108.251,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,311-323,277,LEVODOPA,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 10:59:04,1738664228,9/15/2015 10:57:56,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,311-323,277-286-294,LEVODOPA induced complications,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 10:59:36,1738664338,9/15/2015 10:59:22,false,neodev,1,11382239,AUS,2,Strathfield,60.241.129.81,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,311-323,277-286,LEVODOPA induced,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 11:01:39,1738664798,9/15/2015 11:00:13,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE Pergolide versus bromocriptine for levodopa induced motor complications in Parkinson's disease Pramipexole for levodopa induced complications in Parkinson's disease Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease Ropinirole for levodopa induced complications in Parkinson's disease Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,311-323-332-342-349-363-367-376-384-390-404-407-419-428-440-444-453-461-475-478-490-499-511-518-532-536-545-553-567-570-582-591-602-606-615-623-637-640-652-661-672-679-693-697-706-714-728-731,254-263-273-277-286-294-308-311-323-332-342-349-363-367-376-384-390-407-419-428-444-453-461-478-490-499-511-518-532-536-545-553-567-570-582-591-602-606-623-640-652-661-672-679-693-697-706-714-728-731-615,disease Pergolide for LEVODOPA induced complications in Parkinson's disease Pergolide versus bromocriptine for levodopa induced motor complications Parkinson's disease Pramipexole levodopa induced complications Parkinson's disease Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease Ropinirole for levodopa induced complications Parkinson's disease Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659435,9/15/2015 11:02:25,1738664962,9/15/2015 11:01:59,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,311,277,,,330,285,PARKINSON'S DISEASE,LEVODOPA,induced complications in PARKINSON'S DISEASE Pergolide versus bromocriptine levodopa,286-294-308-311-323-332-342-349-367,254-263-273-277-286-294-308-349,disease Pergolide for LEVODOPA induced complications in bromocriptine,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's.,311 323,277,311,277,330,285,-1,RO-may_treat,820053,complications in Parkinson's disease  Lisuride for levodopa-induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease  Non-pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for levodopa-induced complications in Parkinson's disease  Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease  Pramipexole for levodopa-induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease  Ropinirole for levodopa-induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's,Parkinson's disease,levodopa
788659436,9/15/2015 09:20:32,1738638235,9/15/2015 09:20:16,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,49,25,,,55,33,PLAQUE,FLUORIDE,PLAQUE acid metabolism,49-56-61,25,FLUORIDE,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 09:38:16,1738643196,9/15/2015 09:37:22,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,49,25,,,55,33,PLAQUE,FLUORIDE,The lack of an effect of fluoride and xylitol on PLAQUE acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,0-4-9-12-15-22-25-34-38-46-49-56-61-72-75-86-89-93-105-108-115-122-126-130-134-149-152-159-171-184-180,0-4-9-12-15-22-25-34-38-46-49-56-61-72-75-86-89-93-105-108-115-122-126-130-134-149-152-159-171-180-184,The lack of an effect of FLUORIDE and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 09:39:55,1738643889,9/15/2015 09:39:33,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,49,25,,,55,33,PLAQUE,FLUORIDE,PLAQUE acid metabolism,49-56-61,25,FLUORIDE,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 09:53:18,1738647493,9/15/2015 09:52:51,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,49,25,,,55,33,PLAQUE,FLUORIDE,xylitol on PLAQUE acid metabolism,38-46-49-56-61,25-34-38-46-49-56-61,FLUORIDE and xylitol on plaque acid metabolism,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 10:02:03,1738649723,9/15/2015 10:01:45,false,neodev,1,20306047,GBR,,,80.41.0.252,49,25,,,55,33,PLAQUE,FLUORIDE,PLAQUE,49,25,FLUORIDE,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 10:06:19,1738650933,9/15/2015 10:05:54,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,49,25,,,55,33,PLAQUE,FLUORIDE,xylitol PLAQUE acid metabolism,38-49-56-61,25-38,FLUORIDE xylitol,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 10:23:38,1738655695,9/15/2015 10:22:53,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,49,25,,,55,33,PLAQUE,FLUORIDE,PLAQUE acid metabolism,49-56-61,25,FLUORIDE,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 10:24:12,1738655866,9/15/2015 10:24:00,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,49,25,,,55,33,PLAQUE,FLUORIDE,fluoride PLAQUE,25-49,25-49,FLUORIDE plaque,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 10:30:39,1738657405,9/15/2015 10:30:13,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,49,25,,,55,33,PLAQUE,FLUORIDE,PLAQUE acid metabolism,49-56-61,25,FLUORIDE,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659436,9/15/2015 10:32:33,1738657834,9/15/2015 10:32:04,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,49,25,,,55,33,PLAQUE,FLUORIDE,effect of fluoride PLAQUE,15-22-49-25,4-9-12-25-49-15,lack of an effect FLUORIDE plaque,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,49,25,55,33,-1,RO-may_prevent,820210,The lack of an effect of fluoride and xylitol on plaque acid metabolism is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque,plaque,fluoride
788659437,9/15/2015 14:05:33,1738728100,9/15/2015 14:05:18,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,14-20-29,intra amniotic THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 14:17:53,1738731516,9/15/2015 14:17:39,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,29,THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 14:36:12,1738736583,9/15/2015 14:34:47,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,14-20-29,intra amniotic THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 14:45:47,1738739404,9/15/2015 14:45:25,false,coinworker,1,20231698,USA,OR,,172.56.33.130,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,14-20-29,intra amniotic THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 14:55:56,1738742083,9/15/2015 14:55:39,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,14-20-29,intra amniotic THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 14:58:20,1738742964,9/15/2015 14:58:08,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,14-20-29,intra amniotic THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 15:17:33,1738751018,9/15/2015 15:17:21,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,29,THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 15:24:10,1738753637,9/15/2015 15:23:38,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,14-20-29,intra amniotic THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 15:26:34,1738754354,9/15/2015 15:25:15,false,clixsense,1,32053717,GBR,,,51.174.76.80,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,intra amniotic thyroxine HYPOTHYROIDISM only correct polyhydramnios.,14-20-29-71-90-125-98,9-14-20-29-39-46-50-53-71,that intra amniotic THYROXINE should not be used hypothyroidism,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659437,9/15/2015 15:36:35,1738757362,9/15/2015 15:35:55,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,71,29,,,85,38,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,71,14-20-29,intra amniotic THYROXINE,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.,71,29,71,29,85,38,-1,RO-may_prevent,820149,We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios,hypothyroidism,thyroxine
788659438,9/15/2015 14:20:38,1738732439,9/15/2015 14:20:21,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,THROMBOEMBOLISM.,125,68,HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 14:48:41,1738740284,9/15/2015 14:48:28,false,coinworker,1,20231698,USA,OR,,172.56.33.130,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,THROMBOEMBOLISM.,125,48-60-65-68,intravenous form of HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 15:02:45,1738744352,9/15/2015 15:01:58,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,THROMBOEMBOLISM.,125,68,HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 15:28:38,1738754940,9/15/2015 15:28:30,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,the treatment of THROMBOEMBOLISM.,108-112-122-125,48-60-65-68,intravenous form of HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 15:32:54,1738756106,9/15/2015 15:32:09,false,clixsense,1,32053717,GBR,,,51.174.76.80,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,calcium heparin intravenous form of heparin treatment of THROMBOEMBOLISM.,13-21-48-60-65-68-112-122-125,13-21-48-60-65-68-122-125-112,calcium heparin intravenous form of HEPARIN treatment of thromboembolism.,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 15:40:18,1738758472,9/15/2015 15:40:04,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,THROMBOEMBOLISM.,125,48-60-65-68,intravenous form of HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 15:43:49,1738759418,9/15/2015 15:43:35,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,THROMBOEMBOLISM.,125,68,HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 16:00:37,1738765894,9/15/2015 16:00:26,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,treatment THROMBOEMBOLISM.,112-125,68,HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 16:01:27,1738766226,9/15/2015 16:00:11,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,THROMBOEMBOLISM.,125,68,HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659438,9/15/2015 16:02:28,1738766709,9/15/2015 16:01:55,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,125,68,,,140,75,THROMBOEMBOLISM,HEPARIN,THROMBOEMBOLISM.,125,68,HEPARIN,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism.,125,68,125,68,140,75,-1,RO-may_prevent,820381,Subcutaneous calcium heparin can substitute the intravenous form of heparin (either bolus or continuous) in the treatment of thromboembolism,thromboembolism,heparin
788659439,9/15/2015 09:17:18,1738637791,9/15/2015 09:16:57,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS,34-43,75,RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 09:27:54,1738640011,9/15/2015 09:27:01,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,"For this purpose 30 patients with DUODENAL ULCERS were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",0-4-17-20-29-34-43-50-55-63-70-75-86-92-97-100-109-114-128-134-140-144-150-153-156-163-170-173-181-186-197-200-9,0-4-9-17-20-29-34-43-50-55-63-70-75-86-92-97-100-109-114-128-134-140-144-150-153-156-163-170-173-181-186-197-200,"For this purpose 30 patients with duodenal ulcers were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.","For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 09:36:48,1738642692,9/15/2015 09:36:31,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS,34-43,75,RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 09:47:44,1738645950,9/15/2015 09:47:30,false,neodev,1,20306047,GBR,,,80.41.0.252,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS,34-43,75,RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 09:47:56,1738645984,9/15/2015 09:47:26,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS,34-43,75-86-114-186-197-200,RANITIDINE alone bacampicillin ampicillin in vitro.,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 10:03:15,1738650107,9/15/2015 10:03:03,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS,34-43,75,RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 10:11:12,1738652436,9/15/2015 10:10:01,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS,34-43,75,RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 10:11:39,1738652523,9/15/2015 10:11:27,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS,34-43,75,RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 10:21:33,1738655101,9/15/2015 10:21:08,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS ranitidine,34-43-75,34-43-75,duodenal ulcers RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659439,9/15/2015 10:23:48,1738655730,9/15/2015 10:22:39,false,points4rewards,1,28703583,USA,,,184.53.33.153,34,75,,,49,85,DUODENAL ULCERS,RANITIDINE,DUODENAL ULCERS treated either with ranitidine or together with bacampicillin,34-43-55-63-70-75-97-100-109-114,34-43-50-55-75,duodenal ulcers were treated RANITIDINE,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",34 43,75,34,75,49,85,-1,RO-may_prevent,820148,"For this purpose 30 patients with duodenal ulcers were treated either with ranitidine alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro",duodenal ulcers,ranitidine
788659440,9/15/2015 15:02:58,1738744440,9/15/2015 15:02:39,false,coinworker,1,20231698,USA,OR,,172.56.33.130,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114,CORTISOL,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 15:04:57,1738745310,9/15/2015 15:04:40,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114,CORTISOL,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 15:35:43,1738757092,9/15/2015 15:35:08,false,clixsense,1,32053717,GBR,,,51.174.76.80,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,"ADRENAL INSUFFICIENCY and with unexplained shock,",55-63-77-81-86-98,86-98-105-107-114-123-129-133-175-183,"unexplained shock, a random CORTISOL value &gt;25 is adrenal insufficiency.","For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 15:41:43,1738758807,9/15/2015 15:41:26,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114-123,CORTISOL value,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 15:45:49,1738760056,9/15/2015 15:45:35,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114,CORTISOL,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 16:01:39,1738766355,9/15/2015 16:01:28,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,105-114-133,a CORTISOL is,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 16:04:17,1738767422,9/15/2015 16:04:10,false,instagc,1,33058612,USA,IL,Glenview,162.229.106.229,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114,CORTISOL,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 16:04:49,1738767575,9/15/2015 16:04:09,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114,CORTISOL,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 16:04:57,1738767605,9/15/2015 16:03:47,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114,CORTISOL,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659440,9/15/2015 16:10:53,1738769913,9/15/2015 16:10:41,false,instagc,1,15577915,USA,IL,Trenton,208.70.36.12,55,114,,,76,122,ADRENAL INSUFFICIENCY,CORTISOL,ADRENAL INSUFFICIENCY,55-63,114,CORTISOL,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency.",55 63,114,55,114,76,122,-1,RO-may_treat,820054,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random cortisol value >25 is reasonable evidence for the absence of adrenal insufficiency",adrenal insufficiency,cortisol
788659441,9/15/2015 10:37:04,1738658929,9/15/2015 10:36:37,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA,86,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 10:59:59,1738664398,9/15/2015 10:59:40,false,neodev,1,33758777,USA,,,38.95.108.251,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA,86,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 11:06:57,1738665983,9/15/2015 11:06:40,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,86,118,,,93,129,MALARIA,CHLOROQUINE,lactating women with MALARIA should avoid the use chloroquine because may cause a spontaneous,65-75-81-86-94-101-107-111-118-130-141-145-153-151,107-111-115-118-130-138-141-145-153-177-191-165,the use of CHLOROQUINE because it may cause spontaneous abortion dry milk.,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 11:07:32,1738666097,9/15/2015 11:07:11,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA should avoid the use chloroquine,86-94-107-111-118-101,86-94-107-111-115-118-130-138-141-101,malaria should avoid the use of CHLOROQUINE because it may,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 11:08:38,1738666430,9/15/2015 11:08:11,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA,86,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 11:23:47,1738673359,9/15/2015 11:23:29,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA,86,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 11:24:40,1738673812,9/15/2015 11:23:09,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA,86,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 11:25:37,1738674325,9/15/2015 11:24:53,false,elite,1,31883685,GBR,,,79.66.254.237,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA,86,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 11:46:46,1738684435,9/15/2015 11:46:24,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,86,118,,,93,129,MALARIA,CHLOROQUINE,MALARIA,86,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659441,9/15/2015 12:11:50,1738693418,9/15/2015 12:10:25,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,86,118,,,93,129,MALARIA,CHLOROQUINE,lactating women with MALARIA,65-75-86-81,118,CHLOROQUINE,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk.,86,118,86,118,93,129,-1,RO-may_prevent,820282,Nearly two-thirds of the interviewees believed that pregnant and lactating women with malaria should avoid the use of chloroquine because it may cause a spontaneous abortion or dry up breast milk,malaria,chloroquine
788659442,9/15/2015 11:13:11,1738667800,9/15/2015 11:12:55,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,165,91,,,177,100,HYPERTENSION,PRINDOLOL,HYPERTENSION,165,91,PRINDOLOL;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 11:29:33,1738676637,9/15/2015 11:29:18,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,165,91,,,177,100,HYPERTENSION,PRINDOLOL,HYPERTENSION,165,91,PRINDOLOL;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 11:41:41,1738682001,9/15/2015 11:40:59,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,165,91,,,177,100,HYPERTENSION,PRINDOLOL,HYPERTENSION,165,91,PRINDOLOL;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 11:43:16,1738682550,9/15/2015 11:41:12,false,elite,1,31883685,GBR,,,79.66.254.237,165,91,,,177,100,HYPERTENSION,PRINDOLOL,HYPERTENSION,165,91,PRINDOLOL;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 11:52:14,1738686850,9/15/2015 11:51:53,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,165,91,,,177,100,HYPERTENSION,PRINDOLOL,HYPERTENSION,165,91,PRINDOLOL;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 12:26:09,1738698480,9/15/2015 12:25:00,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,165,91,,,177,100,HYPERTENSION,PRINDOLOL,Hypertension Management of HYPERTENSION,137-151-162-165,68-74-80-91-102-112-123,CV100 (VA) Synonyms: PRINDOLOL; Pindolol; Viskazide; Visken,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 13:18:26,1738713615,9/15/2015 13:17:19,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,165,91,,,177,100,HYPERTENSION,PRINDOLOL,Hypertension Management of HYPERTENSION,137-151-162-165,68-74-80-91-102-112,CV100 (VA) Synonyms: PRINDOLOL; Pindolol; Viskazide;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 13:34:16,1738718350,9/15/2015 13:33:09,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,165,91,,,177,100,HYPERTENSION,PRINDOLOL,Visken Management of HYPERTENSION,123-151-162-165,91-102-112-123-131-137-151,PRINDOLOL; Pindolol; Viskazide; Visken Uses Hypertension Management,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 13:58:19,1738726284,9/15/2015 13:57:50,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,165,91,,,177,100,HYPERTENSION,PRINDOLOL,HYPERTENSION,165,91,PRINDOLOL;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659442,9/15/2015 13:58:32,1738726364,9/15/2015 13:57:33,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,165,91,,,177,100,HYPERTENSION,PRINDOLOL,HYPERTENSION,165,29-34-45-54-91,beta Adrenergic Blocking Agents PRINDOLOL;,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents.",165,91,165,91,177,100,-1,RO-may_treat,820020,"1 ,   2 ,   3 ,   4  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  Prindolol; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of hypertension (alone or in combination with other classes of antihypertensive agents",hypertension,Prindolol
788659443,9/15/2015 09:11:52,1738636772,9/15/2015 09:11:36,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,for ANGINA PECTORIS.,106-110-117,76-81,oral METOPROLOL,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:12:12,1738636823,9/15/2015 09:11:53,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,Pharmacokinetic interaction between oral metoprolol and verapamil for ANGINA PECTORIS.,40-56-68-76-92-96-106-110-117-81,40-56-68-76-81-92-96-106-117-110,Pharmacokinetic interaction between oral METOPROLOL and verapamil for angina pectoris.,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:13:26,1738637149,9/15/2015 09:13:09,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,Pharmacokinetic interaction between oral metoprolol and verapamil for ANGINA PECTORIS.,40-56-68-76-92-96-106-110-117-81,40-56-68-76-81-92-96-106-110-117,Pharmacokinetic interaction between oral METOPROLOL and verapamil for angina pectoris.,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:15:19,1738637509,9/15/2015 09:14:54,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,and verapamil for ANGINA PECTORIS.,92-96-106-110-117,76-81,oral METOPROLOL,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:20:44,1738638294,9/15/2015 09:20:29,false,neodev,1,20306047,GBR,,,80.41.0.252,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,ANGINA PECTORIS.,110-117,81,METOPROLOL,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:32:15,1738641129,9/15/2015 09:32:04,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,ANGINA PECTORIS.,110-117,76-81,oral METOPROLOL,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:38:43,1738643475,9/15/2015 09:36:17,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,ANGINA PECTORIS.,110-117,81-96-110-117,METOPROLOL verapamil angina pectoris.,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:49:53,1738646503,9/15/2015 09:49:39,false,neodev,1,33758777,USA,,,38.95.108.251,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,ANGINA PECTORIS.,110-117,81,METOPROLOL,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:54:20,1738647783,9/15/2015 09:51:54,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,ANGINA PECTORIS.,110-117,76-81,oral METOPROLOL,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659443,9/15/2015 09:58:28,1738648800,9/15/2015 09:57:56,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,110,81,,,125,91,ANGINA PECTORIS,METOPROLOL,ANGINA PECTORIS.,110-117,81-110-117,METOPROLOL angina pectoris.,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.",110 117,81,110,81,125,91,-1,RO-may_treat,820001,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris",angina pectoris,metoprolol
788659444,9/15/2015 09:19:10,1738638037,9/15/2015 09:18:57,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA.,138,92-100,INSULIN release,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 09:33:06,1738641361,9/15/2015 09:32:30,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,"Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in HYPERGLYCEMIA.",5-15-30-33-37-44-52-60-67-70-79-83-92-100-108-115-125-135-138-111,5-15-30-33-37-44-52-60-67-70-79-83-92-100-108-111-115-125-135-138,"Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in hyperglycemia.","a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 09:38:30,1738643361,9/15/2015 09:38:14,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA.,138,83-92-100,inhibits INSULIN release,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 09:51:23,1738646996,9/15/2015 09:50:57,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA.,138,92-108,INSULIN in,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 09:59:47,1738649118,9/15/2015 09:58:45,false,neodev,1,20306047,GBR,,,80.41.0.252,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA.,138,92,INSULIN,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 10:04:51,1738650536,9/15/2015 10:04:42,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,"pancreas, HYPERGLYCEMIA.",115-138,92,INSULIN,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 10:13:33,1738653030,9/15/2015 10:13:25,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA.,138,92,INSULIN,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 10:19:11,1738654506,9/15/2015 10:17:14,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA.,138,92,INSULIN,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 10:23:13,1738655576,9/15/2015 10:22:59,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,insulin HYPERGLYCEMIA.,138-92,92-138,INSULIN hyperglycemia.,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659444,9/15/2015 10:28:21,1738656807,9/15/2015 10:27:50,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,138,92,,,151,99,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA.,138,92-100,INSULIN release,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.",138,92,138,92,151,99,-1,RO-may_treat,820005,"a   Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia",hyperglycemia,insulin
788659445,9/15/2015 11:09:10,1738666600,9/15/2015 11:08:59,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,74,107,,,87,115,DENTAL CARIES,FLUORIDE,the relationship between DENTAL CARIES and drinking water fluoride concentration accepted,49-53-66-74-81-88-92-101-107-158-116,88-92-101-107-116-130-140-149,and drinking water FLUORIDE concentration suggested that commonly,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 11:11:48,1738667228,9/15/2015 11:11:28,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,74,107,,,87,115,DENTAL CARIES,FLUORIDE,DENTAL CARIES,74-81,92-101-107-116,drinking water FLUORIDE concentration,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 11:27:47,1738675594,9/15/2015 11:27:27,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,74,107,,,87,115,DENTAL CARIES,FLUORIDE,DENTAL CARIES,74-81,107-116,FLUORIDE concentration,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 11:35:44,1738679335,9/15/2015 11:35:01,false,elite,1,31883685,GBR,,,79.66.254.237,74,107,,,87,115,DENTAL CARIES,FLUORIDE,DENTAL CARIES,74-81,107,FLUORIDE,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 11:36:54,1738679878,9/15/2015 11:35:15,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,74,107,,,87,115,DENTAL CARIES,FLUORIDE,DENTAL CARIES,74-81,107-116,FLUORIDE concentration,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 11:50:17,1738685970,9/15/2015 11:49:55,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,74,107,,,87,115,DENTAL CARIES,FLUORIDE,DENTAL CARIES,74-81,107,FLUORIDE,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 12:21:04,1738696896,9/15/2015 12:20:17,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,74,107,,,87,115,DENTAL CARIES,FLUORIDE,the relationship between DENTAL CARIES,49-53-66-74-81,88-92-101-107-116,and drinking water FLUORIDE concentration,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 13:15:01,1738712516,9/15/2015 13:14:31,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,74,107,,,87,115,DENTAL CARIES,FLUORIDE,DENTAL CARIES,74-81,107-116,FLUORIDE concentration,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 13:31:09,1738717545,9/15/2015 13:30:25,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,74,107,,,87,115,DENTAL CARIES,FLUORIDE,relationship between DENTAL CARIES and drinking water,53-66-74-81-88-92-101,107-116-167-175,FLUORIDE concentration inverse relationship,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659445,9/15/2015 13:53:39,1738725197,9/15/2015 13:52:29,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,74,107,,,87,115,DENTAL CARIES,FLUORIDE,DENTAL CARIES,74-81,107,FLUORIDE,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist.,74 81,107,74,107,87,115,-1,RO-may_prevent,820162,A recent analysis of data from earlier papers on the relationship between dental caries and drinking water fluoride concentration suggested that the commonly accepted inverse relationship did not exist,dental caries,fluoride
788659446,9/15/2015 11:14:08,1738668187,9/15/2015 11:13:55,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,128,93,,,131,100,CHF,DIGOXIN,CHF.,128,93,DIGOXIN,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 11:30:31,1738677074,9/15/2015 11:30:09,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,128,93,,,131,100,CHF,DIGOXIN,CHF.,128,93,DIGOXIN,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 11:44:15,1738683114,9/15/2015 11:44:01,false,elite,1,31883685,GBR,,,79.66.254.237,128,93,,,131,100,CHF,DIGOXIN,CHF.,128,93,DIGOXIN,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 11:53:21,1738687340,9/15/2015 11:53:04,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,128,93,,,131,100,CHF,DIGOXIN,CHF.,128,93,DIGOXIN,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 12:29:07,1738699407,9/15/2015 12:27:45,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,128,93,,,131,100,CHF,DIGOXIN,used concomitantly for CHF.,105-110-124-128,74-79-89-93-101-105-110,when captopril and DIGOXIN are used concomitantly,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 13:36:35,1738719877,9/15/2015 13:35:28,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,128,93,,,131,100,CHF,DIGOXIN,captopril and digoxin used for CHF.,79-89-93-105-124-128,6-16-22-30-45-49-79-89-93-101-105-110-124-128-74,Captopril Serum digoxin concentrations may increase when captopril and DIGOXIN are used concomitantly for CHF.,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 13:59:09,1738726463,9/15/2015 13:58:56,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,128,93,,,131,100,CHF,DIGOXIN,CHF.,128,93,DIGOXIN,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 14:00:58,1738726876,9/15/2015 14:00:09,false,vivatic,1,15201808,GBR,,,87.112.19.240,128,93,,,131,100,CHF,DIGOXIN,CHF.,128,79-89-93,captopril and DIGOXIN,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 14:01:51,1738727108,9/15/2015 14:00:41,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,128,93,,,131,100,CHF,DIGOXIN,CHF.,128,93-105-124-128,DIGOXIN used for CHF.,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659446,9/15/2015 14:02:51,1738727458,9/15/2015 14:01:40,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,128,93,,,131,100,CHF,DIGOXIN,captopril and digoxin are used concomitantly for CHF.,79-89-93-101-110-124-128-105,79-89-93-101-105-110,captopril and DIGOXIN are used concomitantly,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF.,128,93,128,93,131,100,-1,RO-may_prevent,820385,a ]   Captopril Serum digoxin concentrations may increase by about 15-30% when captopril and digoxin are used concomitantly for CHF,CHF,digoxin
788659447,9/15/2015 15:03:44,1738744790,9/15/2015 15:03:22,false,coinworker,1,20231698,USA,OR,,172.56.33.130,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409,ANAKINRA,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 15:06:10,1738745879,9/15/2015 15:05:49,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409,ANAKINRA,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 15:37:08,1738757464,9/15/2015 15:36:38,false,clixsense,1,32053717,GBR,,,51.174.76.80,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,TNF blocking agent) in RHEUMATOID ARTHRITIS 1 10.,446-455-462-465-476-488-492-442,377-386-395-404-409-418-422,"clinical benefit, reported with ANAKINRA and etanercept","1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 15:42:22,1738759052,9/15/2015 15:42:01,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409-418-422,ANAKINRA and etanercept,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 15:46:22,1738760225,9/15/2015 15:46:08,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409,ANAKINRA,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 16:02:02,1738766505,9/15/2015 16:01:51,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409,ANAKINRA,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 16:06:50,1738768343,9/15/2015 16:05:53,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409,ANAKINRA,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 16:07:06,1738768501,9/15/2015 16:05:59,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409,ANAKINRA,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 16:11:28,1738770103,9/15/2015 16:11:15,false,instagc,1,15577915,USA,IL,Trenton,208.70.36.12,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,RHEUMATOID ARTHRITIS,465-476,409,ANAKINRA,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659447,9/15/2015 16:26:25,1738775694,9/15/2015 16:25:46,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,465,409,,,485,417,RHEUMATOID ARTHRITIS,ANAKINRA,anakinra and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS,409-418-422-433-442-446-455-462-465-476,358-386-395-404-409-418-422-377,"without clinical benefit, reported with ANAKINRA and etanercept","1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10.",465 476,409,465,409,485,417,-1,RO-may_treat,820009,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis [ 1 , 10",rheumatoid arthritis,anakinra
788659448,9/15/2015 10:27:23,1738656585,9/15/2015 10:27:02,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,149,195,,,152,202,CHF,DIGOXIN,CHF refractory,149-161,149,CHF,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 10:34:22,1738658284,9/15/2015 10:34:06,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,149,195,,,152,202,CHF,DIGOXIN,CHF,149,194,(DIGOXIN),"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 10:57:09,1738663834,9/15/2015 10:56:44,false,neodev,1,33758777,USA,,,38.95.108.251,149,195,,,152,202,CHF,DIGOXIN,CHF,149,194,(DIGOXIN),"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 11:00:10,1738664484,9/15/2015 10:59:00,false,points4rewards,1,28703583,USA,,,184.53.32.113,149,195,,,152,202,CHF,DIGOXIN,CHF May improve cardiac output CHF,35-40-44-52-60-149,117-123-128-139-142-194-149,short term management of severe CHF (DIGOXIN),"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 11:04:27,1738665407,9/15/2015 11:04:11,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,149,195,,,152,202,CHF,DIGOXIN,cardiac and short management of severe CHF that is refractory,85-117-128-139-142-149-153-158-161-52,142-149-153-175-183-194-204-208-161,severe CHF that refractory cardiac glycosides (DIGOXIN) and diuretics.,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 11:04:50,1738665507,9/15/2015 11:04:34,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,149,195,,,152,202,CHF,DIGOXIN,severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.,142-149-153-158-161-172-175-183-194-204-208,161-175-183-194-204-208-172,refractory to cardiac glycosides (DIGOXIN) and diuretics.,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 11:05:23,1738665669,9/15/2015 11:04:31,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,149,195,,,152,202,CHF,DIGOXIN,severe CHF,142-149,175-183-194,cardiac glycosides (DIGOXIN),"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 11:05:36,1738665693,9/15/2015 11:05:14,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,149,195,,,152,202,CHF,DIGOXIN,CHF,149,194,(DIGOXIN),"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 11:20:35,1738671321,9/15/2015 11:19:47,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,149,195,,,152,202,CHF,DIGOXIN,CHF,149,194,(DIGOXIN),"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659448,9/15/2015 11:20:49,1738671527,9/15/2015 11:20:12,false,elite,1,31883685,GBR,,,79.66.254.237,149,195,,,152,202,CHF,DIGOXIN,CHF,149,175-183-194,cardiac glycosides (DIGOXIN),"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics.",149,,149,195,152,202,-1,RO-may_prevent,820248,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short-term management of severe CHF that is refractory to cardiac glycosides (digoxin) and diuretics",CHF,digoxin
788659449,9/15/2015 10:37:55,1738659162,9/15/2015 10:37:37,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,9,65,,,13,74,PAIN,LIDOCAINE,PAIN scores,9-14,65,"LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 11:01:01,1738664649,9/15/2015 11:00:44,false,neodev,1,33758777,USA,,,38.95.108.251,9,65,,,13,74,PAIN,LIDOCAINE,PAIN,9,65,"LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 11:07:48,1738666185,9/15/2015 11:07:29,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,9,65,,,13,74,PAIN,LIDOCAINE,The mean PAIN scores for the four solutions were: 44.2,0-4-9-14-21-25-29-34-44-50,50-55-59-65-76-81-85-92-103-112-121-132-136-145-141,"44.2 for plain LIDOCAINE, 42.2 for warmed lidocaine, 36.7 buffered lidocaine, and 29.2 for warmed,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 11:09:43,1738666703,9/15/2015 11:09:24,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,9,65,,,13,74,PAIN,LIDOCAINE,mean PAIN scores,4-9-14,59-65,"plain LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 11:24:45,1738673897,9/15/2015 11:24:23,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,9,65,,,13,74,PAIN,LIDOCAINE,PAIN,9,65,"LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 11:27:26,1738675320,9/15/2015 11:26:39,false,elite,1,31883685,GBR,,,79.66.254.237,9,65,,,13,74,PAIN,LIDOCAINE,PAIN scores,9-14,65,"LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 11:28:26,1738676062,9/15/2015 11:27:47,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,9,65,,,13,74,PAIN,LIDOCAINE,mean PAIN scores,4-9-14,59-65,"plain LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 11:47:49,1738684871,9/15/2015 11:47:28,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,9,65,,,13,74,PAIN,LIDOCAINE,PAIN,9,65,"LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 12:12:29,1738693628,9/15/2015 12:11:51,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,9,65,,,13,74,PAIN,LIDOCAINE,The mean PAIN scores,0-4-9-14,59-65,"plain LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659449,9/15/2015 12:13:59,1738694199,9/15/2015 12:12:31,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,9,65,,,13,74,PAIN,LIDOCAINE,The mean PAIN scores for the four solutions,0-4-9-14-21-25-29-34,50-55-59-65,"44.2 for plain LIDOCAINE,","The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",9,65,9,65,13,74,-1,RO-may_prevent,820326,"The mean pain scores for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed lidocaine, 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine",pain,lidocaine
788659450,9/15/2015 14:06:15,1738728328,9/15/2015 14:05:52,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA method LH,0-12-23-31,31-37-49-58-65-85,LH luteinizing hormone MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 14:18:28,1738731684,9/15/2015 14:18:11,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,12,58,,,22,61,AMENORRHEA,MPA,AMENORRHEA,12,58-65-85,MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 14:39:57,1738737526,9/15/2015 14:37:53,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA method LH,0-12-23-31,37-49-58-65-85,luteinizing hormone MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 14:46:28,1738739555,9/15/2015 14:46:11,false,coinworker,1,20231698,USA,OR,,172.56.33.130,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA method LH,0-12-23-31,31-37-49-58-65-85,LH luteinizing hormone MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 14:56:31,1738742322,9/15/2015 14:56:11,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA method LH,0-12-23-31,37-49-58-65-85,luteinizing hormone MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 14:59:02,1738743168,9/15/2015 14:58:40,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA,0-12,37-49-58-65-85-31,LH luteinizing hormone MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 15:18:08,1738751286,9/15/2015 15:17:50,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,12,58,,,22,61,AMENORRHEA,MPA,AMENORRHEA,12,58-65-85,MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 15:24:58,1738753888,9/15/2015 15:24:34,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA method,0-12-23,37-49-58,luteinizing hormone MPA,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 15:27:44,1738754685,9/15/2015 15:27:18,false,clixsense,1,32053717,GBR,,,51.174.76.80,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA method LH luteinizing hormone MPA,0-12-23-31-37-49-58,31-37-49-58-65-85-94,LH luteinizing hormone MPA medroxyprogesterone acetate OR,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659450,9/15/2015 15:37:59,1738757804,9/15/2015 15:37:22,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,12,58,,,22,61,AMENORRHEA,MPA,lactational AMENORRHEA method LH luteinizing hormone,0-12-23-31-37-49,58-65-85,MPA medroxyprogesterone acetate,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism.",12,58,12,58,22,61,-1,RO-may_treat,820060,"lactational amenorrhea method  LH  - luteinizing hormone  MPA  - medroxyprogesterone acetate  OR  - odds ratio  PE  - pulmonary embolism  PID  - pelvic inflammatory disease  POC  - progestin-only contraceptive pill  RR  - risk ratio  STD  - sexually transmitted disease  STI  - sexually transmitted infection  TOP  - termination of pregnancy, medical abortion  TSS  - toxic shock syndrome  UTI  - urinary tract infection  VTE  - venous thromboembolism",amenorrhea,MPA
788659451,9/15/2015 11:12:54,1738667686,9/15/2015 11:12:36,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,83,119,,,90,130,MALARIA,CHLOROQUINE,MALARIA,83,119,"CHLOROQUINE,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 11:29:18,1738676443,9/15/2015 11:28:29,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,83,119,,,90,130,MALARIA,CHLOROQUINE,MALARIA,83,119,"CHLOROQUINE,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 11:40:56,1738681539,9/15/2015 11:40:06,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,83,119,,,90,130,MALARIA,CHLOROQUINE,severe MALARIA,76-83,119,"CHLOROQUINE,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 11:41:02,1738681599,9/15/2015 11:40:45,false,elite,1,31883685,GBR,,,79.66.254.237,83,119,,,90,130,MALARIA,CHLOROQUINE,MALARIA,83,119,"CHLOROQUINE,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 11:51:52,1738686674,9/15/2015 11:51:18,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,83,119,,,90,130,MALARIA,CHLOROQUINE,MALARIA,83,119,"CHLOROQUINE,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 12:24:58,1738698110,9/15/2015 12:23:55,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,83,119,,,90,130,MALARIA,CHLOROQUINE,children with severe MALARIA,62-71-76-83,83-91-108-119-132-141-154,"malaria (phenobarbitone, phenytoin, CHLOROQUINE, quinine, sulfadoxine, pyrimethamine,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 13:17:18,1738713230,9/15/2015 13:16:08,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,83,119,,,90,130,MALARIA,CHLOROQUINE,severe MALARIA,76-83,91-108-119-132-141-154-169-183-196-214-232-228,"(phenobarbitone, phenytoin, CHLOROQUINE, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 13:33:09,1738718056,9/15/2015 13:32:26,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,83,119,,,90,130,MALARIA,CHLOROQUINE,drugs commonly administered to children with severe MALARIA,31-37-46-59-62-71-76-83,91-108-119-132-141-154-169-183-196-214-228-232,"(phenobarbitone, phenytoin, CHLOROQUINE, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 13:57:32,1738726157,9/15/2015 13:56:25,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,83,119,,,90,130,MALARIA,CHLOROQUINE,MALARIA,83,31-37-46-59-62-71-76-83-119,"drugs commonly administered to children with severe malaria CHLOROQUINE,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659451,9/15/2015 13:57:50,1738726210,9/15/2015 13:57:28,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,83,119,,,90,130,MALARIA,CHLOROQUINE,MALARIA,83,119,"CHLOROQUINE,","There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",83,119,83,119,90,130,-1,RO-may_prevent,820183,"There was no interference from drugs commonly administered to children with severe malaria (phenobarbitone, phenytoin, chloroquine, quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate",malaria,chloroquine
788659452,9/15/2015 10:37:16,1738659002,9/15/2015 10:37:05,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM,76,0,LEVOTHYROXINE,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:00:15,1738664491,9/15/2015 11:00:01,false,neodev,1,33758777,USA,,,38.95.108.251,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM,76,0,LEVOTHYROXINE,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:07:13,1738666034,9/15/2015 11:06:58,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,the treatment of HYPOTHYROIDISM and for the suppression of,59-63-73-76-91-95-99-103-115,0-14-17-21-34-41-44-55-59-63-73-76,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of hypothyroidism,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:08:00,1738666265,9/15/2015 11:07:34,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules,59-63-73-76-91-95-99-103-115-118-125-129-137,0-55-63-76-91-103-118-129-137,LEVOTHYROXINE for treatment hypothyroidism and suppression goitre thyroid nodules,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:08:55,1738666509,9/15/2015 11:08:40,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM,76,0,LEVOTHYROXINE,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:24:01,1738673512,9/15/2015 11:23:48,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM,76,0,LEVOTHYROXINE,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:26:13,1738674658,9/15/2015 11:25:38,false,elite,1,31883685,GBR,,,79.66.254.237,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM,76,0,LEVOTHYROXINE,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:26:52,1738675073,9/15/2015 11:24:43,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM,76,0,LEVOTHYROXINE,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 11:47:05,1738684558,9/15/2015 11:46:47,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM,76,0,LEVOTHYROXINE,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659452,9/15/2015 12:11:37,1738693289,9/15/2015 12:11:21,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,76,0,,,90,13,HYPOTHYROIDISM,LEVOTHYROXINE,the treatment of HYPOTHYROIDISM,59-63-73-76,0-14-17-21-34,LEVOTHYROXINE is the overwhelming choice,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases.,76,0,76,0,90,13,-1,RO-may_prevent,820147,Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism and for the suppression of goitre and thyroid nodules in selected cases,hypothyroidism,Levothyroxine
788659453,9/15/2015 10:27:34,1738656612,9/15/2015 10:27:25,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,70,42,,,76,53,EMESIS,ONDANSETRON,Ondansetron EMESIS,42-70,42-70,ONDANSETRON Emesis,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 10:34:40,1738658371,9/15/2015 10:34:24,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,70,42,,,76,53,EMESIS,ONDANSETRON,EMESIS,70,42,ONDANSETRON,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 10:57:28,1738663869,9/15/2015 10:57:11,false,neodev,1,33758777,USA,,,38.95.108.251,70,42,,,76,53,EMESIS,ONDANSETRON,EMESIS,70,42,ONDANSETRON,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 11:04:41,1738665457,9/15/2015 11:04:28,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,70,42,,,76,53,EMESIS,ONDANSETRON,Ondansetron and Granisetron EMESIS Study Group.,42-54-58-70-77-83,31-34-38-42-54-58-70-77-83,al for the ONDANSETRON and Granisetron Emesis Study Group.,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 11:05:05,1738665606,9/15/2015 11:04:51,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,70,42,,,76,53,EMESIS,ONDANSETRON,Ondansetron and Granisetron EMESIS,42-54-58-70,42-54-58-70,ONDANSETRON and Granisetron Emesis,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 11:05:58,1738665772,9/15/2015 11:05:37,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,70,42,,,76,53,EMESIS,ONDANSETRON,Granisetron EMESIS,58-70,42,ONDANSETRON,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 11:06:24,1738665865,9/15/2015 11:05:26,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,70,42,,,76,53,EMESIS,ONDANSETRON,Granisetron EMESIS Study Group.,58-70-77-83,42,ONDANSETRON,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 11:21:02,1738671588,9/15/2015 11:20:36,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,70,42,,,76,53,EMESIS,ONDANSETRON,EMESIS,70,42,ONDANSETRON,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 11:21:12,1738671762,9/15/2015 11:20:50,false,elite,1,31883685,GBR,,,79.66.254.237,70,42,,,76,53,EMESIS,ONDANSETRON,EMESIS,70,42,ONDANSETRON,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659453,9/15/2015 11:43:02,1738682469,9/15/2015 11:42:22,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,70,42,,,76,53,EMESIS,ONDANSETRON,EMESIS,70,42,ONDANSETRON,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group.",70,42,70,42,76,53,-1,RO-may_prevent,820319,"Ruff P, Paska W, Goedhals L et al for the Ondansetron and Granisetron Emesis Study Group",Emesis,Ondansetron
788659454,9/15/2015 09:16:56,1738637756,9/15/2015 09:16:42,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA,0,31-42,(NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 09:27:00,1738639771,9/15/2015 09:26:19,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,"PELLAGRA Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0-10-21-24-31-42-48-54-57-60-76-79-84-87-97-106-117-125-129-132-145-152-162-170-174,0-10-21-24-31-42-48-54-57-60-76-79-84-87-97-106-117-125-129-132-145-152-162-170-174,"Pellagra Deficiency of niacin (NICOTINIC ACID) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.","Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 09:36:28,1738642618,9/15/2015 09:36:15,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA,0,24-31-42,niacin (NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 09:47:25,1738645842,9/15/2015 09:47:04,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA Deficiency of niacin,0-10-21-24,0-10-21-24-31-42,Pellagra Deficiency of niacin (NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 09:47:30,1738645848,9/15/2015 09:47:00,false,neodev,1,20306047,GBR,,,80.41.0.252,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA,0,42-31,(NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 10:03:02,1738650042,9/15/2015 10:02:40,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA Deficiency of niacin (nicotinic acid),0-10-21-24-31-42,0-10-24-31-42-21,Pellagra Deficiency of niacin (NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 10:09:59,1738651987,9/15/2015 10:08:53,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA,0,24-31-42,niacin (NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 10:11:26,1738652505,9/15/2015 10:10:48,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA,0,31-42,(NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 10:21:07,1738654977,9/15/2015 10:20:44,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA Deficiency of niacin,0-10-24-21,31-42,(NICOTINIC ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659454,9/15/2015 10:22:34,1738655395,9/15/2015 10:21:41,false,points4rewards,1,28703583,USA,,,184.53.33.153,0,32,,,8,46,PELLAGRA,NICOTINIC ACID,PELLAGRA Deficiency of niacin,0-10-21-24,0-10-24-42-21,Pellagra Deficiency of niacin ACID),"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea.",0,42,0,32,8,46,-1,RO-may_treat,820006,"Pellagra  Deficiency of niacin (nicotinic acid) leads to an encephalopathy, as well as cutaneous lesions, glossitis, anemia, and GI disturbances (e.g., anorexia, nausea, and diarrhea",Pellagra,nicotinic acid
788659455,9/15/2015 11:13:54,1738668108,9/15/2015 11:13:32,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,294,PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 11:30:08,1738676814,9/15/2015 11:29:52,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,294,PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 11:44:00,1738683005,9/15/2015 11:43:34,false,elite,1,31883685,GBR,,,79.66.254.237,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,281-294,chemotherapy PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 11:53:03,1738687231,9/15/2015 11:52:42,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,294,PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 12:27:43,1738698952,9/15/2015 12:27:17,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,"resistance, among new TUBERCULOSIS",337-349-355-359,262-270-281-294-307-314-318,regimen containing chemotherapy PYRAZINAMIDE unless the prevalence,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 13:19:39,1738713971,9/15/2015 13:19:09,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,281-294,chemotherapy PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 13:35:27,1738718553,9/15/2015 13:34:51,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,"prevalence of drug resistance, among new TUBERCULOSIS cases is low.",318-329-332-337-349-355-359-372-378-381,238-244-249-252-257-262-270-281-294,three drug or four drug regimen containing chemotherapy PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 13:58:55,1738726427,9/15/2015 13:58:37,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,281-294,chemotherapy PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 14:00:40,1738726795,9/15/2015 13:58:32,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,262-270-281-294,regimen containing chemotherapy PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659455,9/15/2015 14:01:32,1738727035,9/15/2015 13:59:38,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,359,294,,,371,306,TUBERCULOSIS,PYRAZINAMIDE,TUBERCULOSIS,359,281-294,chemotherapy PYRAZINAMIDE,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low.",359,294,359,294,371,306,-1,RO-may_prevent,820317,"Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low",tuberculosis,pyrazinamide
788659456,9/15/2015 14:04:00,1738727739,9/15/2015 14:03:46,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,255-263,VITAMIN D,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 14:16:22,1738731023,9/15/2015 14:16:06,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,255-263,VITAMIN D,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 14:18:24,1738731665,9/15/2015 14:17:43,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,255-263,VITAMIN D,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 14:28:28,1738734578,9/15/2015 14:27:23,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,246-255-263-265-269,"calcium, VITAMIN D and bisphosphonates","The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 14:39:56,1738737524,9/15/2015 14:39:28,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,vitamin D and bisphosphonates in the treatment of OSTEOPOROSIS.,255-263-265-269-288-292-302-305-285,246-255-263-265-269-292,"calcium, VITAMIN D and bisphosphonates treatment","The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 14:43:45,1738738751,9/15/2015 14:43:23,false,coinworker,1,20231698,USA,OR,,172.56.33.130,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,255-263,VITAMIN D,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 14:53:27,1738741470,9/15/2015 14:52:49,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,255-263,VITAMIN D,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 14:56:51,1738742427,9/15/2015 14:56:38,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,255-263,VITAMIN D,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 15:16:27,1738750456,9/15/2015 15:16:15,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,305,255-263,VITAMIN D,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659456,9/15/2015 15:21:54,1738752971,9/15/2015 15:20:03,false,clixsense,1,32053717,GBR,,,51.174.76.80,305,255,,,317,264,OSTEOPOROSIS,VITAMIN D,"aspirin (acetylsalicylic acid) calcium, vitamin D bisphosphonates the treatment of OSTEOPOROSIS.",171-179-246-255-263-269-288-292-302-305-196,171-196-246-255-263-265-269-292-179,"aspirin (acetylsalicylic acid) calcium, VITAMIN D and bisphosphonates treatment","The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis.",305,255 263,305,255,317,264,-1,RO-may_prevent,820230,"The government-produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, vitamin D and bisphosphonates in the treatment of osteoporosis",osteoporosis,vitamin D
788659457,9/15/2015 14:20:20,1738732316,9/15/2015 14:20:04,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA,",57,110,CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 14:48:26,1738740234,9/15/2015 14:48:05,false,coinworker,1,20231698,USA,OR,,172.56.33.130,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA,",57,110-122-125,CHLOROQUINE in blood.,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 15:01:52,1738744038,9/15/2015 15:01:29,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA, 53",57-66,110,CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 15:28:30,1738754910,9/15/2015 15:28:02,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,57,110,,,64,121,MALARIA,CHLOROQUINE,"symptoms of MALARIA,",45-54-57,100-107-110,levels of CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 15:32:08,1738755901,9/15/2015 15:31:09,false,clixsense,1,32053717,GBR,,,51.174.76.80,57,110,,,64,121,MALARIA,CHLOROQUINE,"Among 56 subjects reporting with symptoms of MALARIA, 53 (95%) had effective levels of chloroquine in blood.",0-6-9-18-40-45-54-57-66-69-75-90-100-107-110-125-122,0-6-9-45-57-69-75-90-100-107-110-122-125-18,"Among 56 subjects reporting symptoms malaria, (95%) had effective levels of CHLOROQUINE in blood.","Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 15:40:04,1738758377,9/15/2015 15:39:44,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA,",57,110,CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 15:43:33,1738759378,9/15/2015 15:43:21,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA,",57,110,CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 16:00:10,1738765706,9/15/2015 15:59:18,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA, 53 had",57-66-75,110,CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 16:00:25,1738765827,9/15/2015 16:00:13,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA, 53 had",57-66-75,110,CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659457,9/15/2015 16:01:54,1738766438,9/15/2015 16:01:13,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,57,110,,,64,121,MALARIA,CHLOROQUINE,"MALARIA,",57,110,CHLOROQUINE,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood.",57,110,57,110,64,121,-1,RO-may_prevent,820242,"Among 56 subjects reporting to a clinic with symptoms of malaria, 53 (95%) had ordinarily effective levels of chloroquine in blood",malaria,chloroquine
788659458,9/15/2015 10:36:35,1738658765,9/15/2015 10:36:18,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA,342,351,CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 10:59:38,1738664341,9/15/2015 10:59:20,false,neodev,1,33758777,USA,,,38.95.108.251,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA,342,351,CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 11:06:39,1738665942,9/15/2015 11:06:17,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,342,351,,,349,362,MALARIA,CHLOROQUINE,curtains for preventing MALARIA Chloroquine or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated malaria,318-327-331-342-351-363-366-378-387-392-404-418-422-431-445,327-331-342-351-363-366-378-387-392-404-418-422-431-445,for preventing malaria CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated malaria,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 11:07:09,1738666016,9/15/2015 11:06:47,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA Chloroquine or amodiaquine,342-351-363-366,351-363-366-378,CHLOROQUINE or amodiaquine combined,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 11:08:10,1738666296,9/15/2015 11:07:39,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA,342,351,CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 11:23:05,1738672745,9/15/2015 11:21:20,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA Chloroquine,342-351,342-351,malaria CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 11:23:29,1738673105,9/15/2015 11:23:11,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA,342,351,CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 11:24:52,1738673947,9/15/2015 11:24:23,false,elite,1,31883685,GBR,,,79.66.254.237,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA,342,351,CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 11:46:23,1738684275,9/15/2015 11:45:58,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA,342,351,CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659458,9/15/2015 12:10:23,1738692677,9/15/2015 12:09:05,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,342,351,,,349,362,MALARIA,CHLOROQUINE,MALARIA Chloroquine,342-351,342-351,malaria CHLOROQUINE,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,342,351,342,351,349,362,-1,RO-may_prevent,820289,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers  Drugs for preventing malaria-related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide-treated bednets and curtains for preventing malaria  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN,malaria,Chloroquine
788659459,9/15/2015 14:04:57,1738727983,9/15/2015 14:04:39,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,120-124,NPH INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 14:17:18,1738731327,9/15/2015 14:17:03,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,124,INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 14:21:27,1738732730,9/15/2015 14:20:24,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,10-19-27-34-112-120-124,biphasic insulin analog combinations regular NPH INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 14:33:08,1738735774,9/15/2015 14:31:09,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,120-124,NPH INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 14:44:59,1738739121,9/15/2015 14:44:39,false,coinworker,1,20231698,USA,OR,,172.56.33.130,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,120-124,NPH INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 14:55:21,1738741948,9/15/2015 14:54:56,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,120-124,NPH INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 14:57:44,1738742741,9/15/2015 14:57:22,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,106-109-120-124-112,70 30 regular NPH INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 15:17:07,1738750806,9/15/2015 15:16:53,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,124,INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 15:23:07,1738753294,9/15/2015 15:21:57,false,clixsense,1,32053717,GBR,,,51.174.76.80,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,biphasic insulin analog glycemic NPH insulin TYPE 2 DIABETES 126.,10-19-75-120-124-149-154-156-167-27,10-19-120-124-149-154-156,biphasic insulin NPH INSULIN type 2 diabetes,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659459,9/15/2015 15:23:15,1738753344,9/15/2015 15:21:52,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,149,124,,,164,131,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,149-154-156,120-124,NPH INSULIN,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126.,149 154 156,124,149,124,164,131,-1,RO-may_treat,820093,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH insulin in subjects with type 2 diabetes ( 126,type 2 diabetes,insulin
788659460,9/15/2015 14:49:47,1738740560,9/15/2015 14:49:34,false,coinworker,1,20231698,USA,OR,,172.56.33.130,49,96,,,53,107,PAIN,BUPIVACAINE,morphine resistant PAIN,30-39-49,84-96-108-111-124,intrathecal BUPIVACAINE or percutaneous cordotomy.,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 15:04:39,1738745179,9/15/2015 15:03:56,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,49,96,,,53,107,PAIN,BUPIVACAINE,have morphine resistant PAIN,25-30-39-49,84-96,intrathecal BUPIVACAINE,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 15:35:06,1738756918,9/15/2015 15:34:42,false,clixsense,1,32053717,GBR,,,51.174.76.80,49,96,,,53,107,PAIN,BUPIVACAINE,morphine resistant PAIN,30-39-49,84-96-108-111-124,intrathecal BUPIVACAINE or percutaneous cordotomy.,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 15:41:26,1738758743,9/15/2015 15:41:05,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,49,96,,,53,107,PAIN,BUPIVACAINE,morphine resistant PAIN,30-39-49,84-96,intrathecal BUPIVACAINE,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 15:45:33,1738759987,9/15/2015 15:45:02,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,49,96,,,53,107,PAIN,BUPIVACAINE,PAIN,49,96,BUPIVACAINE,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 16:01:28,1738766239,9/15/2015 16:01:16,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,49,96,,,53,107,PAIN,BUPIVACAINE,morphine resistant PAIN,30-39-49,96,BUPIVACAINE,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 16:03:46,1738767250,9/15/2015 16:03:00,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,49,96,,,53,107,PAIN,BUPIVACAINE,morphine resistant PAIN,30-39-49,84-96,intrathecal BUPIVACAINE,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 16:04:09,1738767336,9/15/2015 16:03:58,false,instagc,1,33058612,USA,IL,Glenview,162.229.106.229,49,96,,,53,107,PAIN,BUPIVACAINE,morphine resistant PAIN,30-49-39,84-96,intrathecal BUPIVACAINE,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 16:04:08,1738767344,9/15/2015 16:03:44,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,49,96,,,53,107,PAIN,BUPIVACAINE,morphine resistant PAIN,30-49-39,96,BUPIVACAINE,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659460,9/15/2015 16:05:08,1738767666,9/15/2015 16:04:58,false,clixsense,1,6338159,CAN,ON,Ottawa,108.168.124.170,49,96,,,53,107,PAIN,BUPIVACAINE,have morphine resistant PAIN and had elected,25-30-39-49-54-58-62,73-81-84-96-108-111-124,proceed to intrathecal BUPIVACAINE or percutaneous cordotomy.,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy.,49,96,49,96,53,107,-1,RO-may_prevent,820187,All patients appeared to have morphine-resistant pain and had elected to proceed to intrathecal bupivacaine or percutaneous cordotomy,pain,bupivacaine
788659461,9/15/2015 10:28:03,1738656721,9/15/2015 10:27:53,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS cimetidine.,252-260-280,252-280-260,gastric ulcers CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 10:35:10,1738658465,9/15/2015 10:34:59,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS,252-260,280,CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 10:58:10,1738663988,9/15/2015 10:57:50,false,neodev,1,33758777,USA,,,38.95.108.251,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS,252-260,280,CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 11:05:23,1738665675,9/15/2015 11:05:02,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with cimetidine.,205-213-218-234-238-247-252-260-267-275-280-230,176-185-190-198-205-213-218-230-238-247-260-267-275-280-234,subjects with gastric ulcers treated with sucralfate; and (4) subjects with ulcers treated with CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 11:05:47,1738665723,9/15/2015 11:05:28,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS treated with cimetidine.,252-260-267-275-280,260-267-275-280-252,gastric ulcers treated with CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 11:06:32,1738665879,9/15/2015 11:06:15,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS,252-260,280,CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 11:09:12,1738666618,9/15/2015 11:07:34,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS,252-260,280,CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 11:21:33,1738671965,9/15/2015 11:21:19,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS,252-260,280,CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 11:23:04,1738672747,9/15/2015 11:22:47,false,elite,1,31883685,GBR,,,79.66.254.237,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,GASTRIC ULCERS,252-260,280,CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659461,9/15/2015 11:40:47,1738681495,9/15/2015 11:40:37,false,elite,1,33798502,USA,VA,Manassas,207.244.86.193,252,280,,,266,290,GASTRIC ULCERS,CIMETIDINE,duodenal duodenal gastric (4) subjects with GASTRIC ULCERS treated with cimetidine.,72-131-234-238-247-252-260-267-275-280-190,58-260-267-275-280-72,subjects duodenal ulcers treated with CIMETIDINE.,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine.,252 260,280,252,280,266,290,-1,RO-may_prevent,820169,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine,gastric ulcers,cimetidine
788659462,9/15/2015 11:32:07,1738677972,9/15/2015 11:31:50,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,80,33,,,85,43,EDEMA,FUROSEMIDE,"EDEMA,",80,33,FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 11:55:10,1738688174,9/15/2015 11:54:39,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,80,33,,,85,43,EDEMA,FUROSEMIDE,"EDEMA,",80,33,FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 12:32:40,1738700588,9/15/2015 12:31:37,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,80,33,,,85,43,EDEMA,FUROSEMIDE,"to reduce general EDEMA,",62-65-72-80,4-15-30-33,occasional administration of FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 13:41:45,1738722566,9/15/2015 13:40:34,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,80,33,,,85,43,EDEMA,FUROSEMIDE,"not effective to reduce general EDEMA,",48-62-65-72-80-52,15-30-33-44-48-52,administration of FUROSEMIDE was not effective,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 14:00:17,1738726716,9/15/2015 14:00:00,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,80,33,,,85,43,EDEMA,FUROSEMIDE,"EDEMA,",80,33,FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 14:03:16,1738727571,9/15/2015 14:02:53,false,vivatic,1,15201808,GBR,,,87.112.19.240,80,33,,,85,43,EDEMA,FUROSEMIDE,"EDEMA,",80,33,FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 14:05:53,1738728249,9/15/2015 14:04:58,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,80,33,,,85,43,EDEMA,FUROSEMIDE,"general EDEMA,",72-80,33-52,FUROSEMIDE effective,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 14:10:20,1738729334,9/15/2015 14:09:38,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,80,33,,,85,43,EDEMA,FUROSEMIDE,"general EDEMA,",72-80,30-33-15,administration of FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 14:12:18,1738729781,9/15/2015 14:11:57,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,80,33,,,85,43,EDEMA,FUROSEMIDE,"EDEMA,",80,33,FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659462,9/15/2015 14:34:20,1738736094,9/15/2015 14:34:10,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,80,33,,,85,43,EDEMA,FUROSEMIDE,"general EDEMA,",72-80,33,FUROSEMIDE,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.",80,33,80,33,85,43,-1,RO-may_treat,820129,"The occasional administration of furosemide was not effective to reduce general edema, but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day",edema,furosemide
788659463,9/15/2015 09:11:34,1738636665,9/15/2015 09:11:13,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,TYPE 2 DIABETES MELLITUS,61-66-68-77,0,METFORMIN:,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:11:52,1738636769,9/15/2015 09:11:12,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,Metformin: TYPE 2 DIABETES MELLITUS a,61-66-68-77-97-0,0-61-66-68-77,METFORMIN: type 2 diabetes mellitus,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:13:08,1738637052,9/15/2015 09:12:16,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,Metformin: an update Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS Effect of a multivitamin and mineral supplement on infection and quality of life.,0-11-14-22-28-31-40-44-48-58-61-66-68-77-87-94-97-99-112-116-124-135-138-148-152-160-163,0-11-14-22-28-31-40-44-48-58-61-66-68-77-87-94-97-99-112-116-124-135-138-148-152-160-163,METFORMIN: an update Tests of glycemia for the diagnosis of type 2 diabetes mellitus Effect of a multivitamin and mineral supplement on infection and quality of life.,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:14:52,1738637421,9/15/2015 09:13:44,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,the diagnosis of TYPE 2 DIABETES MELLITUS Effect of a,44-48-58-61-66-68-77-87-94-97,0,METFORMIN:,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:20:28,1738638232,9/15/2015 09:20:12,false,neodev,1,20306047,GBR,,,80.41.0.252,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,TYPE 2 DIABETES MELLITUS,61-66-68-77,0,METFORMIN:,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:32:03,1738641058,9/15/2015 09:31:45,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,TYPE 2 DIABETES MELLITUS,61-66-68-77,0,METFORMIN:,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:36:16,1738642558,9/15/2015 09:35:44,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,TYPE 2 DIABETES MELLITUS a,61-66-68-77-97,0-61-66-68,METFORMIN: type 2 diabetes,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:49:37,1738646374,9/15/2015 09:49:19,false,neodev,1,33758777,USA,,,38.95.108.251,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,TYPE 2 DIABETES MELLITUS,61-66-68-77,0,METFORMIN:,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:51:52,1738647073,9/15/2015 09:49:35,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,TYPE 2 DIABETES MELLITUS,61-66-68-77,0,METFORMIN:,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659463,9/15/2015 09:59:21,1738648988,9/15/2015 09:59:07,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,61,0,,,85,9,TYPE 2 DIABETES MELLITUS,METFORMIN,TYPE 2 DIABETES MELLITUS,61-66-68-77,0,METFORMIN:,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life.,61 66 68 77,0,61,0,85,9,-1,RO-may_treat,820072,Metformin: an update  Tests of glycemia for the diagnosis of type 2 diabetes mellitus  Effect of a multivitamin and mineral supplement on infection and quality of life,type 2 diabetes mellitus,Metformin
788659464,9/15/2015 09:12:38,1738636896,9/15/2015 09:12:14,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA,",22,30,ZAFIRLUKAST,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:13:10,1738637050,9/15/2015 09:12:52,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA, zafirlukast inhibited bronchospasm",22-30-42-52,22-30-42-52,"asthma, ZAFIRLUKAST inhibited bronchospasm","In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:14:31,1738637331,9/15/2015 09:14:04,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"In clinical models of ASTHMA, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",0-3-12-19-22-30-42-52-65-71-80-83-92-102-105-114-119,0-3-12-19-22-30-42-52-65-71-80-83-92-102-105-114-119,"In clinical models of asthma, ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.","In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:16:16,1738637644,9/15/2015 09:15:45,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"clinical models of ASTHMA, zafirlukast inhibited bronchospasm",3-12-19-22-30-42-52,30,ZAFIRLUKAST,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:21:22,1738638442,9/15/2015 09:20:58,false,neodev,1,20306047,GBR,,,80.41.0.252,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA,",22,30,ZAFIRLUKAST,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:32:45,1738641264,9/15/2015 09:32:31,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA,",22,30,ZAFIRLUKAST,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:39:49,1738643855,9/15/2015 09:39:25,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA, zafirlukast inhibited bronchospasm",22-30-52-42,22-30-42-52,"asthma, ZAFIRLUKAST inhibited bronchospasm","In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:50:31,1738646710,9/15/2015 09:50:16,false,neodev,1,33758777,USA,,,38.95.108.251,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA,",22,30,ZAFIRLUKAST,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:57:16,1738648519,9/15/2015 09:56:08,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA,",22,30,ZAFIRLUKAST,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659464,9/15/2015 09:59:06,1738648908,9/15/2015 09:58:45,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,22,30,,,28,41,ASTHMA,ZAFIRLUKAST,"ASTHMA, zafirlukast inhibited bronchospasm",22-30-42-52,22-30-42-52,"asthma, ZAFIRLUKAST inhibited bronchospasm","In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma.",22,30,22,30,28,41,-1,RO-may_prevent,820295,"In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma",asthma,zafirlukast
788659465,9/15/2015 14:20:59,1738732535,9/15/2015 14:20:39,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER,306-316-327,361,FLUVOXAMINE,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 14:49:11,1738740408,9/15/2015 14:48:42,false,coinworker,1,20231698,USA,OR,,172.56.33.130,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER,306-316-327,306-316-327-337-361-373-385-388-350,Obsessive compulsive disorder Clomipramine Fluoxetine FLUVOXAMINE Paroxetine 25 50,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 15:03:31,1738744700,9/15/2015 15:02:48,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER Clomipramine Fluoxetine Fluvoxamine,306-316-327-337-350-361,306-316-327-337-350-361,Obsessive compulsive disorder Clomipramine Fluoxetine FLUVOXAMINE,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 15:34:05,1738756563,9/15/2015 15:32:58,false,clixsense,1,32053717,GBR,,,51.174.76.80,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER Clomipramine Fluoxetine Fluvoxamine Paroxetine,306-316-327-337-350-361-373,306-327-337-350-361-373-316,Obsessive compulsive disorder Clomipramine Fluoxetine FLUVOXAMINE Paroxetine,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 15:40:44,1738758568,9/15/2015 15:40:19,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER,306-316-327,337-350-361-373,Clomipramine Fluoxetine FLUVOXAMINE Paroxetine,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 15:44:05,1738759502,9/15/2015 15:43:50,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER,306-316-327,361,FLUVOXAMINE,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 16:00:50,1738765996,9/15/2015 16:00:38,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,50 200 mg OBSESSIVE COMPULSIVE DISORDER Clomipramine,296-299-303-306-316-327-337,361-385-388,FLUVOXAMINE 25 50,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 16:02:28,1738766705,9/15/2015 16:01:28,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER,306-316-327,337-350-361-373,Clomipramine Fluoxetine FLUVOXAMINE Paroxetine,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 16:03:10,1738766975,9/15/2015 16:02:29,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER,306-316-327,361-373,FLUVOXAMINE Paroxetine,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659465,9/15/2015 16:10:35,1738769764,9/15/2015 16:10:09,false,instagc,1,15577915,USA,IL,Trenton,208.70.36.12,306,361,,,335,372,OBSESSIVE-COMPULSIVE DISORDER,FLUVOXAMINE,OBSESSIVE COMPULSIVE DISORDER,306-316-327,361-373-385-388-391,FLUVOXAMINE Paroxetine 25 50 mg,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s.,306 316 327,361,306,361,335,372,-1,RO-may_treat,820080,Posttraumatic stress disorder  Sertraline Paroxetine  50 mg 10 mg  50-200 mg 10-60 mg Generalized anxiety disorder  Venlafaxine  75 mg in two or three divided doses  150-300 mg in two or three divided doses Social anxiety disorder (social phobia)  Paroxetine Sertraline  10-20 mg 50 mg  10-60 mg 50-200 mg Obsessive-compulsive disorder  Clomipramine Fluoxetine Fluvoxamine Paroxetine  25-50 mg 5-10 mg 50 mg h.s,Obsessive-compulsive disorder,Fluvoxamine
788659466,9/15/2015 10:26:15,1738656401,9/15/2015 10:26:00,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"Famciclovir GENITAL HERPES,",0-74-82,0-82-74,"FAMCICLOVIR genital herpes,","Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 10:33:06,1738657956,9/15/2015 10:32:54,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"GENITAL HERPES,",74-82,0,FAMCICLOVIR,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 10:35:12,1738658464,9/15/2015 10:34:54,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"Famciclovir GENITAL HERPES, treatment of",0-74-82-101-111,0-74-82-101-111,"FAMCICLOVIR genital herpes, treatment of","Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 10:55:39,1738663525,9/15/2015 10:55:06,false,points4rewards,1,28703583,USA,,,184.53.32.113,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"Famciclovir GENITAL HERPES,",74-82-0,0-74-82,"FAMCICLOVIR genital herpes,","Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 10:55:45,1738663544,9/15/2015 10:55:30,false,neodev,1,33758777,USA,,,38.95.108.251,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"GENITAL HERPES,",74-82,0,FAMCICLOVIR,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 11:00:19,1738664505,9/15/2015 11:00:11,false,neodev,1,11382239,AUS,2,Strathfield,60.241.129.81,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"GENITAL HERPES,",74-82,0,FAMCICLOVIR,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 11:00:51,1738664621,9/15/2015 11:00:34,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"GENITAL HERPES,",74-82,0,FAMCICLOVIR,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 11:02:58,1738665080,9/15/2015 11:02:27,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"recurrent episodes of GENITAL HERPES, and orolabial herpes, immunocompetent patients.",52-62-71-74-82-90-114-124-135-151,0-12-17-21-37-49-52-62-71-74-82-101-111-114-124-135-151,"FAMCICLOVIR also has efficacy suppression of recurrent episodes of genital herpes, treatment of orolabial herpes, immunocompetent patients.","Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 11:03:04,1738665107,9/15/2015 11:02:47,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"recurrent episodes of GENITAL HERPES, and in the treatment herpes, immunocompetent",52-62-71-74-82-90-94-97-101-135-124,0-12-17-21-37-114-124,"FAMCICLOVIR also has efficacy suppression orolabial herpes,","Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659466,9/15/2015 11:03:56,1738665296,9/15/2015 11:03:39,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,74,0,,,88,11,GENITAL HERPES,FAMCICLOVIR,"GENITAL HERPES,",74-82,0,FAMCICLOVIR,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.",74 82,0,74,0,88,11,-1,RO-may_prevent,820189,"Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients",genital herpes,Famciclovir
788659467,9/15/2015 09:16:14,1738637638,9/15/2015 09:15:56,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,ASTHMA,166,105-120,BECLOMETHASONE DIPROPIONATE,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 09:24:24,1738639152,9/15/2015 09:23:21,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of beclomethasone dipropionate in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,0-5-10-17-25-28-43-56-60-63-74-78-80-84-89-94-102-105-120-133-136-140-150-153-162-166-173-177-187-191-195-206-209-213-222-227-230-235,0-5-10-17-25-28-43-56-60-63-74-78-80-84-89-94-102-105-120-133-136-140-150-153-162-166-173-177-187-191-195-206-209-213-222-227-235-230,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 09:35:54,1738642316,9/15/2015 09:35:32,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,ASTHMA,166,105-120,BECLOMETHASONE DIPROPIONATE,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 09:46:25,1738645654,9/15/2015 09:46:12,false,neodev,1,20306047,GBR,,,80.41.0.252,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,ASTHMA,166,105-120,BECLOMETHASONE DIPROPIONATE,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 09:46:31,1738645695,9/15/2015 09:46:08,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,rhinitis and ASTHMA,153-162-166,105-120,BECLOMETHASONE DIPROPIONATE,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 10:02:15,1738649764,9/15/2015 10:02:03,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,rhinitis and ASTHMA,153-162-166,105-120,BECLOMETHASONE DIPROPIONATE,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 10:07:34,1738651299,9/15/2015 10:06:33,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,ASTHMA,166,105-120,BECLOMETHASONE DIPROPIONATE,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 10:08:59,1738651735,9/15/2015 10:08:35,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,ASTHMA,166,105-120,BECLOMETHASONE DIPROPIONATE,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 10:19:13,1738654518,9/15/2015 10:19:03,false,gifthunterclub,1,30901412,GBR,H9,London,77.89.149.62,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,beclomethasone dipropionate rhinitis and ASTHMA are available for,105-153-162-166-173-177-187-120,89-94-102-105-120-133-136-140-63,budesonide term studies of BECLOMETHASONE DIPROPIONATE in the treatment,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659467,9/15/2015 10:21:37,1738655116,9/15/2015 10:20:10,false,points4rewards,1,28703583,USA,,,184.53.33.153,166,105,,,172,132,ASTHMA,BECLOMETHASONE DIPROPIONATE,beclomethasone dipropionate and of budesonide ASTHMA,28-43-56-60-63-166,105-120-133-136-140-150-153-162-166,BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and asthma,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects.,166,105 120,166,105,172,132,-1,RO-may_prevent,820364,Long-term animal studies of beclomethasone dipropionate and of budesonide and a few long-term studies of beclomethasone dipropionate in the treatment of rhinitis and asthma are available for the assessment of the possible risk of side effects,asthma,beclomethasone dipropionate
788659468,9/15/2015 09:11:12,1738636552,9/15/2015 09:10:53,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,MYOCARDIAL INFARCTION.,115-126,32,CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:11:11,1738636553,9/15/2015 09:10:33,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,anti platelet drug clopidogrel treatment of MYOCARDIAL INFARCTION.,13-27-32-102-112-115-126-18,13-18-27-32-102-112-115-126,anti platelet drug CLOPIDOGREL treatment of myocardial infarction.,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:12:15,1738636826,9/15/2015 09:11:31,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,Recently the anti platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION.,0-9-13-18-27-32-44-48-53-64-67-71-77-80-82-98-102-112-115-126-95,0-9-13-18-27-32-44-48-53-64-67-71-77-80-82-95-98-102-112-115-126,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:13:43,1738637216,9/15/2015 09:12:53,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,the treatment of MYOCARDIAL INFARCTION.,98-102-112-115-126,13-18-27-32,anti platelet drug CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:20:11,1738638200,9/15/2015 09:19:53,false,neodev,1,20306047,GBR,,,80.41.0.252,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,MYOCARDIAL INFARCTION.,115-126,32,CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:31:44,1738640953,9/15/2015 09:31:27,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,MYOCARDIAL INFARCTION.,115-126,32,CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:35:44,1738642295,9/15/2015 09:35:19,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,MYOCARDIAL INFARCTION.,115-126,32,CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:46:37,1738645706,9/15/2015 09:46:27,false,elite,1,28548715,USA,,,208.31.49.20,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,MYOCARDIAL INFARCTION.,115-126,32,CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:49:17,1738646296,9/15/2015 09:49:00,false,neodev,1,33758777,USA,,,38.95.108.251,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,MYOCARDIAL INFARCTION.,115-126,32,CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659468,9/15/2015 09:49:32,1738646334,9/15/2015 09:49:17,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,115,32,,,136,43,MYOCARDIAL INFARCTION,CLOPIDOGREL,MYOCARDIAL INFARCTION.,115-126,32,CLOPIDOGREL,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction.,115 126,32,115,32,136,43,-1,RO-may_prevent,820386,Recently the anti-platelet drug clopidogrel has been publicized in the press as a breakthrough in the treatment of myocardial infarction,myocardial infarction,clopidogrel
788659469,9/15/2015 14:05:17,1738728071,9/15/2015 14:04:58,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION Kidney.,668-675-689,603-609,ESRD WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 14:17:37,1738731453,9/15/2015 14:17:19,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION,668-675,609,WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 14:22:47,1738733141,9/15/2015 14:21:27,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION,668-675,609,WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 14:34:42,1738736168,9/15/2015 14:33:12,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION,668-675,603-609,ESRD WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 14:45:23,1738739263,9/15/2015 14:45:01,false,coinworker,1,20231698,USA,OR,,172.56.33.130,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION Kidney.,668-675-689,603-609,ESRD WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 14:55:39,1738741982,9/15/2015 14:55:22,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION Kidney.,668-675-689,603-609,ESRD WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 14:58:06,1738742853,9/15/2015 14:57:45,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION,668-675,603-609,ESRD WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 15:17:20,1738750879,9/15/2015 15:17:07,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION,668-675,609,WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 15:23:37,1738753450,9/15/2015 15:23:16,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,ATRIAL FIBRILLATION Kidney.,668-675-689,603-609,ESRD WARFARIN,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659469,9/15/2015 15:25:09,1738753946,9/15/2015 15:23:12,false,clixsense,1,32053717,GBR,,,51.174.76.80,668,609,,,687,617,ATRIAL FIBRILLATION,WARFARIN,chronic kidney hyperphosphatemia hemodialysis ATRIAL FIBRILLATION Kidney.,78-86-312-641-668-675-689,589-600-603-609-618-622-675-689-668,prediction of ESRD WARFARIN and stroke atrial fibrillation Kidney.,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney.,668 675,609,668,609,687,617,-1,RO-may_treat,820044,Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial  Prevalence of chronic kidney disease in the United States  Altitude and all-cause mortality in incident dialysis patients  Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial  Cardiovascular and noncardiovascular mortality among patients starting dialysis  Journal of the American Society of Nephrology  Combining GFR and albuminuria to classify CKD improves prediction of ESRD  Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation  Kidney,atrial fibrillation,Warfarin
788659470,9/15/2015 14:06:54,1738728491,9/15/2015 14:06:42,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26-36,LIDOCAINE ointment,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 14:19:18,1738731847,9/15/2015 14:19:01,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26,LIDOCAINE,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 14:44:29,1738738984,9/15/2015 14:43:04,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26-36-49,LIDOCAINE ointment sitz,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 14:47:22,1738739900,9/15/2015 14:47:04,false,coinworker,1,20231698,USA,OR,,172.56.33.130,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26-36,LIDOCAINE ointment,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 14:59:36,1738743300,9/15/2015 14:59:26,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26-36,LIDOCAINE ointment,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 15:00:41,1738743668,9/15/2015 15:00:24,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26-36,LIDOCAINE ointment,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 15:26:33,1738754339,9/15/2015 15:26:16,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26-36,LIDOCAINE ointment,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 15:29:17,1738755114,9/15/2015 15:28:52,false,clixsense,1,32053717,GBR,,,51.174.76.80,4,26,,,8,35,PAIN,LIDOCAINE,The PAIN was treated with lidocaine,0-4-9-13-21-26,0-4-9-13-21-26,The pain was treated with LIDOCAINE,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 15:38:45,1738757998,9/15/2015 15:38:34,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26-36,LIDOCAINE ointment,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659470,9/15/2015 15:42:43,1738759100,9/15/2015 15:42:28,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,4,26,,,8,35,PAIN,LIDOCAINE,PAIN,4,26,LIDOCAINE,The pain was treated with lidocaine ointment and sitz baths with partial success.,4,26,4,26,8,35,-1,RO-may_prevent,820296,The pain was treated with lidocaine ointment and sitz baths with partial success,pain,lidocaine
788659471,9/15/2015 09:18:40,1738637964,9/15/2015 09:18:18,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,56-65,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 09:31:17,1738640857,9/15/2015 09:30:50,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,Cimetidine was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,0-11-15-20-30-33-38-46-52-56-65-71-80-83-87-93-95-101-107,0-11-15-20-30-33-38-46-52-56-65-71-80-83-87-93-95-101-107,CIMETIDINE was cost effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 09:38:00,1738643122,9/15/2015 09:37:43,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER patients,56-65-71,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 09:50:35,1738646776,9/15/2015 09:50:15,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,gastric ulcer DUODENAL ULCER the first,38-46-56-65-83-87,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 09:58:31,1738648805,9/15/2015 09:58:09,false,neodev,1,20306047,GBR,,,80.41.0.252,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,56-65,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 10:04:27,1738650455,9/15/2015 10:04:13,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,gastric ulcer DUODENAL ULCER,38-46-56-65,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 10:13:12,1738652944,9/15/2015 10:12:54,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,gastric ulcer and DUODENAL ULCER,38-46-52-56-65,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 10:15:50,1738653704,9/15/2015 10:14:55,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,56-65,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 10:22:42,1738655445,9/15/2015 10:22:28,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,Cimetidine DUODENAL ULCER,56-65-0,0-56-65,CIMETIDINE duodenal ulcer,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659471,9/15/2015 10:30:12,1738657283,9/15/2015 10:29:54,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,56,0,,,70,10,DUODENAL ULCER,CIMETIDINE,DUODENAL ULCER,56-65,0,CIMETIDINE,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing.,56 65,0,56,0,70,10,-1,RO-may_prevent,820145,Cimetidine was cost-effective in both gastric ulcer and duodenal ulcer patients in the first 2 years after healing,duodenal ulcer,Cimetidine
788659472,9/15/2015 09:18:16,1738637932,9/15/2015 09:17:58,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,HEPATITIS B INFECTION,70-80-82,47,"HBSAG,","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 09:30:49,1738640735,9/15/2015 09:30:18,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",0-3-7-13-18-21-29-34-43-47-54-65-70-80-82-92-95-99-106-112-116-122-126-139,0-3-7-13-18-21-29-34-43-47-54-65-70-80-82-92-95-99-106-112-116-122-126-139,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG, indicating that hepatitis B infection in the target group was below the intermediate endemicity.","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 09:37:42,1738643047,9/15/2015 09:37:25,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,HEPATITIS B INFECTION,70-80-82,47,"HBSAG,","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 09:50:14,1738646591,9/15/2015 09:49:03,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,"HBsAg, HEPATITIS B INFECTION",47-70-80-82,47-70-80-82,"HBSAG, hepatitis B infection","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 09:58:07,1738648722,9/15/2015 09:57:55,false,neodev,1,20306047,GBR,,,80.41.0.252,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,HEPATITIS B INFECTION,70-80-82,47,"HBSAG,","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 10:04:12,1738650395,9/15/2015 10:03:53,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,"HBsAg, HEPATITIS B INFECTION",47-70-80-82,47-70-80-82,"HBSAG, hepatitis B infection","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 10:12:54,1738652876,9/15/2015 10:12:36,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,HEPATITIS B INFECTION,70-80-82,47,"HBSAG,","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 10:14:52,1738653422,9/15/2015 10:13:34,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,HEPATITIS B INFECTION,70-80-82,47,"HBSAG,","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 10:22:28,1738655346,9/15/2015 10:22:10,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,"HBsAg, HEPATITIS B INFECTION",47-70-80-82,47-70-80,"HBSAG, hepatitis B","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659472,9/15/2015 10:27:38,1738656622,9/15/2015 10:26:38,false,points4rewards,1,28703583,USA,,,184.53.33.153,70,47,,,91,52,HEPATITIS B INFECTION,HBSAG,"positive for HBsAg, HEPATITIS B INFECTION",34-47-70-80-82-43,47-54-65-70-80-82,"HBSAG, indicating that hepatitis B infection","Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity.",70 80 82,47,70,47,91,52,-1,RO-may_prevent,820307,"Of the 2,585 men, 24 (0.93%) were positive for HBsAg, indicating that hepatitis B infection in the target group was below the intermediate endemicity",hepatitis B infection,HBsAg
788659473,9/15/2015 11:08:31,1738666367,9/15/2015 11:08:21,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,"clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",113-123-127-139-148-156-164-168-104,64-69-80-84-100-104-113-127,"with danaparoid and HYDROCORTISONE, the clinical evolution favourable,","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 11:10:41,1738666896,9/15/2015 11:10:23,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,ADRENAL FAILURE,148-156,84,"HYDROCORTISONE,","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 11:26:16,1738674684,9/15/2015 11:25:50,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,ADRENAL FAILURE,148-156,84,"HYDROCORTISONE,","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 11:29:23,1738676518,9/15/2015 11:28:22,false,elite,1,31883685,GBR,,,79.66.254.237,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,ADRENAL FAILURE,148-156,84,"HYDROCORTISONE,","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 11:30:02,1738676809,9/15/2015 11:29:22,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,ADRENAL FAILURE,148-156,84,"HYDROCORTISONE,","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 11:49:05,1738685419,9/15/2015 11:48:46,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,ADRENAL FAILURE,148-156,84,"HYDROCORTISONE,","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 12:17:36,1738695786,9/15/2015 12:15:57,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,"was favourable, although ADRENAL FAILURE was irreversible.",123-127-139-148-156-164-168,64-69-80-84,"with danaparoid and HYDROCORTISONE,","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 12:38:20,1738702775,9/15/2015 12:38:10,false,neodev,1,33701549,USA,CA,San Jose,23.27.248.252,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,"immediate and clinical was favourable, although ADRENAL FAILURE was irreversible.",6-80-123-127-139-148-156-164-168-104,16-64-69-80-84-100-104-113-148-0,"After discontinuation with danaparoid and HYDROCORTISONE, the clinical evolution adrenal","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 12:54:12,1738707022,9/15/2015 12:53:55,false,zoombucks,1,4711962,CAN,ON,Markham,174.88.29.138,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,"clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",104-123-127-139-148-156-164-168-113,64-69-80-84-100-104-113-56,"therapy with danaparoid and HYDROCORTISONE, the clinical evolution","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659473,9/15/2015 13:12:38,1738711933,9/15/2015 13:12:25,false,neodev,1,30581619,USA,CA,San Jose,50.118.172.208,148,84,,,163,98,ADRENAL FAILURE,HYDROCORTISONE,"was favourable, although ADRENAL FAILURE was irreversible.",123-127-139-148-156-164-168,64-69-80-84-100-104-113-43,"and with danaparoid and HYDROCORTISONE, the clinical evolution","After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible.",148 156,84,148,84,163,98,-1,RO-may_treat,820118,"After immediate discontinuation of heparin and starting therapy with danaparoid and hydrocortisone, the clinical evolution was favourable, although adrenal failure was irreversible",adrenal failure,hydrocortisone
788659474,9/15/2015 12:38:35,1738702864,9/15/2015 12:38:04,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,glucagon response to HYPOGLYCEMIA,38-47-56-59,22-34-38-47-56-59,epinephrine and GLUCAGON response to hypoglycemia, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 13:55:06,1738725571,9/15/2015 13:53:31,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,response to HYPOGLYCEMIA with prolonged duration of diabetes,47-56-59-72-77-87-96-99,2-19-22-34-38-47-56-59-14,Progressive loss of epinephrine and GLUCAGON response to hypoglycemia, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 14:03:07,1738727531,9/15/2015 14:02:50,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,59,38,GLUCAGON, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 14:15:19,1738730650,9/15/2015 14:13:44,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,59,38,GLUCAGON, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 14:15:30,1738730730,9/15/2015 14:15:14,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,59,38,GLUCAGON, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 14:24:29,1738733609,9/15/2015 14:23:12,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,glucagon response to HYPOGLYCEMIA with prolonged duration,38-47-56-59-72-77-87,2-19-22-34-38-47-56-59-14,Progressive loss of epinephrine and GLUCAGON response to hypoglycemia, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 14:42:23,1738738341,9/15/2015 14:41:45,false,coinworker,1,20231698,USA,OR,,172.56.33.130,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,59,38,GLUCAGON, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 14:51:39,1738741067,9/15/2015 14:51:05,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,59,38,GLUCAGON, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 14:55:58,1738742090,9/15/2015 14:55:39,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,59,38-47,GLUCAGON response, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659474,9/15/2015 15:17:37,1738751063,9/15/2015 15:15:02,false,clixsense,1,32053717,GBR,,,51.174.76.80,59,38,,,71,46,HYPOGLYCEMIA,GLUCAGON,glucagon response to HYPOGLYCEMIA with prolonged duration,38-47-56-59-72-77-87,19-22-34-38-47-56-59,of epinephrine and GLUCAGON response to hypoglycemia, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events.,59,38,59,38,71,46,-1,RO-may_treat,820092, Progressive loss of epinephrine and glucagon response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of hypoglycemia and increases the risk of severe events,hypoglycemia,glucagon
788659475,9/15/2015 10:38:14,1738659252,9/15/2015 10:37:56,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,64,80,ANTIARRHYTHMIC,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 11:08:04,1738666279,9/15/2015 11:07:49,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,the susceptibility to ARRHYTHMIAS and antiarrhythmic treatment have been reported.,42-46-61-64-76-80-95-105-110-115,61-64-76-80-95-105-110-115-46,susceptibility to arrhythmias and ANTIARRHYTHMIC treatment have been reported.,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 11:10:01,1738666755,9/15/2015 11:09:44,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,64,80-95,ANTIARRHYTHMIC treatment,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 11:25:17,1738674119,9/15/2015 11:24:45,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,64,80-95,ANTIARRHYTHMIC treatment,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 11:28:00,1738675762,9/15/2015 11:27:27,false,elite,1,31883685,GBR,,,79.66.254.237,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,64,80-95,ANTIARRHYTHMIC treatment,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 11:28:49,1738676236,9/15/2015 11:28:29,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,64,80-95,ANTIARRHYTHMIC treatment,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 11:48:17,1738685107,9/15/2015 11:47:51,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,64,80-95,ANTIARRHYTHMIC treatment,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 12:12:56,1738693789,9/15/2015 12:12:30,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,susceptibility to ARRHYTHMIAS,46-61-64,64-76-80-95,arrhythmias and ANTIARRHYTHMIC treatment,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 12:15:01,1738694597,9/15/2015 12:14:00,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,the susceptibility to ARRHYTHMIAS,42-46-61-64,64-76-80-95,arrhythmias and ANTIARRHYTHMIC treatment,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659475,9/15/2015 12:20:56,1738696857,9/15/2015 12:20:22,false,neodev,1,34429821,USA,CA,Torrance,66.171.228.249,64,80,,,75,94,ARRHYTHMIAS,ANTIARRHYTHMIC,the susceptibility to ARRHYTHMIAS and antiarrhythmic treatment,42-46-61-64-76-80-95,61-64-76-80-95-105-110,to arrhythmias and ANTIARRHYTHMIC treatment have been,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported.,64,80,64,80,75,94,-1,RO-may_prevent,820362,Sexual dimorphisms of atherosclerosis and the susceptibility to arrhythmias and antiarrhythmic treatment have been reported,arrhythmias,antiarrhythmic
788659476,9/15/2015 09:19:30,1738638102,9/15/2015 09:19:12,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,286,342,,,301,344,PULMONARY EDEMA,O2,PULMONARY EDEMA;,286-296,342,O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 09:35:40,1738642281,9/15/2015 09:33:08,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,286,342,,,301,344,PULMONARY EDEMA,O2,"Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 - 80 mg / day in adults and dexamethasone 1 mg / m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites Nitroprusside See.",4-8-21-26-31-43-52-56-61-66-76-81-89-96-108-111-124-131-141-150-159-168-177-186-194-200-203-212-217-226-233-240-246-261-270-277-286-296-303-310-322-332-336-342-345-348-353-356-365-374-378-388-398-404-413-422-432-445-456-458-459-462-464-465-469-472-479-483-497-499-501-502-505-509-512-521-524-533-541-551-560-574-578-593-607,4-8-21-26-31-43-52-56-61-66-76-81-89-96-108-111-124-131-141-150-159-168-177-186-194-200-203-212-217-226-233-240-246-261-270-277-286-296-303-310-322-332-336-342-345-348-353-356-365-374-378-388-398-404-413-422-432-445-456-458-459-462-464-465-469-472-479-483-497-499-501-502-505-509-512-521-524-533-541-551-560-574-578-593-607,"Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 - 80 mg / day in adults and dexamethasone 1 mg / m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites Nitroprusside See.","57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 09:38:54,1738643510,9/15/2015 09:38:31,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,286,342,,,301,344,PULMONARY EDEMA,O2,PULMONARY EDEMA;,286-296,342,O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 09:51:49,1738647071,9/15/2015 09:51:24,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,286,342,,,301,344,PULMONARY EDEMA,O2,"fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia",261-270-277-286-296-303-310-322,322-342,pneumonia O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 10:01:02,1738649422,9/15/2015 09:59:49,false,neodev,1,20306047,GBR,,,80.41.0.252,286,342,,,301,344,PULMONARY EDEMA,O2,PULMONARY EDEMA;,286-296,342,O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 10:05:14,1738650664,9/15/2015 10:04:53,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,286,342,,,301,344,PULMONARY EDEMA,O2,"fatigue, cough, dyspnea, PULMONARY EDEMA; bronchitis, pneumonia",261-270-277-286-296-310-322,322-342,pneumonia O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 10:20:53,1738654948,9/15/2015 10:19:13,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,286,342,,,301,344,PULMONARY EDEMA,O2,PULMONARY EDEMA;,286-296,342,O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 10:23:31,1738655652,9/15/2015 10:23:14,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,286,342,,,301,344,PULMONARY EDEMA,O2,PULMONARY EDEMA; O2,286-296-342,286-342-353-296,pulmonary edema; O2 as,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 10:28:52,1738656907,9/15/2015 10:28:22,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,286,342,,,301,344,PULMONARY EDEMA,O2,PULMONARY EDEMA;,286-296,342,O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659476,9/15/2015 10:30:56,1738657458,9/15/2015 10:30:28,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,286,342,,,301,344,PULMONARY EDEMA,O2,PULMONARY EDEMA; pneumonia,286-296-322,286-342-296,pulmonary edema; O2,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",286 296,342,286,342,301,344,-1,RO-may_prevent,820224,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, pulmonary edema; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30-80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See",pulmonary edema,O2
788659477,9/15/2015 09:17:57,1738637874,9/15/2015 09:17:39,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,moderate INFLAMMATION,343-352,413-426,PREDNISOLONE ACETATE,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 09:30:16,1738640612,9/15/2015 09:28:34,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,Agent Mechanism of Action Dosage Benefits Side Effects Notes Diclofenac Nonsteroidal anti inflammatory 1 gtt qid Anti inflammatory Corneal toxicity Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac Nonsteroidal anti inflammatory 1 gtt qid Anti inflammatory Corneal toxicity Reserve for moderate INFLAMMATION where topical steroids might be contraindicated Prednisolone acetate Anti inflammatory 1 gtt tid qid Relief of discomfort.,0-7-17-20-28-36-46-51-60-66-78-91-96-110-112-116-121-126-140-148-158-166-170-179-192-198-206-215-221-224-240-251-264-269-283-285-289-294-299-313-321-331-339-343-352-365-371-379-388-394-397-413-426-435-440-454-456-460-464-469-476-479,0-7-17-20-28-36-46-51-60-66-78-91-96-110-112-116-121-126-140-148-158-166-170-179-192-198-206-215-221-224-240-251-264-269-283-285-289-294-299-313-321-331-339-343-352-365-371-379-388-394-397-413-426-435-440-454-456-460-464-469-476-479,Agent Mechanism of Action Dosage Benefits Side Effects Notes Diclofenac Nonsteroidal anti inflammatory 1 gtt qid Anti inflammatory Corneal toxicity Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac Nonsteroidal anti inflammatory 1 gtt qid Anti inflammatory Corneal toxicity Reserve for moderate inflammation where topical steroids might be contraindicated PREDNISOLONE ACETATE Anti inflammatory 1 gtt tid qid Relief of discomfort.,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 09:37:24,1738642999,9/15/2015 09:37:06,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,moderate INFLAMMATION,343-352,413-426,PREDNISOLONE ACETATE,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 09:48:32,1738646116,9/15/2015 09:48:11,false,neodev,1,20306047,GBR,,,80.41.0.252,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,INFLAMMATION,352,413-426,PREDNISOLONE ACETATE,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 09:49:01,1738646203,9/15/2015 09:48:30,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,INFLAMMATION,352,413-426-435-440-454,PREDNISOLONE ACETATE Anti inflammatory 1,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 10:03:51,1738650297,9/15/2015 10:03:31,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,INFLAMMATION,352,413-426-435-440-454-456-460-464-469-479-476,PREDNISOLONE ACETATE Anti inflammatory 1 gtt tid qid Relief of discomfort.,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 10:12:36,1738652801,9/15/2015 10:12:08,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,moderate INFLAMMATION,343-352,413-426-435-440,PREDNISOLONE ACETATE Anti inflammatory,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 10:13:32,1738653029,9/15/2015 10:12:37,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,INFLAMMATION,352,397-413-426-435-440-454,contraindicated PREDNISOLONE ACETATE Anti inflammatory 1,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 10:22:09,1738655279,9/15/2015 10:21:49,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,INFLAMMATION Prednisolone acetate,352-413-426,352-413-426,inflammation PREDNISOLONE ACETATE,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659477,9/15/2015 10:26:34,1738656435,9/15/2015 10:24:44,false,points4rewards,1,28703583,USA,,,184.53.33.153,352,413,,,364,433,INFLAMMATION,PREDNISOLONE ACETATE,INFLAMMATION Prednisolone acetate Anti inflammatory 1 gtt tid qid Relief of discomfort.,352-413-426-435-440-454-456-460-464-469-479-476,343-352-365-371-388-394-397-413-426-454-379,moderate inflammation where topical steroids might be contraindicated PREDNISOLONE ACETATE 1,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort.,352,413 426,352,413,364,433,-1,RO-may_treat,820040,Agent  Mechanism of Action  Dosage  Benefits  Side Effects  Notes Diclofenac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Ketorolac  Nonsteroidal anti-inflammatory  1 gtt qid  Anti-inflammatory  Corneal toxicity  Reserve for moderate inflammation where topical steroids might be contraindicated Prednisolone acetate  Anti-inflammatory  1 gtt tid-qid  Relief of discomfort,inflammation,Prednisolone acetate
788659478,9/15/2015 12:38:03,1738702646,9/15/2015 12:37:28,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,Some SEIZURES occurred in patients,0-5-14-23-26,26-35-38-43-53,patients in whom MAGNESIUM SULFATE,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 13:53:30,1738725161,9/15/2015 13:52:56,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,Some SEIZURES occurred,0-5-14,26-35-38-43-53-61-68-73-80-92,patients in whom MAGNESIUM SULFATE levels were in therapeutic range.,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:02:49,1738727442,9/15/2015 14:02:36,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,SEIZURES,5,43-53,MAGNESIUM SULFATE,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:13:43,1738730216,9/15/2015 14:12:46,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,SEIZURES,5,43-53,MAGNESIUM SULFATE,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:15:12,1738730634,9/15/2015 14:14:57,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,SEIZURES,5,43-53,MAGNESIUM SULFATE,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:23:10,1738733283,9/15/2015 14:21:50,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,SEIZURES,5,43-53-61,MAGNESIUM SULFATE levels,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:36:47,1738736735,9/15/2015 14:36:37,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,SEIZURES,5,43-53,MAGNESIUM SULFATE,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:41:17,1738737981,9/15/2015 14:40:52,false,elite,1,30782237,GBR,H9,London,164.143.240.34,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,Some SEIZURES occurred in patients,0-5-14-23-26,26-35-38-43-53-61-68-73,patients in whom MAGNESIUM SULFATE levels were in,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:41:22,1738738001,9/15/2015 14:40:50,false,coinworker,1,20231698,USA,OR,,172.56.33.130,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,SEIZURES,5,43-53,MAGNESIUM SULFATE,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659478,9/15/2015 14:51:05,1738740936,9/15/2015 14:50:22,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,5,43,,,13,60,SEIZURES,MAGNESIUM SULFATE,SEIZURES,5,43-53-61,MAGNESIUM SULFATE levels,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range.,5,43 53,5,43,13,60,-1,RO-may_prevent,820366,Some seizures occurred in patients in whom magnesium sulfate levels were in the therapeutic range,seizures,magnesium sulfate
788659479,9/15/2015 11:08:46,1738666451,9/15/2015 11:08:33,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,83,27,,,87,38,PAIN,AMETHOCAINE,at reducing the PAIN of heel prick and peripherally inserted central catheters.,67-70-79-83-88-91-96-102-106-119-128-136,3-7-16-27-39-43-49-55,the neonatal population AMETHOCAINE was found to ineffective,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 11:11:02,1738666979,9/15/2015 11:10:42,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,83,27,,,87,38,PAIN,AMETHOCAINE,PAIN,83,27,AMETHOCAINE,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 11:26:37,1738674884,9/15/2015 11:26:17,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,83,27,,,87,38,PAIN,AMETHOCAINE,PAIN,83,27,AMETHOCAINE,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 11:32:57,1738678220,9/15/2015 11:30:04,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,83,27,,,87,38,PAIN,AMETHOCAINE,PAIN of heel prick,83-88-96-91,7-16-27,neonatal population AMETHOCAINE,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 11:34:25,1738678801,9/15/2015 11:31:28,false,elite,1,31883685,GBR,,,79.66.254.237,83,27,,,87,38,PAIN,AMETHOCAINE,PAIN,83,27,AMETHOCAINE,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 11:49:30,1738685630,9/15/2015 11:49:05,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,83,27,,,87,38,PAIN,AMETHOCAINE,PAIN,83,27,AMETHOCAINE,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 12:19:13,1738696245,9/15/2015 12:17:37,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,83,27,,,87,38,PAIN,AMETHOCAINE,at reducing the PAIN,67-70-79-83,3-7-16-27,the neonatal population AMETHOCAINE,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 12:38:29,1738702824,9/15/2015 12:38:22,false,neodev,1,33701549,USA,CA,San Jose,23.27.248.252,83,27,,,87,38,PAIN,AMETHOCAINE,neonatal found at reducing the PAIN of heel prick catheters.,7-43-67-70-79-83-88-91-96-136,3-7-16-27-39-43-49-83-102,the neonatal population AMETHOCAINE was found to pain and,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 12:54:25,1738707070,9/15/2015 12:54:12,false,zoombucks,1,4711962,CAN,ON,Markham,174.88.29.138,83,27,,,87,38,PAIN,AMETHOCAINE,ineffective at reducing the PAIN of heel prick,67-70-79-83-88-91-96-55,3-7-16-27-39-43-49-55,the neonatal population AMETHOCAINE was found to ineffective,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659479,9/15/2015 13:12:47,1738711940,9/15/2015 13:12:39,false,neodev,1,30581619,USA,CA,San Jose,50.118.172.208,83,27,,,87,38,PAIN,AMETHOCAINE,was at reducing the PAIN of heel prick,67-70-79-83-88-91-96-39,3-7-16-27-39-43-49-55,the neonatal population AMETHOCAINE was found to ineffective,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters.,83,27,83,27,87,38,-1,RO-may_prevent,820298,In the neonatal population amethocaine was found to be ineffective at reducing the pain of heel prick and peripherally inserted central catheters,pain,amethocaine
788659480,9/15/2015 09:13:41,1738637213,9/15/2015 09:13:25,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 09:14:52,1738637416,9/15/2015 09:14:31,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA receive 600 mg chloroquine phosphate,17-25-33-37-40-52,17-25-33-40-52,malaria receive 600 CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 09:17:08,1738637784,9/15/2015 09:16:22,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,All persons with MALARIA receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,0-4-12-17-25-33-37-40-52-62-65-69-76-81-84-88-90-103-107-115-119-122-126-130-132-136-140-143-146-150,0-4-12-17-25-33-37-40-52-62-65-69-76-81-84-88-90-103-107-115-119-122-126-130-132-136-140-143-146-150,All persons with malaria receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 09:22:28,1738638690,9/15/2015 09:22:09,false,neodev,1,20306047,GBR,,,80.41.0.252,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 09:33:31,1738641541,9/15/2015 09:33:18,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 09:41:36,1738644349,9/15/2015 09:41:13,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 09:51:43,1738647061,9/15/2015 09:51:24,false,neodev,1,33758777,USA,,,38.95.108.251,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 10:00:20,1738649230,9/15/2015 09:59:53,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 10:00:21,1738649231,9/15/2015 09:59:08,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659480,9/15/2015 10:04:14,1738650422,9/15/2015 10:02:49,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,17,40,,,24,61,MALARIA,CHLOROQUINE PHOSPHATE,MALARIA,17,40-52,CHLOROQUINE PHOSPHATE,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,17,40 52,17,40,24,61,-1,RO-may_prevent,820352,All persons with malaria receive 600 mg chloroquine phosphate at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2,malaria,chloroquine phosphate
788659481,9/15/2015 09:15:35,1738637551,9/15/2015 09:15:11,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION and salt loading in SW,43-55-59-64-72-75,43-55-59-64-72-75,dehydration and SALT loading in SW,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 09:22:50,1738638825,9/15/2015 09:22:14,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,43,59,,,54,63,DEHYDRATION,SALT,UII appears to be more important to combat DEHYDRATION and salt loading in SW than the hemodilution faced in FW.,0-4-12-15-18-23-33-36-43-55-59-64-72-75-78-83-87-100-106-109,0-4-12-15-18-23-33-36-43-55-59-64-72-75-78-83-87-100-106-109,UII appears to be more important to combat dehydration and SALT loading in SW than the hemodilution faced in FW.,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 09:24:36,1738639240,9/15/2015 09:24:21,false,neodev,1,20306047,GBR,,,80.41.0.252,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION,43,59,SALT,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 09:35:16,1738642167,9/15/2015 09:35:02,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION,43,59-64,SALT loading,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 09:45:20,1738645381,9/15/2015 09:44:46,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION salt loading hemodilution,43-59-64-87,43-59-64-72-75,dehydration SALT loading in SW,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 10:01:45,1738649657,9/15/2015 10:01:31,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION and salt - loading,43-55-59-63-64,43-55-59-64,dehydration and SALT loading,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 10:05:51,1738650848,9/15/2015 10:04:50,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION,43,59-64,SALT loading,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 10:08:05,1738651447,9/15/2015 10:07:45,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION and salt loading,43-55-59-64,43-55-59-64,dehydration and SALT loading,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 10:18:51,1738654406,9/15/2015 10:18:36,false,gifthunterclub,1,30901412,GBR,H9,London,77.89.149.62,43,59,,,54,63,DEHYDRATION,SALT,UII important to combat DEHYDRATION and salt loading,23-33-36-43-55-59-64-0,36-43-55-59-64-72-75-0,UII combat dehydration and SALT loading in SW,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659481,9/15/2015 10:20:01,1738654742,9/15/2015 10:19:29,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,43,59,,,54,63,DEHYDRATION,SALT,DEHYDRATION salt,43-59,43-59,dehydration SALT,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW.,43,59,43,59,54,63,-1,RO-may_prevent,820247,UII appears to be more important to combat dehydration and salt-loading in SW than the hemodilution faced in FW,dehydration,salt
788659482,9/15/2015 10:27:51,1738656694,9/15/2015 10:27:36,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,Amphotericin B MYCOSES;,0-71-13,0-13-71,AMPHOTERICIN B mycoses;,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 10:34:58,1738658417,9/15/2015 10:34:42,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,MYCOSES;,71,0-13,AMPHOTERICIN B,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 10:57:48,1738663922,9/15/2015 10:57:30,false,neodev,1,33758777,USA,,,38.95.108.251,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,MYCOSES;,71,0-13,AMPHOTERICIN B,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 11:05:01,1738665551,9/15/2015 11:04:42,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,"classical deep seated MYCOSES; frequently, the drug used empiric treatment candida",49-59-64-71-80-92-96-104-112-120-134,0-13-15-18-21-28-33-49-59-64-71,AMPHOTERICIN B is no longer used exclusively classical deep seated mycoses;,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 11:05:27,1738665685,9/15/2015 11:05:05,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,classical deep seated MYCOSES; drug is,49-59-64-71-96-101,0-13-45-49-59-64-71,AMPHOTERICIN B for classical deep seated mycoses;,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 11:06:15,1738665816,9/15/2015 11:06:00,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,classical deep seated MYCOSES;,49-59-64-71,0-13,AMPHOTERICIN B,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 11:07:30,1738666095,9/15/2015 11:06:28,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,classical deep seated MYCOSES;,59-64-71-49,0-13,AMPHOTERICIN B,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 11:21:18,1738671814,9/15/2015 11:21:03,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,MYCOSES;,71,0-13,AMPHOTERICIN B,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 11:22:46,1738672639,9/15/2015 11:22:02,false,elite,1,31883685,GBR,,,79.66.254.237,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,MYCOSES;,71,0-13,AMPHOTERICIN B,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659482,9/15/2015 11:40:35,1738681438,9/15/2015 11:40:16,false,elite,1,33798502,USA,VA,Manassas,207.244.86.193,71,0,,,78,14,MYCOSES,AMPHOTERICIN B,"classical deep seated MYCOSES; frequently, empiric treatment",49-59-64-71-80-112-120,0-13-15-18-21-71-80,"AMPHOTERICIN B is no longer mycoses; frequently,","Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",71,0 13,71,0,78,14,-1,RO-may_prevent,820167,"Amphotericin B is no longer used exclusively for classical deep-seated mycoses; frequently, the drug is used as empiric treatment for candida and aspergillus infections",mycoses,Amphotericin B
788659483,9/15/2015 11:56:59,1738688755,9/15/2015 11:56:14,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,PRECOCIOUS PUBERTY,119-130,56-69-79-87,gonadotropin releasing hormone (GNRH),"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 12:35:24,1738701771,9/15/2015 12:34:23,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,PRECOCIOUS PUBERTY familial male,119-130-152-161,69-79-87-94,releasing hormone (GNRH) independent,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 13:44:07,1738723099,9/15/2015 13:43:24,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,(GnRH) independent (peripheral) PRECOCIOUS PUBERTY,87-94-106-119-130,56-69-79-87-94-106-119-130,gonadotropin releasing hormone (GNRH) independent (peripheral) precocious puberty,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 14:01:41,1738727058,9/15/2015 14:01:07,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,PRECOCIOUS PUBERTY,119-130,69-79-87,releasing hormone (GNRH),"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 14:09:27,1738729102,9/15/2015 14:08:09,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,PRECOCIOUS PUBERTY + familial male precocious puberty [testotoxicosis.,119-130-140-152-161-166-177-185,56-69-79-87,gonadotropin releasing hormone (GNRH),"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 14:13:25,1738730046,9/15/2015 14:13:05,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,PRECOCIOUS PUBERTY,119-130,5-87-119,Precocious (GNRH) precocious,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 14:15:55,1738730867,9/15/2015 14:14:04,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,(GnRH) independent (peripheral) PRECOCIOUS PUBERTY,87-94-106-119-130,56-69-79-87,gonadotropin releasing hormone (GNRH),"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 14:35:21,1738736305,9/15/2015 14:34:52,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,hormone (GnRH) - independent (peripheral) PRECOCIOUS PUBERTY,87-93-94-106-119-130-79,79-87-93-94-106-119-130,hormone (GNRH) - independent (peripheral) precocious puberty,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 14:38:58,1738737256,9/15/2015 14:38:46,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,(GnRH) independent (peripheral) PRECOCIOUS PUBERTY familial male,87-94-106-119-130-152-161,69-79-87-94-106-119-130,releasing hormone (GNRH) independent (peripheral) precocious puberty,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659483,9/15/2015 14:40:13,1738737599,9/15/2015 14:38:24,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,119,88,,,137,92,PRECOCIOUS PUBERTY,GNRH,PRECOCIOUS PUBERTY,119-130,56-69-79-87,gonadotropin releasing hormone (GNRH),"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis.",119 130,,119,88,137,92,-1,RO-may_treat,820002,"265  Precocious Puberty  Management of certain forms of gonadotropin releasing hormone (GnRH)-independent (peripheral) precocious puberty   +    (e.g., familial male precocious puberty [testotoxicosis",precocious puberty,GnRH
788659484,9/15/2015 14:06:41,1738728414,9/15/2015 14:06:29,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18,LEVOTHYROXINE,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 14:19:00,1738731776,9/15/2015 14:18:47,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18,LEVOTHYROXINE,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 14:42:57,1738738520,9/15/2015 14:41:12,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,0-15-18-32,Bioequivalence of LEVOTHYROXINE preparations,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 14:47:02,1738739801,9/15/2015 14:46:46,false,coinworker,1,20231698,USA,OR,,172.56.33.130,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18,LEVOTHYROXINE,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 14:57:13,1738742572,9/15/2015 14:57:00,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18,LEVOTHYROXINE,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 14:59:26,1738743258,9/15/2015 14:59:16,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18-32,LEVOTHYROXINE preparations,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 15:18:29,1738751533,9/15/2015 15:18:20,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18,LEVOTHYROXINE,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 15:26:16,1738754258,9/15/2015 15:25:39,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18,LEVOTHYROXINE,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 15:28:51,1738754970,9/15/2015 15:28:29,false,clixsense,1,32053717,GBR,,,51.174.76.80,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,Bioequivalence levothyroxine for treatment of HYPOTHYROIDISM.,0-45-49-59-62-18,0-15-18-32-45-49-62,Bioequivalence of LEVOTHYROXINE preparations for treatment hypothyroidism.,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659484,9/15/2015 15:38:33,1738757989,9/15/2015 15:38:18,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,62,18,,,76,31,HYPOTHYROIDISM,LEVOTHYROXINE,HYPOTHYROIDISM.,62,18,LEVOTHYROXINE,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism.,62,18,62,18,76,31,-1,RO-may_prevent,820342,Bioequivalence of levothyroxine preparations for treatment of hypothyroidism,hypothyroidism,levothyroxine
788659485,9/15/2015 09:17:38,1738637812,9/15/2015 09:17:18,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"persistent HYPERTENSION,",58-47,72-89-97-102-113-117,antihypertensive therapy with INDAPAMIDE and perindopril,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 09:28:32,1738640130,9/15/2015 09:27:55,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"CONCLUSION In patients  80 years of age with persistent HYPERTENSION, antihypertensive therapy with indapamide and perindopril reduced all cause mortality.",0-12-15-24-26-29-35-38-42-47-58-72-89-97-102-113-117-129-137-141-147,0-12-15-24-26-29-35-38-42-47-58-72-89-97-102-113-117-129-137-141-147,"CONCLUSION In patients  80 years of age with persistent hypertension, antihypertensive therapy with INDAPAMIDE and perindopril reduced all cause mortality.","CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 09:37:05,1738642843,9/15/2015 09:36:49,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"HYPERTENSION,",58,72-89-97-102-113-117,antihypertensive therapy with INDAPAMIDE and perindopril,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 09:48:10,1738646021,9/15/2015 09:47:45,false,neodev,1,20306047,GBR,,,80.41.0.252,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"HYPERTENSION,",58,102,INDAPAMIDE,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 09:48:29,1738646113,9/15/2015 09:47:57,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"HYPERTENSION, antihypertensive therapy",58-72-89,72-89-102-117,antihypertensive therapy INDAPAMIDE perindopril,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 10:03:30,1738650198,9/15/2015 10:03:17,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"HYPERTENSION, antihypertensive therapy",58-72-89,72-89-97-102,antihypertensive therapy with INDAPAMIDE,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 10:12:08,1738652684,9/15/2015 10:11:40,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"persistent HYPERTENSION,",47-58,102-113-117,INDAPAMIDE and perindopril,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 10:12:34,1738652802,9/15/2015 10:11:14,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"persistent HYPERTENSION,",47-58,102,INDAPAMIDE,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 10:21:49,1738655160,9/15/2015 10:21:34,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"HYPERTENSION, indapamide",58-102,58-102,"hypertension, INDAPAMIDE","CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659485,9/15/2015 10:24:39,1738656023,9/15/2015 10:23:52,false,points4rewards,1,28703583,USA,,,184.53.33.153,58,102,,,70,112,HYPERTENSION,INDAPAMIDE,"HYPERTENSION, antihypertensive therapy with indapamide and perindopril",58-72-89-97-102-113-117,47-58-102,"persistent hypertension, INDAPAMIDE","CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.",58,102,58,102,70,112,-1,RO-may_treat,820069,"CONCLUSION  In patients  80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality",hypertension,indapamide
788659486,9/15/2015 09:09:56,1738636289,9/15/2015 09:09:47,false,clixsense,1,22751911,NLD,4,Groningen,195.241.153.97,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"the treatment of GASTRIC ULCER, in comparison with",41-45-55-58-66-73-76-87,73-76-87-92-103-106,in comparison with CIMETIDINE or carbenoxolone.,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:10:32,1738636378,9/15/2015 09:09:32,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"GASTRIC ULCER, comparison with cimetidine or carbenoxolone.",58-66-76-87-92-103-106,66-73-76-87-92-103-106-58,"gastric ulcer, in comparison with CIMETIDINE or carbenoxolone.","This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:10:51,1738636490,9/15/2015 09:10:29,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"GASTRIC ULCER,",58-66,92,CIMETIDINE,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:11:30,1738636641,9/15/2015 09:09:20,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"This underlines its therapeutic value in the treatment of GASTRIC ULCER, in comparison with cimetidine or carbenoxolone.",0-5-16-20-32-38-41-45-55-58-66-73-76-87-92-103-106,0-5-16-20-32-38-41-45-55-58-73-76-87-92-103-106-66,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with CIMETIDINE or carbenoxolone.","This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:12:52,1738636975,9/15/2015 09:11:19,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"the treatment of GASTRIC ULCER, in comparison with",41-45-55-58-66-73-76-87,92,CIMETIDINE,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:19:52,1738638134,9/15/2015 09:19:07,false,neodev,1,20306047,GBR,,,80.41.0.252,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"GASTRIC ULCER,",58-66,92,CIMETIDINE,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:31:27,1738640872,9/15/2015 09:28:27,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"GASTRIC ULCER,",58-66,92,CIMETIDINE,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:35:19,1738642171,9/15/2015 09:33:32,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"GASTRIC ULCER,",58-66,92-106,CIMETIDINE carbenoxolone.,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:46:26,1738645662,9/15/2015 09:45:49,false,elite,1,28548715,USA,,,208.31.49.20,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"GASTRIC ULCER,",58-66,92,CIMETIDINE,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659486,9/15/2015 09:48:58,1738646202,9/15/2015 09:48:38,false,neodev,1,33758777,USA,,,38.95.108.251,58,92,,,71,102,GASTRIC ULCER,CIMETIDINE,"GASTRIC ULCER,",58-66,92,CIMETIDINE,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.",58 66,92,58,92,71,102,-1,RO-may_prevent,820276,"This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone",gastric ulcer,cimetidine
788659487,9/15/2015 11:12:34,1738667549,9/15/2015 11:12:12,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"BACTERIAL INFECTIONS,",173-183,107,AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 11:28:29,1738676066,9/15/2015 11:28:08,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"BACTERIAL INFECTIONS,",173-183,107,AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 11:40:02,1738681130,9/15/2015 11:39:13,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"serious BACTERIAL INFECTIONS,",165-173-183,107,AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 11:40:34,1738681417,9/15/2015 11:39:58,false,elite,1,31883685,GBR,,,79.66.254.237,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"BACTERIAL INFECTIONS,",173-183,107,AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 11:51:09,1738686356,9/15/2015 11:50:39,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"BACTERIAL INFECTIONS,",173-183,107,AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 12:23:54,1738697837,9/15/2015 12:23:06,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"serious BACTERIAL INFECTIONS,",165-173-183,88-99-104-107-122-125,ampicillin with an AMINOGLYCOSIDE is adequate,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 13:16:06,1738712814,9/15/2015 13:15:28,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"serious BACTERIAL INFECTIONS,",165-173-183,73-88-99-104-107-85,combination of ampicillin with an AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 13:32:25,1738717842,9/15/2015 13:31:35,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"serious BACTERIAL INFECTIONS,",165-173-183,88-99-107-104,ampicillin with an AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 13:56:25,1738725879,9/15/2015 13:54:55,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"BACTERIAL INFECTIONS,",173-183,107,AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659487,9/15/2015 13:58:01,1738726233,9/15/2015 13:56:48,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,173,107,,,193,121,BACTERIAL INFECTIONS,AMINOGLYCOSIDE,"BACTERIAL INFECTIONS,",173-183,88-99-104-107,ampicillin with an AMINOGLYCOSIDE,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections.",173 183,107,173,107,193,121,-1,RO-may_prevent,820303,"A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an aminoglycoside is adequate for initial treatment of these serious bacterial infections, but the combination is not optimal for the treatment of Salmonella infections",bacterial infections,aminoglycoside
788659488,9/15/2015 10:26:30,1738656424,9/15/2015 10:26:16,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,23,70,,,28,78,APNEA,CAFFEINE,APNEA caffeine,23-70,70-23,Apnea CAFFEINE,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 10:33:31,1738658075,9/15/2015 10:33:07,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,23,70,,,28,78,APNEA,CAFFEINE,Renal Impairment APNEA of Prematurity,5-11-23-29-32,70-79,CAFFEINE citrate,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 10:35:36,1738658534,9/15/2015 10:35:13,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,23,70,,,28,78,APNEA,CAFFEINE,APNEA caffeine to avoid toxicity;,23-94-97-103-70,23-70-94-97-103,Apnea CAFFEINE to avoid toxicity;,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 10:56:05,1738663632,9/15/2015 10:55:47,false,neodev,1,33758777,USA,,,38.95.108.251,23,70,,,28,78,APNEA,CAFFEINE,APNEA,23,70,CAFFEINE,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 10:56:51,1738663783,9/15/2015 10:55:43,false,points4rewards,1,28703583,USA,,,184.53.32.113,23,70,,,28,78,APNEA,CAFFEINE,APNEA Oral or IV Adjust caffeine citrate dosage to avoid toxicity;,23-51-56-59-63-70-79-87-94-97-103,23-51-56-63-70-79-59,Apnea Oral or IV Adjust CAFFEINE citrate,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 11:01:46,1738664814,9/15/2015 11:00:53,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,23,70,,,28,78,APNEA,CAFFEINE,Renal Impairment APNEA of Prematurity,5-23-29-32-11,70-79,CAFFEINE citrate,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 11:03:12,1738665120,9/15/2015 11:03:00,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,23,70,,,28,78,APNEA,CAFFEINE,115 Renal Impairment APNEA of Prematurity Oral IV Adjust caffeine citrate dosage,0-5-11-23-29-32-51-59-63-70-79-87,56-59-63-70-79-87-94-103-97,or IV Adjust CAFFEINE citrate dosage to avoid toxicity;,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 11:03:21,1738665149,9/15/2015 11:03:05,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,23,70,,,28,78,APNEA,CAFFEINE,115 Renal Impairment APNEA of Prematurity Oral caffeine with,0-5-11-23-29-32-51-117-70,56-59-63-70-79-87-94-103,or IV Adjust CAFFEINE citrate dosage to toxicity;,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 11:04:25,1738665404,9/15/2015 11:03:57,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,23,70,,,28,78,APNEA,CAFFEINE,Renal Impairment APNEA of Prematurity,5-11-23-29-32,70-79,CAFFEINE citrate,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659488,9/15/2015 11:19:37,1738670814,9/15/2015 11:16:46,false,elite,1,31883685,GBR,,,79.66.254.237,23,70,,,28,78,APNEA,CAFFEINE,Renal Impairment APNEA,5-11-23,70-79,CAFFEINE citrate,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations.,23,70,23,70,28,78,-1,RO-may_treat,820013,115  Renal Impairment  Apnea of Prematurity  >     Oral or IV  Adjust caffeine citrate dosage to avoid toxicity; use with caution and monitor serum caffeine concentrations,Apnea,caffeine
788659489,9/15/2015 10:36:17,1738658696,9/15/2015 10:35:52,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B virus DNA,300-306-316-318-324,332,HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 10:59:17,1738664260,9/15/2015 10:58:51,false,neodev,1,33758777,USA,,,38.95.108.251,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS,300-306,332,HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 11:06:16,1738665825,9/15/2015 11:06:01,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,300,332,,,315,337,SERUM HEPATITIS,HBSAG,mo before treatment and were positive for SERUM HEPATITIS B virus DNA,258-261-268-282-287-296-300-306-316-318-324-278,287-296-300-306-318-324-328-332-316,positive for serum hepatitis B virus DNA and HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 11:06:46,1738665956,9/15/2015 11:06:26,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B virus DNA and HBsAg.,300-306-316-318-324-328-332,306-316-318-324-328-332-300,serum hepatitis B virus DNA and HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 11:07:38,1738666127,9/15/2015 11:07:17,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B virus DNA,300-306-316-318-324,332,HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 11:21:17,1738671767,9/15/2015 11:20:45,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B virus DNA,300-306-316-318-324,332,HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 11:23:10,1738672810,9/15/2015 11:22:27,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B,300-306-316,332,HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 11:24:22,1738673709,9/15/2015 11:24:05,false,elite,1,31883685,GBR,,,79.66.254.237,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B,300-306-316,332,HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 11:45:56,1738683888,9/15/2015 11:45:25,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B virus,300-306-316-318,332,HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659489,9/15/2015 12:09:05,1738692284,9/15/2015 12:08:40,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,300,332,,,315,337,SERUM HEPATITIS,HBSAG,SERUM HEPATITIS B virus DNA,300-306-316-318-324,318-324-328-332,virus DNA and HBSAG.,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.",300 306,332,300,332,315,337,-1,RO-may_prevent,820151,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg",serum hepatitis,HBsAg
788659490,9/15/2015 11:56:13,1738688433,9/15/2015 11:55:37,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,94,51,,,105,56,HEPATITIS B,HBSAG,HEPATITIS B virus associated DNA polymerase,94-104-106-112-123-127,22-32-34-42-50,"hepatitis B surface antigen (HBSAG),","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 12:34:22,1738701322,9/15/2015 12:33:36,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,94,51,,,105,56,HEPATITIS B,HBSAG,"antigen (HBeAg), and HEPATITIS B",73-81-90-94-104,34-42-50-59,"surface antigen (HBSAG), hepatitis","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 13:43:24,1738722919,9/15/2015 13:42:28,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,94,51,,,105,56,HEPATITIS B,HBSAG,"hepatitis B antigen (HBeAg), and HEPATITIS B virus associated DNA polymerase (DNA p)",59-69-73-81-90-94-104-106-112-123-127-138-143,9-18-22-32-34-42-50,"positive for hepatitis B surface antigen (HBSAG),","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 14:01:06,1738726900,9/15/2015 14:00:40,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,94,51,,,105,56,HEPATITIS B,HBSAG,HEPATITIS B virus associated DNA,94-104-106-112-123,50-59-69-71,"(HBSAG), hepatitis B e","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 14:08:08,1738728794,9/15/2015 14:06:51,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,94,51,,,105,56,HEPATITIS B,HBSAG,HEPATITIS B virus,94-104-106,22-34-42-50-32,"hepatitis B surface antigen (HBSAG),","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 14:13:04,1738729978,9/15/2015 14:12:38,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,94,51,,,105,56,HEPATITIS B,HBSAG,HEPATITIS B,94-104,50,"(HBSAG),","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 14:14:03,1738730274,9/15/2015 14:12:25,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,94,51,,,105,56,HEPATITIS B,HBSAG,"antigen (HBeAg), and HEPATITIS B virus associated DNA",73-81-90-94-104-106-112-123,34-42-50-59-69-71-73-81,"surface antigen (HBSAG), hepatitis B e antigen (HBeAg),","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 14:34:51,1738736214,9/15/2015 14:34:31,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,94,51,,,105,56,HEPATITIS B,HBSAG,HEPATITIS B virus associated DNA polymerase (DNA - p),94-104-106-112-123-127-138-143-142,22-32-34-42-50,"hepatitis B surface antigen (HBSAG),","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 14:38:24,1738737113,9/15/2015 14:36:03,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,94,51,,,105,56,HEPATITIS B,HBSAG,HEPATITIS B,94-104,22-32-34-50-42,"hepatitis B surface antigen (HBSAG),","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659490,9/15/2015 14:38:46,1738737184,9/15/2015 14:38:32,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,94,51,,,105,56,HEPATITIS B,HBSAG,"(HBeAg), and HEPATITIS B virus associated DNA polymerase",81-90-94-104-106-112-123-127,34-42-50-59-69-71,"surface antigen (HBSAG), hepatitis B e","All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry.",94 104,,94,51,105,56,-1,RO-may_prevent,820331,"All were positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B virus-associated DNA polymerase (DNA-p) for at least 6 months before entry",hepatitis B,HBsAg
788659491,9/15/2015 09:14:46,1738637389,9/15/2015 09:14:27,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,158,218,,,170,228,INFLAMMATION,PREDNISONE,"airway INFLAMMATION,",151-158,218,PREDNISONE.,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 09:20:30,1738638233,9/15/2015 09:19:36,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,158,218,,,170,228,INFLAMMATION,PREDNISONE,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway INFLAMMATION, we investigated whether they are inhibited by prednisone.",0-3-13-21-26-36-46-50-54-65-74-77-84-99-107-110-118-131-137-141-148-151-158-172-175-188-196-201-205-218-215,0-3-13-21-26-36-46-50-54-65-74-77-84-99-107-110-118-131-137-141-148-151-158-172-175-188-201-205-215-218-196,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by PREDNISONE.","To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 09:23:42,1738639016,9/15/2015 09:23:22,false,neodev,1,20306047,GBR,,,80.41.0.252,158,218,,,170,228,INFLAMMATION,PREDNISONE,"INFLAMMATION,",158,218,PREDNISONE.,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 09:34:39,1738641922,9/15/2015 09:34:23,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,158,218,,,170,228,INFLAMMATION,PREDNISONE,"airway INFLAMMATION,",158-151,218,PREDNISONE.,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 09:43:39,1738644984,9/15/2015 09:42:56,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,158,218,,,170,228,INFLAMMATION,PREDNISONE,"toluene diisocyanate (TDI) INFLAMMATION,",110-118-158-131,110-118-131-218,toluene diisocyanate (TDI) PREDNISONE.,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 10:01:14,1738649475,9/15/2015 10:01:03,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,158,218,,,170,228,INFLAMMATION,PREDNISONE,"INFLAMMATION,",158,218,PREDNISONE.,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 10:03:37,1738650240,9/15/2015 10:02:29,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,158,218,,,170,228,INFLAMMATION,PREDNISONE,"airway INFLAMMATION,",151-158,218,PREDNISONE.,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 10:07:14,1738651216,9/15/2015 10:06:37,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,158,218,,,170,228,INFLAMMATION,PREDNISONE,"airway INFLAMMATION,",151-158,218,PREDNISONE.,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 10:18:17,1738654306,9/15/2015 10:17:36,false,gifthunterclub,1,30901412,GBR,H9,London,77.89.149.62,158,218,,,170,228,INFLAMMATION,PREDNISONE,"toluene diisocyanate linked to airway INFLAMMATION,",110-141-148-151-158-118,151-201-205-215-218-158,"airway inflammation, are inhibited by PREDNISONE.","To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659491,9/15/2015 10:18:50,1738654400,9/15/2015 10:16:43,false,points4rewards,1,28703583,USA,,,184.53.33.153,158,218,,,170,228,INFLAMMATION,PREDNISONE,"INFLAMMATION, we investigated whether they are inhibited by prednisone.",158-172-175-188-196-201-205-215-218,131-137-141-151-158-218-148,"(TDI) are linked to airway inflammation, PREDNISONE.","To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone.",158,218,158,218,170,228,-1,RO-may_treat,820101,"To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to airway inflammation, we investigated whether they are inhibited by prednisone",inflammation,prednisone
788659492,9/15/2015 09:13:03,1738637016,9/15/2015 09:12:39,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY,47-56,14,IRBESARTAN,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:14:00,1738637246,9/15/2015 09:13:11,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY type 2 diabetes.,47-56-85-90-92,14-47-56-85-90-92,IRBESARTAN diabetic nephropathy type 2 diabetes.,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:14:55,1738637425,9/15/2015 09:14:32,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,The effect of irbesartan on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,0-4-11-14-25-28-32-44-47-56-68-71-80-85-90-92,0-4-11-14-25-28-32-44-47-56-68-71-80-85-90-92,The effect of IRBESARTAN on the development of diabetic nephropathy in patients with type 2 diabetes.,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:16:40,1738637718,9/15/2015 09:16:17,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,the development of DIABETIC NEPHROPATHY in patients with,28-32-44-47-56-68-71-80,14,IRBESARTAN,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:21:49,1738638531,9/15/2015 09:21:23,false,neodev,1,20306047,GBR,,,80.41.0.252,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY,47-56,14,IRBESARTAN,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:33:01,1738641347,9/15/2015 09:32:46,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY,47-56,14,IRBESARTAN,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:40:22,1738643999,9/15/2015 09:39:49,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY type 2 diabetes.,47-56-85-90-92,14-47-56-85-90-92,IRBESARTAN diabetic nephropathy type 2 diabetes.,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:51:00,1738646867,9/15/2015 09:50:34,false,neodev,1,33758777,USA,,,38.95.108.251,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY,47-56,14,IRBESARTAN,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:57:57,1738648683,9/15/2015 09:57:19,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY,47-56,14,IRBESARTAN,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659492,9/15/2015 09:59:37,1738649038,9/15/2015 09:59:22,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,47,14,,,67,24,DIABETIC NEPHROPATHY,IRBESARTAN,DIABETIC NEPHROPATHY type 2 diabetes.,47-56-85-90-92,14,IRBESARTAN,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,47 56,14,47,14,67,24,-1,RO-may_treat,820014,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,diabetic nephropathy,irbesartan
788659493,9/15/2015 09:12:11,1738636822,9/15/2015 09:11:54,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,PREECLAMPSIA,86,30-40,MAGNESIUM SULFATE,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:12:51,1738636970,9/15/2015 09:12:13,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,magnesium sulfate for seizure prophylaxis with PREECLAMPSIA,30-40-48-52-60-81-86,30-40-48-52-60-86-81,MAGNESIUM SULFATE for seizure prophylaxis with preeclampsia,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:14:03,1738637251,9/15/2015 09:13:27,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,the routine use of magnesium sulfate for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.,11-15-23-27-30-40-48-52-60-72-75-81-86-99-102-105-115-125,11-15-23-27-30-40-48-52-60-72-75-81-86-99-102-105-115-125,the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:15:44,1738637560,9/15/2015 09:15:20,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,in women with PREECLAMPSIA is an ingrained,72-75-81-86-99-102-105,30-40,MAGNESIUM SULFATE,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:20:57,1738638360,9/15/2015 09:20:45,false,neodev,1,20306047,GBR,,,80.41.0.252,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,PREECLAMPSIA,86,30-40,MAGNESIUM SULFATE,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:32:30,1738641182,9/15/2015 09:32:16,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,PREECLAMPSIA,86,30-40,MAGNESIUM SULFATE,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:39:24,1738643726,9/15/2015 09:38:44,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,seizure prophylaxis PREECLAMPSIA,52-86-60,30-40-52-60,MAGNESIUM SULFATE seizure prophylaxis,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:50:13,1738646592,9/15/2015 09:49:55,false,neodev,1,33758777,USA,,,38.95.108.251,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,PREECLAMPSIA,86,30-40,MAGNESIUM SULFATE,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:56:07,1738648259,9/15/2015 09:54:22,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,PREECLAMPSIA,86,30-40,MAGNESIUM SULFATE,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659493,9/15/2015 09:58:43,1738648863,9/15/2015 09:58:29,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,86,30,,,98,47,PREECLAMPSIA,MAGNESIUM SULFATE,PREECLAMPSIA,86,30-40-52-60,MAGNESIUM SULFATE seizure prophylaxis,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice.",86,30 40,86,30,98,47,-1,RO-may_treat,820135,"In the US, the routine use of magnesium sulfate for seizure prophylaxis in women with preeclampsia is an ingrained obstetric practice",preeclampsia,magnesium sulfate
788659494,9/15/2015 12:39:09,1738703052,9/15/2015 12:38:38,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,80,39,,,91,44,HEPATITIS B,HBSAG,reactivation of HEPATITIS B was unlikely,64-77-80-90-92-96,22-30-38-46-50,"surface antigen (HBSAG) was positive,","The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 13:56:18,1738725864,9/15/2015 13:55:06,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,80,39,,,91,44,HEPATITIS B,HBSAG,reactivation of HEPATITIS B was unlikely,64-77-80-90-92-96,4-10-20-22-30-38-46-50,"serum hepatitis B surface antigen (HBSAG) was positive,","The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 14:03:30,1738727615,9/15/2015 14:03:08,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,80,39,,,91,44,HEPATITIS B,HBSAG,HEPATITIS B,80-90,22-30-38,surface antigen (HBSAG),"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 14:15:47,1738730822,9/15/2015 14:15:31,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,80,39,,,91,44,HEPATITIS B,HBSAG,HEPATITIS B,80-90,38,(HBSAG),"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 14:16:16,1738730992,9/15/2015 14:15:20,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,80,39,,,91,44,HEPATITIS B,HBSAG,HEPATITIS B virus,80-90-185,10-20-22-30-38,hepatitis B surface antigen (HBSAG),"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 14:26:07,1738734039,9/15/2015 14:24:31,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,80,39,,,91,44,HEPATITIS B,HBSAG,reactivation of HEPATITIS B,64-77-80-90,22-30-38,surface antigen (HBSAG),"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 14:42:58,1738738521,9/15/2015 14:42:24,false,coinworker,1,20231698,USA,OR,,172.56.33.130,80,39,,,91,44,HEPATITIS B,HBSAG,HEPATITIS B,80-90,10-20-22-30-38,hepatitis B surface antigen (HBSAG),"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 14:52:08,1738741208,9/15/2015 14:51:46,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,80,39,,,91,44,HEPATITIS B,HBSAG,HEPATITIS B,80-90,10-22-30-38-20,hepatitis B surface antigen (HBSAG),"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 14:56:18,1738742275,9/15/2015 14:55:58,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,80,39,,,91,44,HEPATITIS B,HBSAG,HEPATITIS B,80-90,10-20-22-30-38,hepatitis B surface antigen (HBSAG),"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659494,9/15/2015 15:11:43,1738748245,9/15/2015 15:11:28,false,superrewards,1,33199643,USA,WI,La Crosse,138.49.1.28,80,39,,,91,44,HEPATITIS B,HBSAG,but reactivation of HEPATITIS B was unlikely in,60-64-77-80-90-92-96-105,10-22-30-38-46-50-60-20,"hepatitis B surface antigen (HBSAG) was positive, but","The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",80 90,,80,39,91,44,-1,RO-may_prevent,820313,"The serum hepatitis B surface antigen (HBsAg) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum hepatitis B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue",hepatitis B,HBsAg
788659495,9/15/2015 14:04:15,1738727763,9/15/2015 14:04:01,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,25,ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 14:16:38,1738731078,9/15/2015 14:16:24,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,25,ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 14:19:12,1738731817,9/15/2015 14:18:25,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,4-13-22-25,pain relieved by ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 14:29:53,1738734981,9/15/2015 14:28:30,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,25,ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 14:40:10,1738737582,9/15/2015 14:39:57,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,4,25,,,8,32,PAIN,ASPIRIN,The PAIN was relieved by Aspirin,0-4-9-13-22-25,13-22-25-33-36-40-46,relieved by ASPIRIN in six cases only.,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 14:44:05,1738738927,9/15/2015 14:43:47,false,coinworker,1,20231698,USA,OR,,172.56.33.130,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,25,ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 14:54:29,1738741768,9/15/2015 14:53:29,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,25,ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 14:57:05,1738742495,9/15/2015 14:56:52,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,25,ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 15:16:39,1738750544,9/15/2015 15:16:28,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,4,25,,,8,32,PAIN,ASPIRIN,PAIN,4,25,ASPIRIN,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659495,9/15/2015 15:19:01,1738751825,9/15/2015 15:17:42,false,clixsense,1,32053717,GBR,,,51.174.76.80,4,25,,,8,32,PAIN,ASPIRIN,The PAIN was relieved by,0-4-9-13-22,9-13-22-25-33-36-40,was relieved by ASPIRIN in six cases,The pain was relieved by Aspirin in six cases only.,4,25,4,25,8,32,-1,RO-may_prevent,820241,The pain was relieved by Aspirin in six cases only,pain,Aspirin
788659496,9/15/2015 14:21:22,1738732690,9/15/2015 14:21:00,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,atopic BRONCHIAL ASTHMA,140-150-133,80,NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 14:49:32,1738740514,9/15/2015 14:49:12,false,coinworker,1,20231698,USA,OR,,172.56.33.130,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,atopic BRONCHIAL ASTHMA,133-140-150,72-80,(sodium NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 15:03:55,1738744844,9/15/2015 15:03:32,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,atopic BRONCHIAL ASTHMA,133-140-150,72-80,(sodium NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 15:34:39,1738756723,9/15/2015 15:34:06,false,clixsense,1,32053717,GBR,,,51.174.76.80,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,atopic BRONCHIAL ASTHMA complicated by obstructive bronchitis.,133-140-150-157-169-172-184,72-80,(sodium NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 15:41:04,1738758653,9/15/2015 15:40:45,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,atopic BRONCHIAL ASTHMA,133-140-150,72-80,(sodium NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 15:44:59,1738759833,9/15/2015 15:44:07,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,BRONCHIAL ASTHMA,140-150,80,NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 16:01:16,1738766175,9/15/2015 16:00:50,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,BRONCHIAL ASTHMA,140-150,80,NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 16:03:00,1738766933,9/15/2015 16:02:29,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,atopic BRONCHIAL ASTHMA,133-140-150,72-80,(sodium NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 16:03:44,1738767226,9/15/2015 16:03:11,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,BRONCHIAL ASTHMA,140-150,72-80,(sodium NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659496,9/15/2015 16:03:57,1738767287,9/15/2015 16:03:39,false,instagc,1,33058612,USA,IL,Glenview,162.229.106.229,140,80,,,156,90,BRONCHIAL ASTHMA,NEDOCROMIL,atopic BRONCHIAL ASTHMA,133-140-150,72-80-65,tailed (sodium NEDOCROMIL),"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis.",140 150,80,140,80,156,90,-1,RO-may_prevent,820257,"As shown by clinical, allergological and immunological findings, tailed (sodium nedocromil) compared to intal is more active against atopic bronchial asthma complicated by obstructive bronchitis",bronchial asthma,nedocromil
788659497,9/15/2015 11:31:49,1738677829,9/15/2015 11:31:31,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,96,137,,,101,147,HIVES,LORATADINE,"HIVES),",96,137,LORATADINE,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 11:54:38,1738687908,9/15/2015 11:54:14,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,96,137,,,101,147,HIVES,LORATADINE,"HIVES),",96,137,LORATADINE,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 12:31:35,1738700291,9/15/2015 12:30:31,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,96,137,,,101,147,HIVES,LORATADINE,"idiopathic urticaria (e.g., HIVES),",68-79-89-96,118-132-137-148-153-158-167,understanding that LORATADINE does not prevent hives.,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 13:40:33,1738722271,9/15/2015 13:38:49,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,96,137,,,101,147,HIVES,LORATADINE,"chronic idiopathic urticaria (e.g., HIVES),",60-68-79-89-96,137-148-153-158-167,LORATADINE does not prevent hives.,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 13:59:59,1738726604,9/15/2015 13:59:41,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,96,137,,,101,147,HIVES,LORATADINE,"idiopathic urticaria (e.g., HIVES),",68-79-89-96,137,LORATADINE,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 14:02:53,1738727459,9/15/2015 14:02:17,false,vivatic,1,15201808,GBR,,,87.112.19.240,96,137,,,101,147,HIVES,LORATADINE,"idiopathic urticaria (e.g., HIVES),",68-79-89-96,137,LORATADINE,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 14:04:58,1738727991,9/15/2015 14:04:14,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,96,137,,,101,147,HIVES,LORATADINE,"idiopathic urticaria (e.g., HIVES),",68-79-89-96,137,LORATADINE,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 14:09:37,1738729122,9/15/2015 14:09:01,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,96,137,,,101,147,HIVES,LORATADINE,"idiopathic urticaria (e.g., HIVES),",68-79-89-96,137,LORATADINE,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 14:11:56,1738729713,9/15/2015 14:11:38,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,96,137,,,101,147,HIVES,LORATADINE,"HIVES),",96,137-148,LORATADINE does,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659497,9/15/2015 14:35:38,1738736438,9/15/2015 14:35:21,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,96,137,,,101,147,HIVES,LORATADINE,"HIVES),",96,137,LORATADINE,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives.",96,137,96,137,101,147,-1,RO-may_treat,820082,"70 ,   73 ,   76   For  self-medication  for management of chronic idiopathic urticaria (e.g., hives), importance of understanding that loratadine does not  prevent  hives",hives,loratadine
788659498,9/15/2015 11:09:20,1738666627,9/15/2015 11:09:11,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,Rare cases of HEPATITIS B continue to occur despite donor,0-5-11-14-24-26-35-38-44-52,58-68-72-76-86-88-96-105-109-114-118-125,"screening for the HEPATITIS B SURFACE ANTIGEN, but most are of non","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 11:12:11,1738667435,9/15/2015 11:11:50,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,HEPATITIS B,14-24,76-86-88-96,"HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 11:28:07,1738675920,9/15/2015 11:27:48,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,HEPATITIS B,14-24,76-86-88-96-118,"HEPATITIS B SURFACE ANTIGEN, of","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 11:39:10,1738680828,9/15/2015 11:36:57,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,HEPATITIS B,14-24,76-86-88-96,"HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 11:39:47,1738681029,9/15/2015 11:39:24,false,elite,1,31883685,GBR,,,79.66.254.237,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,HEPATITIS B,14-24,76-86-88-96,"HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 11:50:38,1738686156,9/15/2015 11:50:18,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,HEPATITIS B,14-24,76-86-88-96,"HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 12:23:06,1738697546,9/15/2015 12:21:05,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,Rare cases of HEPATITIS B,0-5-11-14-24,58-68-72-76-86-88-96,"screening for the HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 13:15:27,1738712661,9/15/2015 13:15:02,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,HEPATITIS B,14-24,76-86-88-96,"HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 13:31:34,1738717651,9/15/2015 13:31:10,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,Rare cases of HEPATITIS B occur,0-5-14-24-38-11,58-68-76-86-88-96,"screening for HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659498,9/15/2015 13:54:54,1738725554,9/15/2015 13:53:40,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,14,76,,,25,103,HEPATITIS B,HEPATITIS B SURFACE ANTIGEN,HEPATITIS B,14-24,76-86-88-96,"HEPATITIS B SURFACE ANTIGEN,","Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type.",14 24,76 86 88 96,14,76,25,103,-1,RO-may_prevent,820155,"Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type",hepatitis B,hepatitis B surface antigen
788659499,9/15/2015 11:31:30,1738677685,9/15/2015 11:30:59,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,primary HYPOTHYROIDISM,55-63,135,THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 11:45:14,1738683568,9/15/2015 11:44:38,false,elite,1,31883685,GBR,,,79.66.254.237,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,63,135,THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 11:54:13,1738687770,9/15/2015 11:53:55,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,primary HYPOTHYROIDISM,55-63,135,THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 12:30:30,1738699875,9/15/2015 12:29:43,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,associated with primary HYPOTHYROIDISM,39-50-55-63,108-120-130-135-145-148,replacement treatment with THYROXINE is reported.,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 13:38:49,1738721735,9/15/2015 13:37:34,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,hypertrichosis associated with primary HYPOTHYROIDISM,24-39-50-55-63,120-130-135-108,replacement treatment with THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 13:59:41,1738726537,9/15/2015 13:59:27,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,primary HYPOTHYROIDISM,55-63,135,THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 14:02:16,1738727246,9/15/2015 14:01:58,false,vivatic,1,15201808,GBR,,,87.112.19.240,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,63,135,THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 14:04:13,1738727760,9/15/2015 14:02:56,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,63,63-120-135-55,primary hypothyroidism treatment THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 14:05:20,1738728069,9/15/2015 14:04:20,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,primary HYPOTHYROIDISM,55-63,120-130-135,treatment with THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659499,9/15/2015 14:14:16,1738730364,9/15/2015 14:13:57,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,63,135,,,77,144,HYPOTHYROIDISM,THYROXINE,HYPOTHYROIDISM,63,135,THYROXINE,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported.,63,135,63,135,77,144,-1,RO-may_prevent,820254,A 10 year old girl with hypertrichosis associated with primary hypothyroidism that resolved after 6 months' replacement treatment with thyroxine is reported,hypothyroidism,thyroxine
788659500,9/15/2015 09:14:26,1738637309,9/15/2015 09:14:00,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,184,199,,,189,206,FEVER,ASPIRIN,FEVER,184,199,ASPIRIN,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 09:16:19,1738637646,9/15/2015 09:15:39,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,184,199,,,189,206,FEVER,ASPIRIN,"fever (Gr V); fasting and FEVER (Gr VI); aspirin fasting (Gr VII); aspirin, fever fasting (Gr VIII.",158-164-168-172-180-184-190-194-199-211-219-223-233-242-252-260-264,146-184-190-194-199-207-211-219-223-233-242-252-260-264-66,"aspirin aspirin fever (Gr VI); ASPIRIN and fasting (Gr VII); aspirin, fever fasting (Gr VIII.","Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 09:19:35,1738638109,9/15/2015 09:18:12,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,184,199,,,189,206,FEVER,ASPIRIN,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and FEVER (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",0-7-18-22-27-30-36-43-50-58-62-66-74-89-94-98-103-111-116-120-126-132-137-141-146-154-158-164-168-172-180-184-190-194-199-207-211-219-223-229-233-242-248-252-260-264,0-7-18-22-27-30-36-43-50-58-62-66-74-89-94-98-103-111-116-120-126-132-137-141-146-154-158-164-168-172-180-184-190-194-199-207-211-219-223-229-233-242-248-252-260-264,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); ASPIRIN and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.","Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 09:23:21,1738638961,9/15/2015 09:23:02,false,neodev,1,20306047,GBR,,,80.41.0.252,184,199,,,189,206,FEVER,ASPIRIN,FEVER,184,199,ASPIRIN,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 09:34:21,1738641804,9/15/2015 09:33:56,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,184,199,,,189,206,FEVER,ASPIRIN,FEVER (Gr VI);,184-190-194,199-207-211-223-219,ASPIRIN and fasting (Gr VII);,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 09:42:55,1738644696,9/15/2015 09:42:28,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,184,199,,,189,206,FEVER,ASPIRIN,FEVER,184,199,ASPIRIN,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 10:01:01,1738649411,9/15/2015 10:00:38,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,184,199,,,189,206,FEVER,ASPIRIN,V); FEVER,168-184,199,ASPIRIN,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 10:02:27,1738649822,9/15/2015 10:01:53,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,184,199,,,189,206,FEVER,ASPIRIN,FEVER,184,199,ASPIRIN,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 10:06:37,1738651036,9/15/2015 10:06:08,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,184,199,,,189,206,FEVER,ASPIRIN,fasting and FEVER,172-180-184,199,ASPIRIN,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659500,9/15/2015 10:16:38,1738653943,9/15/2015 10:14:03,false,points4rewards,1,28703583,USA,,,184.53.33.153,184,199,,,189,206,FEVER,ASPIRIN,aspirin administration only FEVER,66-74-184-89,184-199-207-211,fever ASPIRIN and fasting,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII.",184,199,184,199,189,206,-1,RO-may_treat,820100,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and aspirin, fever and fasting (Gr VIII",fever,aspirin
788659501,9/15/2015 14:04:38,1738727884,9/15/2015 14:04:15,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,Q wave MYOCARDIAL INFARCTION;,380-382-387-398,455-464,Standard HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 14:17:01,1738731224,9/15/2015 14:16:43,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION;,387-398,464,HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 14:20:23,1738732353,9/15/2015 14:19:13,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION;,387-398,464-495-508-512-522-529,HEPARIN; Subcutaneous low molecular weight heparin;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 14:31:07,1738735299,9/15/2015 14:29:59,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,Q wave MYOCARDIAL INFARCTION;,380-382-387-398,455-464,Standard HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 14:44:38,1738739001,9/15/2015 14:44:07,false,coinworker,1,20231698,USA,OR,,172.56.33.130,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION;,387-398,464,HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 14:54:54,1738741822,9/15/2015 14:54:30,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,Q wave MYOCARDIAL INFARCTION;,380-382-387-398,455-464,Standard HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 14:57:21,1738742616,9/15/2015 14:57:06,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,Q wave MYOCARDIAL INFARCTION;,380-382-387-398,455-464,Standard HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 15:16:52,1738750647,9/15/2015 15:16:40,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION;,387-398,464,HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 15:19:57,1738752164,9/15/2015 15:19:02,false,clixsense,1,32053717,GBR,,,51.174.76.80,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,PTT; Q wave MYOCARDIAL INFARCTION; Safety; South America;,375-380-382-387-398-410-418-424,436-444-455-464-473-486-495,"segment elevation; Standard HEPARIN; Stimulators, cardiac; Subcutaneous","Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659501,9/15/2015 15:21:51,1738752969,9/15/2015 15:21:36,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,387,464,,,408,471,MYOCARDIAL INFARCTION,HEPARIN,PTT; Q wave MYOCARDIAL INFARCTION;,375-380-382-387-398,455-464,Standard HEPARIN;,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia.",387 398,464,387,464,408,471,-1,RO-may_treat,820077,"Lovenox; Low-molecular-weight heparin; Medication; MI - myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non-Q-wave MI; Pacemakers; Partial thromboplastin time; Persistent ST-segment elevation; Postoperative MI; Pre-exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q-wave myocardial infarction; Safety; South America; ST-segment elevation; Standard heparin; Stimulators, cardiac; Subcutaneous low-molecular-weight heparin; Tedelparin; Thrombocytopenia",myocardial infarction,heparin
788659502,9/15/2015 09:13:59,1738637247,9/15/2015 09:13:43,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"POSTMENOPAUSAL OSTEOPOROSIS,",127-142,175,(RISEDRONATE),"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 09:15:39,1738637540,9/15/2015 09:14:53,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"POSTMENOPAUSAL OSTEOPOROSIS, and for prevention (risedronate) (alendronate and risedronate) glucocorticoid induced osteoporosis.",127-142-156-160-164-175-203-220-236-251-259-216,142-175-127,"postmenopausal osteoporosis, (RISEDRONATE)","Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 09:18:10,1738637907,9/15/2015 09:17:09,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid induced osteoporosis.",0-12-16-28-32-41-44-48-52-56-67-70-75-80-83-92-103-110-114-124-127-142-156-160-164-175-189-193-203-216-220-233-236-251-259,0-12-16-28-32-41-44-48-52-56-67-70-75-80-83-92-103-110-114-124-127-142-156-160-164-175-189-193-203-216-220-233-236-251-259,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (RISEDRONATE) and treatment (alendronate and risedronate) of glucocorticoid induced osteoporosis.","Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 09:23:01,1738638890,9/15/2015 09:22:29,false,neodev,1,20306047,GBR,,,80.41.0.252,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"POSTMENOPAUSAL OSTEOPOROSIS,",127-142,175,(RISEDRONATE),"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 09:33:55,1738641682,9/15/2015 09:33:32,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"POSTMENOPAUSAL OSTEOPOROSIS,",127-142,164-175-189-193-203-216-220,prevention (RISEDRONATE) and treatment (alendronate and risedronate),"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 09:42:27,1738644578,9/15/2015 09:41:37,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"of POSTMENOPAUSAL OSTEOPOROSIS, glucocorticoid induced osteoporosis.",124-127-142-236-251-259,127-142-175-236-251-259,"postmenopausal osteoporosis, (RISEDRONATE) glucocorticoid induced osteoporosis.","Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 10:00:36,1738649283,9/15/2015 10:00:22,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"POSTMENOPAUSAL OSTEOPOROSIS,",127-142,175,(RISEDRONATE),"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 10:01:51,1738649672,9/15/2015 10:00:23,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"POSTMENOPAUSAL OSTEOPOROSIS,",127-142,175,(RISEDRONATE),"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 10:06:08,1738650905,9/15/2015 10:04:15,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"POSTMENOPAUSAL OSTEOPOROSIS,",127-142,236-251-259,glucocorticoid induced osteoporosis.,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659502,9/15/2015 10:14:00,1738653220,9/15/2015 10:11:52,false,points4rewards,1,28703583,USA,,,184.53.32.137,127,176,,,154,187,POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE,"for treatment of POSTMENOPAUSAL OSTEOPOROSIS, and for prevention",110-114-124-127-142-156-160-164,110-114-124-160-164,for treatment of for prevention,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis.",127 142,,127,176,154,187,-1,RO-may_prevent,820281,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of postmenopausal osteoporosis, and for prevention (risedronate) and treatment (alendronate and risedronate) of glucocorticoid-induced osteoporosis",postmenopausal osteoporosis,risedronate
788659503,9/15/2015 09:15:10,1738637474,9/15/2015 09:14:47,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,0,14-20-25-30-43-51-56,&gt; High Dose METHOTREXATE Therapy with Leucovorin,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 09:22:13,1738638649,9/15/2015 09:20:31,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,"OSTEOSARCOMA High Dose Methotrexate Therapy with Leucovorin Rescue IV: Initially, 12 g / m 2 infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0-20-25-30-43-51-56-67-75-80-91-94-95-96-98-101-109-114-116-122-125-131-134-137-140-143-147-151-155-159-163-167-171-175-178-184-192-195-197-206-209-221-226-232-245-252-259-272-283-295-298-309-327-331,0-14-20-25-30-43-51-56-67-75-80-91-94-95-96-98-101-109-114-116-122-125-131-134-137-140-143-147-151-155-159-163-167-171-175-178-184-192-195-197-206-209-221-226-232-245-252-259-272-283-295-298-309-327-331,"Osteosarcoma &gt; High Dose METHOTREXATE Therapy with Leucovorin Rescue IV: Initially, 12 g / m 2 infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.","Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 09:24:20,1738639144,9/15/2015 09:23:44,false,neodev,1,20306047,GBR,,,80.41.0.252,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,0,30,METHOTREXATE,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 09:35:01,1738642048,9/15/2015 09:34:40,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,0,20-25-30-43,High Dose METHOTREXATE Therapy,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 09:44:44,1738645256,9/15/2015 09:43:40,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,0,14-30,&gt; METHOTREXATE,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 10:01:29,1738649572,9/15/2015 10:01:15,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA High Dose Methotrexate Therapy,0-20-25-30-43,14-20-25-30-43,&gt; High Dose METHOTREXATE Therapy,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 10:04:49,1738650518,9/15/2015 10:03:39,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,0,30,METHOTREXATE,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 10:07:45,1738651352,9/15/2015 10:07:15,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA High Dose Methotrexate Therapy with Leucovorin Rescue IV:,0-20-25-30-43-51-56-67-75,20-25-30-43-51-56,High Dose METHOTREXATE Therapy with Leucovorin,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 10:18:35,1738654359,9/15/2015 10:18:18,false,gifthunterclub,1,30901412,GBR,H9,London,77.89.149.62,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA High Dose Methotrexate chemotherapy agents,0-20-25-30-232-245,14-20-25-30-43-51-56-232-245,&gt; High Dose METHOTREXATE Therapy with Leucovorin chemotherapy agents,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659503,9/15/2015 10:20:00,1738654728,9/15/2015 10:18:54,false,points4rewards,1,28703583,USA,,,184.53.33.153,0,30,,,12,42,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA High Dose Methotrexate Therapy with Leucovorin,0-20-25-30-43-51-56,14-20-25-30-43-51-56-206-209-221-226-232-245,&gt; High Dose METHOTREXATE Therapy with Leucovorin in combination with other chemotherapy agents,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin.",0,30,0,30,12,42,-1,RO-may_treat,820087,"Osteosarcoma  >     High-Dose Methotrexate Therapy with Leucovorin Rescue  IV:  Initially, 12 g/m 2  infused over 4 hours on weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 after surgery on a schedule in combination with other chemotherapy agents (e.g., doxorubicin; cisplatin; combination of bleomycin, cyclophosphamide, and dactinomycin",Osteosarcoma,Methotrexate
788659504,9/15/2015 12:39:47,1738703294,9/15/2015 12:39:12,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,85,28,,,96,33,HEPATITIS B,HBSAG,vaccination against HEPATITIS B,65-77-85-95,4-11-20-28-34-37,immune response against HBSAG is helper,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 13:58:24,1738726297,9/15/2015 13:56:20,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,85,28,,,96,33,HEPATITIS B,HBSAG,vaccination against HEPATITIS B,65-77-85-95,4-11-20-28-34-37-44-46-51,immune response against HBSAG is helper T cell dependent,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 14:03:45,1738727684,9/15/2015 14:03:31,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,85,28,,,96,33,HEPATITIS B,HBSAG,HEPATITIS B,85-95,28,HBSAG,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 14:16:05,1738730938,9/15/2015 14:15:49,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,85,28,,,96,33,HEPATITIS B,HBSAG,HEPATITIS B,85-95,28,HBSAG,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 14:17:42,1738731456,9/15/2015 14:16:17,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,85,28,,,96,33,HEPATITIS B,HBSAG,HEPATITIS B,85-95,28,HBSAG,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 14:27:22,1738734319,9/15/2015 14:26:09,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,85,28,,,96,33,HEPATITIS B,HBSAG,vaccination against HEPATITIS B,65-77-85-95,4-11-20-28,immune response against HBSAG,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 14:43:21,1738738647,9/15/2015 14:43:00,false,coinworker,1,20231698,USA,OR,,172.56.33.130,85,28,,,96,33,HEPATITIS B,HBSAG,HEPATITIS B low,85-95-103,28,HBSAG,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 14:52:48,1738741352,9/15/2015 14:52:09,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,85,28,,,96,33,HEPATITIS B,HBSAG,HEPATITIS B,85-95,28,HBSAG,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 14:56:36,1738742347,9/15/2015 14:56:19,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,85,28,,,96,33,HEPATITIS B,HBSAG,HEPATITIS B,85-95,28,HBSAG,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659504,9/15/2015 15:11:50,1738748316,9/15/2015 15:11:44,false,superrewards,1,33199643,USA,WI,La Crosse,138.49.1.28,85,28,,,96,33,HEPATITIS B,HBSAG,and vaccination against HEPATITIS B is of low,61-65-77-85-95-97-100-103,4-11-20-28-34-37-44-46,immune response against HBSAG is helper T cell,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness.,85 95,28,85,28,96,33,-1,RO-may_prevent,820213,The immune response against HBsAg is helper T-cell dependent and vaccination against hepatitis B is of low effectiveness,hepatitis B,HBsAg
788659505,9/15/2015 15:03:20,1738744585,9/15/2015 15:03:00,false,coinworker,1,20231698,USA,OR,,172.56.33.130,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 15:05:48,1738745712,9/15/2015 15:05:03,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 15:36:37,1738757354,9/15/2015 15:35:44,false,clixsense,1,32053717,GBR,,,51.174.76.80,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,24-39-153-161-168-171-177-180-189-36,improvement of hemodynamics DIGOXIN should be added to standard therapy.,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 15:42:00,1738758939,9/15/2015 15:41:44,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 15:46:07,1738760160,9/15/2015 15:45:50,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 16:01:51,1738766417,9/15/2015 16:01:39,false,prodege,1,3587109,CAN,NS,Sydney,142.177.43.123,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 16:05:53,1738767932,9/15/2015 16:04:50,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 16:05:58,1738767978,9/15/2015 16:04:57,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 16:11:14,1738770009,9/15/2015 16:10:54,false,instagc,1,15577915,USA,IL,Trenton,208.70.36.12,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"CONGESTIVE HEART FAILURE,",65-76-82,153,DIGOXIN,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659505,9/15/2015 16:15:38,1738771612,9/15/2015 16:15:33,false,neodev,1,33011398,USA,VA,Manassas,207.244.82.153,65,153,,,89,160,CONGESTIVE HEART FAILURE,DIGOXIN,"is needed in CONGESTIVE HEART FAILURE, this knowledge should",52-55-62-65-76-82-91-96-106,139-142-147-153-161-168-171,in many cases DIGOXIN should be added,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy.",65 76 82,153,65,153,89,160,-1,RO-may_prevent,820263,"It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy",congestive heart failure,digoxin
788659506,9/15/2015 10:37:36,1738659085,9/15/2015 10:37:17,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"ASTHMA,",250,157-171,BECLOMETASONE DIPROPIONATE,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:00:42,1738664577,9/15/2015 11:00:17,false,neodev,1,33758777,USA,,,38.95.108.251,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"ASTHMA,",250,157-171,BECLOMETASONE DIPROPIONATE,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:07:28,1738666094,9/15/2015 11:07:14,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"recommended adult patients with ASTHMA, a recommendation that",230-236-245-250-258-260-275-215,140-143-147-157-171-184-196-200-205-215,of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:08:40,1738666439,9/15/2015 11:08:01,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"beclometasone dipropionate formulation has been recommended in adult patients with ASTHMA,",157-171-184-196-200-215-230-236-245-250-227,157-171-184-196-200-215-227-230-236-245-250,"BECLOMETASONE DIPROPIONATE formulation has been recommended in adult patients with asthma,","Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:09:22,1738666630,9/15/2015 11:08:55,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"ASTHMA,",250,147-157-171-184,reference BECLOMETASONE DIPROPIONATE formulation,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:24:22,1738673710,9/15/2015 11:24:02,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"ASTHMA,",250,157-171,BECLOMETASONE DIPROPIONATE,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:26:38,1738674910,9/15/2015 11:26:13,false,elite,1,31883685,GBR,,,79.66.254.237,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"ASTHMA,",250,157-171-184,BECLOMETASONE DIPROPIONATE formulation,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:27:44,1738675526,9/15/2015 11:26:56,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"ASTHMA,",250,157-171-184,BECLOMETASONE DIPROPIONATE formulation,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 11:47:26,1738684714,9/15/2015 11:47:05,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"ASTHMA,",250,157-171,BECLOMETASONE DIPROPIONATE,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659506,9/15/2015 12:12:30,1738693634,9/15/2015 12:11:37,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,250,157,,,256,183,ASTHMA,BECLOMETASONE DIPROPIONATE,"adult patients with ASTHMA,",230-236-245-250,140-143-147-157-171-184-196-200-205-215,of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials.",250,157 171,250,157,256,183,-1,RO-may_prevent,820176,"Since the 2- to 3-fold increase in pulmonary deposition results in a 2.6- to 3-fold difference in relative efficacy for Qvar, half the dose of the reference beclometasone dipropionate formulation has been currently recommended in adult patients with asthma, a recommendation that is supported by a large number of clinical trials",asthma,beclometasone dipropionate
788659507,9/15/2015 10:35:52,1738658578,9/15/2015 10:35:36,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,nocturnal HYPOGLYCEMIA,12-22,67-75-81,fasting blood GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 10:58:49,1738664177,9/15/2015 10:58:31,false,neodev,1,33758777,USA,,,38.95.108.251,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,22,81,GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 11:05:59,1738665773,9/15/2015 11:05:43,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,"risk of nocturnal HYPOGLYCEMIA is lower with this regimen,",4-9-12-22-35-38-44-49-54,63-67-75-81-89-92-99,and fasting blood GLUCOSE is better controlled.,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 11:06:25,1738665863,9/15/2015 11:06:06,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,"nocturnal HYPOGLYCEMIA is lower with this regimen, and fasting blood glucose",12-22-35-38-44-49-54-67-75-81-63,81-89-92-99,GLUCOSE is better controlled.,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 11:07:15,1738666042,9/15/2015 11:06:56,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,nocturnal HYPOGLYCEMIA,12-22,75-81,blood GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 11:13:29,1738667946,9/15/2015 11:11:22,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,nocturnal HYPOGLYCEMIA,12-22,67-75-81,fasting blood GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 11:22:25,1738672428,9/15/2015 11:21:57,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,nocturnal HYPOGLYCEMIA,22-12,67-75-81,fasting blood GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 11:24:03,1738673519,9/15/2015 11:23:34,false,elite,1,31883685,GBR,,,79.66.254.237,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,nocturnal HYPOGLYCEMIA,12-22,75-81-67,fasting blood GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 11:45:24,1738683648,9/15/2015 11:44:47,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,HYPOGLYCEMIA,22,81,GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659507,9/15/2015 12:08:39,1738692147,9/15/2015 12:08:03,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,22,81,,,34,88,HYPOGLYCEMIA,GLUCOSE,nocturnal HYPOGLYCEMIA,12-22,75-81,blood GLUCOSE,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled.",22,81,22,81,34,88,-1,RO-may_treat,820004,"The risk of nocturnal hypoglycemia is lower with this regimen, and fasting blood glucose is better controlled",hypoglycemia,glucose
788659508,9/15/2015 11:14:29,1738668374,9/15/2015 11:14:09,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"chronic CONGESTIVE CARDIAC FAILURE,",112-120-131-139,71-81,DIGITALIS glycosides,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 11:30:58,1738677388,9/15/2015 11:30:31,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"chronic CONGESTIVE CARDIAC FAILURE,",112-120-131-139,71-81,DIGITALIS glycosides,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 11:44:37,1738683226,9/15/2015 11:44:16,false,elite,1,31883685,GBR,,,79.66.254.237,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"CONGESTIVE CARDIAC FAILURE,",120-131-139,71-81,DIGITALIS glycosides,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 11:53:53,1738687621,9/15/2015 11:53:22,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"chronic CONGESTIVE CARDIAC FAILURE,",120-131-139-112,71-81,DIGITALIS glycosides,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 12:29:42,1738699632,9/15/2015 12:29:10,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"treatment of chronic CONGESTIVE CARDIAC FAILURE,",99-109-112-120-131-139,58-62-68-71-81-92-95-99,the place of DIGITALIS glycosides in the treatment,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 13:37:33,1738721261,9/15/2015 13:36:36,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"treatment of chronic CONGESTIVE CARDIAC FAILURE,",99-109-112-120-131-139,71-81-92-95-99-109-112-120-131-139,"DIGITALIS glycosides in the treatment of chronic congestive cardiac failure,","Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 13:59:26,1738726490,9/15/2015 13:59:10,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"chronic CONGESTIVE CARDIAC FAILURE,",112-120-131-139,71-81,DIGITALIS glycosides,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 14:01:57,1738727195,9/15/2015 14:00:59,false,vivatic,1,15201808,GBR,,,87.112.19.240,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"CONGESTIVE CARDIAC FAILURE,",120-131-139,71-81-95,DIGITALIS glycosides the,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 14:02:55,1738727470,9/15/2015 14:01:51,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"CONGESTIVE CARDIAC FAILURE, in myocardial infarction and mitral stenosis.",120-131-139-148-151-162-173-180-187,71-81,DIGITALIS glycosides,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659508,9/15/2015 14:04:18,1738727774,9/15/2015 14:02:53,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,120,71,,,146,80,CONGESTIVE CARDIAC FAILURE,DIGITALIS,"chronic CONGESTIVE CARDIAC FAILURE, in myocardial infarction",112-120-131-139-148-151-162,71-81,DIGITALIS glycosides,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis.",120 131 139,71,120,71,146,80,-1,RO-may_prevent,820322,"Atrial was undertaken of assessment of the usefulness and the place of digitalis glycosides in the treatment of chronic congestive cardiac failure, in myocardial infarction and in mitral stenosis",congestive cardiac failure,digitalis
788659509,9/15/2015 11:13:30,1738667949,9/15/2015 11:13:13,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,NSAID induced GASTRIC ULCERS,40-46-54-62,80,MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 11:29:51,1738676747,9/15/2015 11:29:34,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,GASTRIC ULCERS,54-62,80,MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 11:43:33,1738682748,9/15/2015 11:43:17,false,elite,1,31883685,GBR,,,79.66.254.237,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,NSAID induced GASTRIC ULCERS,40-46-54-62,80,MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 11:52:40,1738687033,9/15/2015 11:52:16,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,GASTRIC ULCERS,54-62,80,MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 12:27:16,1738698792,9/15/2015 12:26:10,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,of NSAID induced GASTRIC ULCERS,37-40-46-54-62,62-69-77-80,ulcers reduced by MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 13:19:08,1738713779,9/15/2015 13:18:27,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,NSAID induced GASTRIC ULCERS,40-46-54-62,80,MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 13:34:50,1738718433,9/15/2015 13:34:17,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,NSAID induced GASTRIC ULCERS,40-46-54-62,54-62-69-77-80,gastric ulcers reduced by MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 13:58:36,1738726365,9/15/2015 13:58:19,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,NSAID induced GASTRIC ULCERS,40-46-54-62,80,MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 13:59:36,1738726524,9/15/2015 13:58:02,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,NSAID induced GASTRIC ULCERS reduced by misoprostol,40-46-54-62-69-77-80,62-69-77-80,ulcers reduced by MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659509,9/15/2015 14:00:07,1738726659,9/15/2015 13:58:31,false,vivatic,1,15201808,GBR,,,87.112.19.240,54,80,,,68,91,GASTRIC ULCERS,MISOPROSTOL,of NSAID induced GASTRIC ULCERS,37-40-46-54-62,80,MISOPROSTOL,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS.,54 62,80,54,80,68,91,-1,RO-may_prevent,820245,The absence of firm data on the rate of NSAID-induced gastric ulcers reduced by misoprostol makes it impossible to conclude whether it is cost-effective in patients with chronic arthritis who use NSAIDS,gastric ulcers,misoprostol
788659510,9/15/2015 11:57:22,1738688859,9/15/2015 11:57:00,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,VON WILLEBRAND'S factor,117-121-134,181-188,FACTOR VIII,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 12:36:24,1738702040,9/15/2015 12:35:24,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,disease Antihemophilic factor VON WILLEBRAND'S factor complex,87-95-110-117-121-134-141,164-166-171-181-188-193,P (CSL Behring) FACTOR VIII replacement,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 13:46:08,1738723524,9/15/2015 13:44:09,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,Willebrand's disease Antihemophilic factor VON WILLEBRAND'S factor complex,87-95-110-117-121-134-141-74,164-166-171-181-188-193-206-217-157,Humate P (CSL Behring) FACTOR VIII replacement Variablea Allergic,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 14:01:58,1738727212,9/15/2015 14:01:42,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,VON WILLEBRAND'S,117-121,181-188,FACTOR VIII,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 14:11:12,1738729549,9/15/2015 14:09:28,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,disease VON WILLEBRAND'S,87-117-121,95-181-188,Antihemophilic FACTOR VIII,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 14:13:56,1738730259,9/15/2015 14:13:27,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,VON WILLEBRAND'S factor complex,117-121-134-141,181-188,FACTOR VIII,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 14:17:39,1738731454,9/15/2015 14:15:57,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,von Willebrand's disease Antihemophilic factor VON WILLEBRAND'S factor complex,70-87-95-110-117-121-134-141-74,164-166-171-181-188,P (CSL Behring) FACTOR VIII,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 14:36:13,1738736572,9/15/2015 14:35:39,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,VON WILLEBRAND'S factor complex,117-121-134-141,157-163-164-166-171-181-188-193,Humate - P (CSL Behring) FACTOR VIII replacement,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 14:39:13,1738737312,9/15/2015 14:39:00,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,disease Antihemophilic factor VON WILLEBRAND'S factor complex,87-95-110-117-121-134-141,164-166-171-181-188-193-206-217-157,Humate P (CSL Behring) FACTOR VIII replacement Variablea Allergic,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659510,9/15/2015 14:39:41,1738737466,9/15/2015 14:38:56,false,coinworker,1,20231698,USA,OR,,172.56.33.130,117,181,,,133,192,VON WILLEBRAND'S,FACTOR VIII,disease Antihemophilic factor VON WILLEBRAND'S factor complex,87-95-110-117-121-134-141,164-166-171-181-188-193-206-217,P (CSL Behring) FACTOR VIII replacement Variablea Allergic,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent.",117 121,181 188,117,181,133,192,-1,RO-may_treat,820048,"Highly enriched with von Willebrand's factor and can be used to treat von Willebrand's disease Antihemophilic factor/von Willebrand's factor complex (human) Humate-P (CSL Behring)  Factor VIII replacement  Variablea  Allergic or injection site reactions (rare)  Intermediate purity, viral inactivated with solvent/detergent",von Willebrand's,Factor VIII
788659511,9/15/2015 11:08:20,1738666339,9/15/2015 11:08:05,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"eumetabolic and have GOITERS, elevated plasma levels",31-43-47-52-61-70-77,97-102-112-116-134-141-149-157,"free thyroxine and TRIIODOTHYRONINE, normal thyroid hormone metabolism,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 11:10:22,1738666815,9/15/2015 11:10:02,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"GOITERS,",52,116,"TRIIODOTHYRONINE,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 11:25:48,1738674440,9/15/2015 11:25:18,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"GOITERS,",52,116,"TRIIODOTHYRONINE,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 11:28:21,1738676011,9/15/2015 11:28:01,false,elite,1,31883685,GBR,,,79.66.254.237,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"GOITERS,",52,116,"TRIIODOTHYRONINE,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 11:29:19,1738676446,9/15/2015 11:28:52,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"GOITERS,",52,116,"TRIIODOTHYRONINE,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 11:48:44,1738685309,9/15/2015 11:48:18,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"GOITERS,",52,116,"TRIIODOTHYRONINE,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 12:13:49,1738694109,9/15/2015 12:12:57,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"GOITERS, elevated plasma levels",52-61-70-77,102-112-116,"thyroxine and TRIIODOTHYRONINE,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 12:15:56,1738694833,9/15/2015 12:15:03,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"eumetabolic and have GOITERS,",31-43-47-52,97-102-112-116,"free thyroxine and TRIIODOTHYRONINE,","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 12:21:02,1738696877,9/15/2015 12:20:57,false,neodev,1,34429821,USA,CA,Torrance,66.171.228.249,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"eumetabolic and have GOITERS, elevated plasma levels",31-43-47-52-61-70-77,97-102-112-116-134-141-149,"free thyroxine and TRIIODOTHYRONINE, normal thyroid hormone","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659511,9/15/2015 12:38:07,1738702671,9/15/2015 12:37:44,false,neodev,1,33701549,USA,CA,San Jose,23.27.248.252,52,116,,,59,132,GOITERS,TRIIODOTHYRONINE,"eumetabolic and have GOITERS, elevated plasma levels metabolism, normal serum",31-43-47-52-61-70-77-157-173-180,52-97-102-112-116-134-141-149-180-190,"goiters, free thyroxine and TRIIODOTHYRONINE, normal thyroid hormone serum levels","Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",52,116,52,116,59,132,-1,RO-may_treat,820137,"Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone",goiters,triiodothyronine
788659512,9/15/2015 10:25:59,1738656335,9/15/2015 10:25:45,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,fluticasone propionate ASTHMA.,133-195-145,133-145-195,FLUTICASONE PROPIONATE asthma.,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 10:32:53,1738657917,9/15/2015 10:32:37,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,mild to moderate ASTHMA.,178-183-186-195,133-145,FLUTICASONE PROPIONATE,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 10:34:53,1738658395,9/15/2015 10:34:23,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,inhaled fluticasone propionate ASTHMA.,133-145-195-125,133-145-195,FLUTICASONE PROPIONATE asthma.,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 10:44:32,1738660877,9/15/2015 10:44:24,false,clixsense,1,21490235,GBR,N7,Woking,86.30.254.232,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,ASTHMA.,195,133-145,FLUTICASONE PROPIONATE,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 10:55:01,1738663330,9/15/2015 10:54:15,false,points4rewards,1,28703583,USA,,,184.53.32.113,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,of low doses of inhaled fluticasone propionate ASTHMA.,109-112-116-122-125-133-145-195,133-145-186-195,FLUTICASONE PROPIONATE moderate asthma.,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 10:55:28,1738663490,9/15/2015 10:55:11,false,neodev,1,33758777,USA,,,38.95.108.251,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,ASTHMA.,195,133-145,FLUTICASONE PROPIONATE,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 11:00:09,1738664468,9/15/2015 10:59:38,false,neodev,1,11382239,AUS,2,Strathfield,60.241.129.81,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,mild to moderate ASTHMA.,178-183-186-195,133-145,FLUTICASONE PROPIONATE,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 11:00:31,1738664546,9/15/2015 10:59:08,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,mild to moderate ASTHMA.,183-186-195-178,125-133-145-156,inhaled FLUTICASONE PROPIONATE (FP),"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 11:02:26,1738664966,9/15/2015 11:01:40,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate ASTHMA.,112-116-125-133-145-156-161-164-173-178-183-186-195-122,133-145-156-161-164-173-178-183-186-195,FLUTICASONE PROPIONATE (FP) in patients with mild to moderate asthma.,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659512,9/15/2015 11:02:46,1738665028,9/15/2015 11:02:26,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,195,133,,,201,155,ASTHMA,FLUTICASONE PROPIONATE,fluticasone mild to moderate ASTHMA.,178-183-186-195-133,116-122-125-133-145-161-164-195,doses of inhaled FLUTICASONE PROPIONATE in patients asthma.,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma.",195,133 145,195,133,201,155,-1,RO-may_prevent,820372,"A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma",asthma,fluticasone propionate
788659513,9/15/2015 09:16:41,1738637717,9/15/2015 09:16:15,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,79,105,,,82,118,CHF,NITROGLYCERIN,CHF,79,91-95-104,] Nitrates (NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 09:26:18,1738639657,9/15/2015 09:24:25,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,79,105,,,82,118,CHF,NITROGLYCERIN,Concomitant therapy generally not recommended in patients with CHF Nitrates (nitroglycerin) Clinically important interaction not observed NSAIAs Possible decreased antihypertensive response to lisinopril (slightly decreased response observed with concomitant indomethacin) Potential for acute reduction of renal function in patients with impaired renal function Lithium Increased serum lithium concentrations; possible toxicity,16-28-36-46-50-62-65-74-79-95-104-120-131-141-153-157-179-186-195-205-222-231-234-263-273-283-292-301-306-318-342-352-356-362-372-375-381-390-393-402-407-416-422-448-456-466-472-480-496-505,16-28-36-46-50-62-65-74-79-95-104-120-131-141-153-157-179-186-195-205-222-231-234-263-273-283-292-301-306-342-352-356-362-372-375-381-390-393-402-407-416-422-448-456-466-472-480-496-505,Concomitant therapy generally not recommended in patients with CHF Nitrates (NITROGLYCERIN) Clinically important interaction not observed NSAIAs Possible decreased antihypertensive response to lisinopril (slightly decreased response observed with concomitant Potential for acute reduction of renal function in patients with impaired renal function Lithium Increased serum lithium concentrations; possible toxicity,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 09:36:14,1738642526,9/15/2015 09:35:55,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,79,105,,,82,118,CHF,NITROGLYCERIN,CHF 1 2,79-85-89,91-95-104,] Nitrates (NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 09:46:59,1738645764,9/15/2015 09:46:26,false,neodev,1,20306047,GBR,,,80.41.0.252,79,105,,,82,118,CHF,NITROGLYCERIN,CHF,79,104,(NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 09:47:03,1738645778,9/15/2015 09:46:32,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,79,105,,,82,118,CHF,NITROGLYCERIN,CHF 1 2 Nitrates,79-85-89-95,91-95-104,] Nitrates (NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 10:02:38,1738649896,9/15/2015 10:02:16,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,79,105,,,82,118,CHF,NITROGLYCERIN,CHF 1 2 Nitrates (nitroglycerin),79-85-89-95-104,79-83-85-89-91-95-104,CHF [ 1 2 ] Nitrates (NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 10:08:51,1738651686,9/15/2015 10:07:37,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,79,105,,,82,118,CHF,NITROGLYCERIN,"CHF 1 , 2",79-85-87-89,91-95-104,] Nitrates (NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 10:10:47,1738652285,9/15/2015 10:09:00,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,79,105,,,82,118,CHF,NITROGLYCERIN,CHF,79,91-95-104,] Nitrates (NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 10:19:23,1738654537,9/15/2015 10:19:15,false,gifthunterclub,1,30901412,GBR,H9,London,77.89.149.62,79,105,,,82,118,CHF,NITROGLYCERIN,Concomitant therapy in patients with CHF 1 2 Nitrates,16-62-65-74-79-85-89-95-28,91-95-104-120-131-141,] Nitrates (NITROGLYCERIN) Clinically important interaction,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659513,9/15/2015 10:20:43,1738654872,9/15/2015 10:20:20,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,79,105,,,82,118,CHF,NITROGLYCERIN,CHF Nitrates (nitroglycerin),79-95-104,91-95-104-79,CHF ] Nitrates (NITROGLYCERIN),"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2.",79,,79,105,82,118,-1,RO-may_treat,820011,"1 , 2 , 3 , 4 ] Concomitant therapy generally not recommended in patients with CHF [ 1 , 2 ]   Nitrates (nitroglycerin) Clinically important interaction not observed [ 1 , 2 ]    NSAIAs Possible decreased antihypertensive response to lisinopril [ 1 , 2 , 3 , 4 ] (slightly decreased response observed with concomitant indomethacin) [ 1 , 2 ] Potential for acute reduction of renal function in patients with impaired renal function [ 1 , 3 , 4 ]    Lithium Increased serum lithium concentrations; possible toxicity [ 1 , 2",CHF,nitroglycerin
788659514,9/15/2015 09:15:55,1738637606,9/15/2015 09:15:37,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,ASTHMA symptom control,66-73-81,0-8-18-23-34,Regular treatment with NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 09:23:20,1738638956,9/15/2015 09:22:50,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,0-8-18-23-34-41-51-55-58-66-73-81-89-93-101-111-126-135-140-148-158-163,0-8-18-23-34-41-51-55-58-66-73-81-89-93-101-111-126-135-140-148-158-163,Regular treatment with NEDOCROMIL SODIUM therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 09:24:54,1738639311,9/15/2015 09:24:37,false,neodev,1,20306047,GBR,,,80.41.0.252,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,ASTHMA,66,23-34,NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 09:35:31,1738642198,9/15/2015 09:35:18,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,ASTHMA symptom control,66-73-81,23-34,NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 09:46:06,1738645568,9/15/2015 09:45:22,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,ASTHMA bronchial responsiveness,66-101-111,23-34,NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 10:02:01,1738649727,9/15/2015 10:01:47,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,ASTHMA,66,23-34,NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 10:06:30,1738650987,9/15/2015 10:05:52,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,ASTHMA,66,23-34,NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 10:08:35,1738651576,9/15/2015 10:08:05,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,ASTHMA,66,23-34,NEDOCROMIL SODIUM,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 10:19:02,1738654455,9/15/2015 10:18:53,false,gifthunterclub,1,30901412,GBR,H9,London,77.89.149.62,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,nedocromil sodium led to greater ASTHMA symptom control and,23-51-55-58-66-73-81-89-34,0-8-18-23-34-41-51-55,Regular treatment with NEDOCROMIL SODIUM therefore led to,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659514,9/15/2015 10:20:19,1738654781,9/15/2015 10:20:01,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,66,23,,,72,40,ASTHMA,NEDOCROMIL SODIUM,nedocromil sodium ASTHMA,23-34-66,23-34-66,NEDOCROMIL SODIUM asthma,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,66,23 34,66,23,72,40,-1,RO-may_prevent,820265,Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol,asthma,nedocromil sodium
788659515,9/15/2015 11:08:58,1738666519,9/15/2015 11:08:47,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,treatment of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.,50-60-63-71-87-97-100-106-110-116-121-132,29-31-34-38-50-60-63-71,T et al. GANCICLOVIR treatment of serious cytomegalovirus,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 11:11:26,1738667084,9/15/2015 11:11:04,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,serious CYTOMEGALOVIRUS INFECTION,63-71-87,38-50,GANCICLOVIR treatment,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 11:27:26,1738675319,9/15/2015 11:26:38,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,CYTOMEGALOVIRUS INFECTION,71-87,38-50,GANCICLOVIR treatment,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 11:34:59,1738679040,9/15/2015 11:34:27,false,elite,1,31883685,GBR,,,79.66.254.237,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,CYTOMEGALOVIRUS INFECTION,71-87,38-50,GANCICLOVIR treatment,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 11:35:12,1738679106,9/15/2015 11:33:01,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,serious CYTOMEGALOVIRUS INFECTION,63-71-87,38-50,GANCICLOVIR treatment,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 11:49:55,1738685845,9/15/2015 11:49:31,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,CYTOMEGALOVIRUS INFECTION,71-87,38,GANCICLOVIR,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 12:20:16,1738696638,9/15/2015 12:19:14,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,treatment of serious CYTOMEGALOVIRUS INFECTION,50-60-63-71-87,29-31-34-38-50-60-63-71,T et al. GANCICLOVIR treatment of serious cytomegalovirus,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 12:54:34,1738707101,9/15/2015 12:54:26,false,zoombucks,1,4711962,CAN,ON,Markham,174.88.29.138,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,Ganciclovir treatment of serious CYTOMEGALOVIRUS INFECTION in heart and,50-60-63-71-87-97-100-106-38,29-31-34-38-50-60-63-71-87,T et al. GANCICLOVIR treatment of serious cytomegalovirus infection,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 13:14:30,1738712376,9/15/2015 13:14:08,false,elite,1,33238902,NLD,6,Budel,77.248.148.5,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,CYTOMEGALOVIRUS INFECTION,71-87,38-50,GANCICLOVIR treatment,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659515,9/15/2015 13:30:23,1738717366,9/15/2015 13:29:51,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,71,38,,,96,49,CYTOMEGALOVIRUS INFECTION,GANCICLOVIR,treatment of CYTOMEGALOVIRUS INFECTION in heart,50-60-71-87-97-100,29-31-34-38-50-20,Icenogle T et al. GANCICLOVIR treatment,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.",71 87,38,71,38,96,49,-1,RO-may_prevent,820156,"Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",cytomegalovirus infection,Ganciclovir
788659516,9/15/2015 09:18:56,1738637995,9/15/2015 09:18:41,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,274,199-207,VITAMIN D,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 09:32:29,1738641177,9/15/2015 09:31:18,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS.",0-11-14-18-23-31-39-51-54-61-70-74-88-98-101-112-119-122-129-131-136-141-144-152-156-167-170-180-189-196-199-207-209-213-216-227-238-241-247-256-265-271-274-253,0-11-14-18-23-31-39-51-54-61-70-74-88-98-101-112-119-122-129-131-136-141-144-152-156-167-170-180-189-196-199-207-209-213-216-227-238-241-247-253-256-265-271-274,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or osteoporosis.","Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 09:38:13,1738643183,9/15/2015 09:38:01,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,274,199-207,VITAMIN D,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 09:50:55,1738646850,9/15/2015 09:50:37,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,274,199-207,VITAMIN D,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 09:58:44,1738648868,9/15/2015 09:58:33,false,neodev,1,20306047,GBR,,,80.41.0.252,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,274,199-207,VITAMIN D,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 10:04:40,1738650497,9/15/2015 10:04:29,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,274,199-207,VITAMIN D,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 10:13:25,1738653005,9/15/2015 10:13:13,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,274,199-207,VITAMIN D,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 10:17:12,1738654042,9/15/2015 10:15:52,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,274,199-207,VITAMIN D,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 10:22:58,1738655496,9/15/2015 10:22:43,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,vitamin D OSTEOPOROSIS.,199-207-274,199-207-274,VITAMIN D osteoporosis.,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659516,9/15/2015 10:31:24,1738657540,9/15/2015 10:30:57,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,274,199,,,286,208,OSTEOPOROSIS,VITAMIN D,vitamin D OSTEOPOROSIS.,199-274-207,88-98-101-112-119-122-199-207-274,"treatment of modifiable causes of falls, VITAMIN D osteoporosis.","Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis.",274,199 207,274,199,286,208,-1,RO-may_prevent,820324,"Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis",osteoporosis,vitamin D
788659517,9/15/2015 14:19:38,1738731984,9/15/2015 14:19:20,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,181,PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 14:45:45,1738739386,9/15/2015 14:44:30,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,172-175-178-181-192-197-200,"15 mg of PRIMAQUINE over 14 d,","The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 14:47:44,1738739997,9/15/2015 14:47:24,false,coinworker,1,20231698,USA,OR,,172.56.33.130,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,181,PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 15:01:10,1738743787,9/15/2015 15:00:43,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,181,PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 15:27:37,1738754667,9/15/2015 15:26:34,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,181,PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 15:30:12,1738755371,9/15/2015 15:29:21,false,clixsense,1,32053717,GBR,,,51.174.76.80,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,"male patients with PLASMODIUM VIVAX MALARIA who were given 15 mg of primaquine over 14 d, chloroquine.",98-103-112-117-128-134-142-146-151-172-175-178-181-192-197-200-230,98-103-117-128-134-172-175-178-181-192-197-200-230-112,"male patients with Plasmodium vivax malaria 15 mg of PRIMAQUINE over 14 d, chloroquine.","The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 15:39:01,1738758085,9/15/2015 15:38:47,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,172-175-178-181,15 mg of PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 15:42:59,1738759188,9/15/2015 15:42:44,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,181,PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 15:58:48,1738764967,9/15/2015 15:58:26,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,181,PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659517,9/15/2015 15:59:59,1738765635,9/15/2015 15:59:03,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,117,181,,,141,191,PLASMODIUM VIVAX MALARIA,PRIMAQUINE,PLASMODIUM VIVAX MALARIA,117-128-134,181,PRIMAQUINE,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine.",117 128 134,181,117,181,141,191,-1,RO-may_prevent,820164,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with Plasmodium vivax malaria who were given daily doses of 15 mg of primaquine over 14 d, following a full course of chloroquine",Plasmodium vivax malaria,primaquine
788659518,9/15/2015 10:07:06,1738651187,9/15/2015 10:06:55,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,5,31,,,12,42,MALARIA,CHLOROQUINE,MALARIA,5,31,"CHLOROQUINE,","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:24:54,1738656058,9/15/2015 10:24:44,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,5,31,,,12,42,MALARIA,CHLOROQUINE,"MALARIA chloroquine,",5-31,5-31,"malaria CHLOROQUINE,","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:31:36,1738657564,9/15/2015 10:31:22,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,5,31,,,12,42,MALARIA,CHLOROQUINE,MALARIA,5,31,"CHLOROQUINE,","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:33:09,1738657980,9/15/2015 10:32:52,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,5,31,,,12,42,MALARIA,CHLOROQUINE,"MALARIA is susceptible to chloroquine,",5-13-16-28-31,5-13-16-31-28,"malaria is susceptible to CHLOROQUINE,","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:37:01,1738658908,9/15/2015 10:36:50,false,neodev,1,33644825,USA,IL,Chicago,65.60.20.67,5,31,,,12,42,MALARIA,CHLOROQUINE,When MALARIA is susceptible to,0-5-13-16-28,13-16-28-31-44-49,"is susceptible to CHLOROQUINE, this drug","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:40:35,1738659961,9/15/2015 10:40:18,false,prodege,1,9169061,CAN,ON,Kitchener,99.235.192.130,5,31,,,12,42,MALARIA,CHLOROQUINE,MALARIA,5,31,"CHLOROQUINE,","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:43:34,1738660675,9/15/2015 10:43:24,false,clixsense,1,21490235,GBR,N7,Woking,86.30.254.232,5,31,,,12,42,MALARIA,CHLOROQUINE,MALARIA,5,31,"CHLOROQUINE,","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:45:50,1738661220,9/15/2015 10:45:47,false,clixsense,1,19162475,GBR,P8,Trowbridge,82.33.126.30,5,31,,,12,42,MALARIA,CHLOROQUINE,When MALARIA is susceptible to,0-5-13-16-28,13-16-28-31-44-49,"is susceptible to CHLOROQUINE, this drug","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:49:32,1738662069,9/15/2015 10:48:10,false,points4rewards,1,28703583,USA,,,184.53.32.113,5,31,,,12,42,MALARIA,CHLOROQUINE,"MALARIA is susceptible to chloroquine,",5-16-28-31-13,31-44-49-54-66-70-73-76,"CHLOROQUINE, this drug (Nivaquine) has to be used.","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659518,9/15/2015 10:54:02,1738663140,9/15/2015 10:53:45,false,neodev,1,33758777,USA,,,38.95.108.251,5,31,,,12,42,MALARIA,CHLOROQUINE,MALARIA,5,31,"CHLOROQUINE,","When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used.",5,31,5,31,12,42,-1,RO-may_prevent,820170,"When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used",malaria,chloroquine
788659519,9/15/2015 10:26:45,1738656475,9/15/2015 10:26:31,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,81,42,,,94,50,DENTAL CARIES,FLUORIDE,fluoride DENTAL CARIES,42-81-88,42-81-88,FLUORIDE dental caries,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 10:33:46,1738658104,9/15/2015 10:33:33,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,81,42,,,94,50,DENTAL CARIES,FLUORIDE,DENTAL CARIES,81-88,42,FLUORIDE,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 10:35:59,1738658606,9/15/2015 10:35:37,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,81,42,,,94,50,DENTAL CARIES,FLUORIDE,fluoride effective in preventing DENTAL CARIES,42-57-67-81-88-70,42-57-67-70-81-88,FLUORIDE effective in preventing dental caries,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 10:56:22,1738663705,9/15/2015 10:56:07,false,neodev,1,33758777,USA,,,38.95.108.251,81,42,,,94,50,DENTAL CARIES,FLUORIDE,DENTAL CARIES,81-88,42,FLUORIDE,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 10:57:47,1738663918,9/15/2015 10:56:56,false,points4rewards,1,28703583,USA,,,184.53.32.113,81,42,,,94,50,DENTAL CARIES,FLUORIDE,no systematic reviews have found fluoride to be effective DENTAL CARIES,9-12-23-31-36-42-51-54-81-88-57,42-70-81-88-95-98-67,FLUORIDE in preventing dental caries in adults.,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 11:03:33,1738665187,9/15/2015 11:03:13,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,81,42,,,94,50,DENTAL CARIES,FLUORIDE,in preventing DENTAL CARIES in adults.,67-81-88-95-98-70,42-57-67-81-88,FLUORIDE effective in dental caries,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 11:03:41,1738665227,9/15/2015 11:01:49,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,81,42,,,94,50,DENTAL CARIES,FLUORIDE,DENTAL CARIES,81-88,42,FLUORIDE,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 11:03:47,1738665273,9/15/2015 11:03:22,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,81,42,,,94,50,DENTAL CARIES,FLUORIDE,fluoride effective in preventing DENTAL CARIES in adults.,57-67-70-81-88-95-98-42,23-31-36-42-51-54-57-70-81,reviews have found FLUORIDE to be effective preventing dental,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 11:04:44,1738665484,9/15/2015 11:04:26,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,81,42,,,94,50,DENTAL CARIES,FLUORIDE,DENTAL CARIES,81-88,42,FLUORIDE,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659519,9/15/2015 11:22:01,1738672250,9/15/2015 11:21:14,false,elite,1,31883685,GBR,,,79.66.254.237,81,42,,,94,50,DENTAL CARIES,FLUORIDE,DENTAL CARIES,81-88,42,FLUORIDE,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults.",81 88,42,81,42,94,50,-1,RO-may_prevent,820275,"To date, no systematic reviews have found fluoride to be effective in preventing dental caries in adults",dental caries,fluoride
788659520,9/15/2015 09:20:15,1738638204,9/15/2015 09:19:47,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,insulin treated TYPE 2 DIABETES,226-234-242-247-249,226-234-242-247-249,INSULIN treated type 2 diabetes,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 09:37:21,1738642958,9/15/2015 09:36:23,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin treated TYPE 2 DIABETES subjects.,0-4-15-24-33-38-45-48-61-70-73-82-88-101-109-112-116-132-145-151-157-164-169-174-178-187-191-199-208-221-226-234-242-247-249-258-216,0-4-15-24-33-38-45-48-61-70-73-82-88-101-109-112-116-132-145-151-157-164-169-174-178-187-191-199-208-216-221-226-234-242-247-249-258,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from INSULIN treated type 2 diabetes subjects.,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 09:39:32,1738643788,9/15/2015 09:39:13,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,insulin treated TYPE 2 DIABETES subjects.,226-234-242-247-249-258,226-234-242-247-249-258,INSULIN treated type 2 diabetes subjects.,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 09:52:50,1738647351,9/15/2015 09:52:23,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,242-247-249,226,INSULIN,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 10:01:44,1738649653,9/15/2015 10:01:18,false,neodev,1,20306047,GBR,,,80.41.0.252,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,242-247-249,226,INSULIN,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 10:05:52,1738650849,9/15/2015 10:05:37,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,242-247-249,191-199-208-216-226-234-242-247-249-258,insulin antibody (IA(+)) sera INSULIN treated type 2 diabetes subjects.,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 10:22:51,1738655474,9/15/2015 10:22:09,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,insulin treated TYPE 2 DIABETES,226-234-242-247-249,226-234-242-247,INSULIN treated type 2,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 10:23:58,1738655791,9/15/2015 10:23:47,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,insulin TYPE 2 DIABETES,226-242-247-249,226-242-247-249,INSULIN type 2 diabetes,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 10:29:53,1738657207,9/15/2015 10:29:12,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,insulin treated TYPE 2 DIABETES,226-234-242-247-249,226,INSULIN,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659520,9/15/2015 10:32:03,1738657657,9/15/2015 10:31:44,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,242,226,,,257,233,TYPE 2 DIABETES,INSULIN,(IA(+)) sera treated TYPE 2 DIABETES,208-234-242-247-249-216,208-216-226-234-242-247-249,(IA(+)) sera INSULIN treated type 2 diabetes,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects.,242 247 249,226,242,226,257,233,-1,RO-may_treat,820110,The phagotopes randomly selected were tested as antiidiotope reagents to displace human radiolabeled insulin in the microfiltration radiobinding assay using IAA(+) sera from T1D subjects and insulin antibody (IA(+)) sera from insulin-treated type 2 diabetes subjects,type 2 diabetes,insulin
788659521,9/15/2015 10:27:00,1738656517,9/15/2015 10:26:46,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND factor VIII,61-65-124-131,61-124-131-65,von Willebrand FACTOR VIII,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 10:34:04,1738658209,9/15/2015 10:33:47,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND disease,61-65-76,124-131,FACTOR VIII,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 10:36:20,1738658712,9/15/2015 10:36:00,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND factor VIII,61-65-89-96,61-65-124-131-76,von Willebrand disease FACTOR VIII,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 10:56:42,1738663757,9/15/2015 10:56:25,false,neodev,1,33758777,USA,,,38.95.108.251,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,VON WILLEBRAND,61-65,124-131,FACTOR VIII,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 10:58:56,1738664201,9/15/2015 10:57:54,false,points4rewards,1,28703583,USA,,,184.53.32.113,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,severe homozygous VON WILLEBRAND disease with factor VIII coagulant activity,43-50-61-65-76-84-89-96-101-111,124-131-136-151-140,FACTOR VIII von Willebrand antigen,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 11:03:56,1738665300,9/15/2015 11:03:33,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,severe homozygous VON WILLEBRAND disease with factor VIII coagulant activity and factor VIII von,43-50-61-65-76-84-89-96-101-111-124-131-136-120,65-76-84-89-96-101-111-120-124-131-136-140-151,Willebrand disease with factor VIII coagulant activity and FACTOR VIII von Willebrand antigen,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 11:04:09,1738665347,9/15/2015 11:03:48,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,with severe homozygous VON WILLEBRAND disease with factor VIII,38-43-50-61-65-76-84-89-96,101-111-120-124-131-136-140-151-159-214,coagulant activity and FACTOR VIII von Willebrand antigen concentrations patients,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 11:04:28,1738665416,9/15/2015 11:03:44,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,severe homozygous VON WILLEBRAND disease,43-50-61-65-76,124-131-136-140-151,FACTOR VIII von Willebrand antigen,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 11:05:13,1738665621,9/15/2015 11:04:45,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,homozygous VON WILLEBRAND disease,50-61-65-76,124-131-136-140-151-159-176-184,FACTOR VIII von Willebrand antigen concentrations 111 116,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659521,9/15/2015 11:20:11,1738671159,9/15/2015 11:19:38,false,elite,1,31883685,GBR,,,79.66.254.237,61,124,,,75,135,VON WILLEBRAND,FACTOR VIII,homozygous VON WILLEBRAND disease,50-61-65-76,124-131-136-140-151,FACTOR VIII von Willebrand antigen,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",61 65,124 131,61,124,75,135,-1,RO-may_treat,820017,"100 ,   111 ,   114 ,   116  Patients with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII/von Willebrand antigen concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen",von Willebrand,factor VIII
788659522,9/15/2015 09:19:46,1738638130,9/15/2015 09:19:31,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,91,58,,,97,66,CARIES,FLUORIDE,CARIES,91,53-58-67,high FLUORIDE areas,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 09:36:22,1738642578,9/15/2015 09:35:41,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,91,58,,,97,66,CARIES,FLUORIDE,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",0-6-11-20-23-31-35-43-50-53-58-67-73-82-86-91-98-103-107-111-116-121-127-131,0-6-11-20-23-31-35-43-50-53-58-67-73-82-86-91-98-103-107-111-116-121-127-131,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.","Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 09:39:12,1738643605,9/15/2015 09:38:55,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,91,58,,,97,66,CARIES,FLUORIDE,CARIES free,91-98,53-58-67-73,"high FLUORIDE areas (Gadag),","Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 09:52:22,1738647218,9/15/2015 09:51:51,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,91,58,,,97,66,CARIES,FLUORIDE,CARIES mean,91-111,58,FLUORIDE,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 10:01:17,1738649491,9/15/2015 10:01:04,false,neodev,1,20306047,GBR,,,80.41.0.252,91,58,,,97,66,CARIES,FLUORIDE,CARIES,91,58,FLUORIDE,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 10:05:35,1738650742,9/15/2015 10:05:16,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,91,58,,,97,66,CARIES,FLUORIDE,CARIES,91,58-67,FLUORIDE areas,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 10:22:08,1738655274,9/15/2015 10:20:56,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,91,58,,,97,66,CARIES,FLUORIDE,CARIES free the,91-98-107,50-53-58-67,in high FLUORIDE areas,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 10:23:47,1738655718,9/15/2015 10:23:32,false,neodev,1,20961587,NLD,5,Maastricht,84.26.48.136,91,58,,,97,66,CARIES,FLUORIDE,fluoride CARIES,58-91,58-91,FLUORIDE caries,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 10:29:11,1738657027,9/15/2015 10:28:53,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,91,58,,,97,66,CARIES,FLUORIDE,CARIES free,91-98,58,FLUORIDE,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659522,9/15/2015 10:31:44,1738657588,9/15/2015 10:31:26,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,91,58,,,97,66,CARIES,FLUORIDE,fluoride CARIES,91-58,58-91,FLUORIDE caries,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39.",91,58,91,58,97,66,-1,RO-may_prevent,820243,"Among 3618 children of similar age groups, living in high fluoride areas (Gadag), 84% were caries free and the mean DMFT value was 0.39",caries,fluoride
788659523,9/15/2015 14:06:28,1738728387,9/15/2015 14:06:16,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,138-146,VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 14:18:45,1738731721,9/15/2015 14:18:29,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,138-146,VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 14:41:11,1738737947,9/15/2015 14:40:04,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,138-146,VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 14:46:44,1738739698,9/15/2015 14:46:29,false,coinworker,1,20231698,USA,OR,,172.56.33.130,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,127-135-138-146,deficit of VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 14:56:59,1738742452,9/15/2015 14:56:31,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,138-146,VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 14:59:15,1738743228,9/15/2015 14:59:03,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,138-146,VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 15:18:19,1738751412,9/15/2015 15:18:09,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,138-146,VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 15:25:39,1738754096,9/15/2015 15:24:59,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,127-135-138-146-123,the deficit of VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 15:28:27,1738754885,9/15/2015 15:27:46,false,clixsense,1,32053717,GBR,,,51.174.76.80,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM and the cause deficit vitamin,87-106-110-114-127-138,41-87-123-127-135-138-146-52,absence hypocalcemia hypoparathyroidism the deficit of VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659523,9/15/2015 15:38:17,1738757883,9/15/2015 15:37:59,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,87,138,,,105,147,HYPOPARATHYROIDISM,VITAMIN D,HYPOPARATHYROIDISM,87,135-138-146-127,deficit of VITAMIN D.,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D.,87,138 146,87,138,105,147,-1,RO-may_treat,820123,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with hypoparathyroidism and the cause of the deficit of vitamin D,hypoparathyroidism,vitamin D
788659524,9/15/2015 12:37:05,1738702306,9/15/2015 12:36:25,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,BALF from nonsmoking ASTHMATIC,69-74-79-90,162-164-168-179-194-196-202,x 100 micrograms BECLOMETHASONE 4 times day,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 13:46:45,1738723671,9/15/2015 13:46:10,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,LC 1 concentration in BALF from nonsmoking ASTHMATIC patients,47-50-52-66-74-79-90-100-69,136-151-159-162-164-168-179-194-196-202-206-210-214,glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times day for 2.5 yr;,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:02:19,1738727269,9/15/2015 14:01:59,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,ASTHMATIC,90,179,BECLOMETHASONE,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:12:06,1738729746,9/15/2015 14:11:12,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,ASTHMATIC patients,90-100,136-151-162-164-168-179-194-196-202-159,glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times day,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:14:36,1738730506,9/15/2015 14:14:17,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,ASTHMATIC patients,90-100,179,BECLOMETHASONE,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:19:04,1738731780,9/15/2015 14:17:50,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,BALF from nonsmoking ASTHMATIC,69-74-79-90,162-164-168-179-194-196-202-159,(2 x 100 micrograms BECLOMETHASONE 4 times day,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:36:25,1738736631,9/15/2015 14:36:14,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,ASTHMATIC,90,179,BECLOMETHASONE,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:39:28,1738737422,9/15/2015 14:39:14,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,BALF from nonsmoking ASTHMATIC patients who were,69-74-79-90-100-109-113,179,BECLOMETHASONE,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:40:00,1738737534,9/15/2015 14:39:06,false,elite,1,30782237,GBR,H9,London,164.143.240.34,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,BALF from nonsmoking ASTHMATIC patients who were,69-74-79-90-100-109-113,162-164-168-179-194-196-202,x 100 micrograms BECLOMETHASONE 4 times day,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659524,9/15/2015 14:40:48,1738737754,9/15/2015 14:39:43,false,coinworker,1,20231698,USA,OR,,172.56.33.130,90,179,,,99,193,ASTHMATIC,BECLOMETHASONE,BALF from nonsmoking ASTHMATIC,69-74-90-79,179,BECLOMETHASONE,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",90,179,90,179,99,193,-1,RO-may_prevent,820227,"We found no significant difference between the LC-1 concentration in BALF from nonsmoking asthmatic patients who were receiving inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr; median 186 ng LC-1/mg albumin; n = 6) and those who were not (median 126 ng LC-1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage",asthmatic,beclomethasone
788659525,9/15/2015 10:35:34,1738658518,9/15/2015 10:35:12,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,46,0,,,49,9,HAV,HEPATITIS,(HAV),45,0-10-13,HEPATITIS A TRANSMISSION,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 10:58:29,1738664048,9/15/2015 10:58:12,false,neodev,1,33758777,USA,,,38.95.108.251,46,0,,,49,9,HAV,HEPATITIS,(HAV),45,0,HEPATITIS,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:05:42,1738665703,9/15/2015 11:05:24,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,46,0,,,49,9,HAV,HEPATITIS,"A virus (HAV) is a small, stranded RNA virus the Picornoviridae",37-39-45-51-54-56-72-81-85-94-99,0-10-13-27-37-45-54-56-39,"HEPATITIS A TRANSMISSION Hepatitis A virus (HAV) a small,","Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:06:05,1738665781,9/15/2015 11:05:47,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,46,0,,,49,9,HAV,HEPATITIS,Hepatitis A TRANSMISSION Hepatitis A virus (HAV),0-10-13-27-37-39-45,0-10-13-27,HEPATITIS A TRANSMISSION Hepatitis,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:06:54,1738665970,9/15/2015 11:06:33,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,46,0,,,49,9,HAV,HEPATITIS,Hepatitis A virus (HAV),27-37-39-45,0-10-13,HEPATITIS A TRANSMISSION,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:11:19,1738667060,9/15/2015 11:09:16,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,46,0,,,49,9,HAV,HEPATITIS,Hepatitis A virus (HAV),27-37-39-45,0-10-13,HEPATITIS A TRANSMISSION,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:21:56,1738672183,9/15/2015 11:21:34,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,46,0,,,49,9,HAV,HEPATITIS,(HAV),45,0-10,HEPATITIS A,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:23:33,1738673168,9/15/2015 11:23:05,false,elite,1,31883685,GBR,,,79.66.254.237,46,0,,,49,9,HAV,HEPATITIS,(HAV),45,0-10,HEPATITIS A,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:40:56,1738681549,9/15/2015 11:40:49,false,elite,1,33798502,USA,VA,Manassas,207.244.86.193,46,0,,,49,9,HAV,HEPATITIS,A virus (HAV) is a,37-39-45-51-54,0-10-13-27-45,HEPATITIS A TRANSMISSION Hepatitis (HAV),"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659525,9/15/2015 11:44:46,1738683319,9/15/2015 11:44:20,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,46,0,,,49,9,HAV,HEPATITIS,Hepatitis A virus (HAV),27-37-39-45,0-10,HEPATITIS A,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water.",,0,46,0,49,9,-1,RO-may_prevent,820234,"Hepatitis A  TRANSMISSION  Hepatitis A virus (HAV) is a small, positive-stranded RNA virus in the  Picornoviridae  family that is usually spread by the fecal-oral route, either person-to-person or by ingestion of contaminated food or water",HAV,Hepatitis
788659526,9/15/2015 12:37:27,1738702464,9/15/2015 12:37:06,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,18,72,,,25,83,MALARIA,CHLOROQUINE,A community based MALARIA control programme,0-2-12-18-26-34,47-57-63-72-84-94-98,"Saradidi, Kenya provided CHLOROQUINE treatment for malaria","A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 13:52:55,1738725056,9/15/2015 13:52:43,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,18,72,,,25,83,MALARIA,CHLOROQUINE,A community based MALARIA control programme,0-2-12-18-26-34,72-84-94-98,CHLOROQUINE treatment for malaria,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:02:35,1738727412,9/15/2015 14:02:20,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,18,72,,,25,83,MALARIA,CHLOROQUINE,MALARIA,18,72,CHLOROQUINE,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:12:46,1738729902,9/15/2015 14:12:06,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,18,72,,,25,83,MALARIA,CHLOROQUINE,MALARIA,18,72-84-94-98,CHLOROQUINE treatment for malaria,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:14:55,1738730571,9/15/2015 14:14:37,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,18,72,,,25,83,MALARIA,CHLOROQUINE,MALARIA,18,72,CHLOROQUINE,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:21:49,1738732822,9/15/2015 14:19:07,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,18,72,,,25,83,MALARIA,CHLOROQUINE,MALARIA control programme,18-26-34,72-84-94-98,CHLOROQUINE treatment for malaria,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:36:37,1738736669,9/15/2015 14:36:26,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,18,72,,,25,83,MALARIA,CHLOROQUINE,MALARIA control programme,18-26-34,72-84,CHLOROQUINE treatment,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:39:35,1738737453,9/15/2015 14:39:28,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,18,72,,,25,83,MALARIA,CHLOROQUINE,A community based MALARIA control programme in,0-2-12-18-26-34-44,47-57-63-72-84-94-98,"Saradidi, Kenya provided CHLOROQUINE treatment for malaria","A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:40:50,1738737773,9/15/2015 14:40:00,false,elite,1,30782237,GBR,H9,London,164.143.240.34,18,72,,,25,83,MALARIA,CHLOROQUINE,A community based MALARIA control programme in,0-2-12-18-26-34-44,47-57-63-72-84-94-98,"Saradidi, Kenya provided CHLOROQUINE treatment for malaria","A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659526,9/15/2015 14:41:44,1738738114,9/15/2015 14:41:23,false,coinworker,1,20231698,USA,OR,,172.56.33.130,18,72,,,25,83,MALARIA,CHLOROQUINE,MALARIA,18,72-84,CHLOROQUINE treatment,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982.",18,72,18,72,25,83,-1,RO-may_prevent,820229,"A community-based malaria control programme in Saradidi, Kenya provided chloroquine treatment for malaria in each village beginning in May 1982",malaria,chloroquine
788659527,9/15/2015 14:05:52,1738728221,9/15/2015 14:05:34,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,GASTRIC ULCER,323-331,274,MISOPROSTOL,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 14:18:10,1738731590,9/15/2015 14:17:54,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,GASTRIC ULCER,323-331,274,MISOPROSTOL,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 14:37:51,1738736993,9/15/2015 14:36:17,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,duodenal ulcer and GASTRIC ULCER,304-313-319-323-331,274-286-290,MISOPROSTOL and cimetidine,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 14:46:09,1738739486,9/15/2015 14:45:49,false,coinworker,1,20231698,USA,OR,,172.56.33.130,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,duodenal ulcer and GASTRIC ULCER,304-313-319-323-331,274-286-290,MISOPROSTOL and cimetidine,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 14:56:10,1738742190,9/15/2015 14:55:56,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,GASTRIC ULCER,323-331,274,MISOPROSTOL,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 14:58:38,1738743055,9/15/2015 14:58:21,false,prodege,1,13300986,CAN,AB,Edmonton,68.150.40.134,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,GASTRIC ULCER,323-331,274,MISOPROSTOL,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 15:17:50,1738751164,9/15/2015 15:17:34,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,GASTRIC ULCER,323-331,274,MISOPROSTOL,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 15:24:33,1738753764,9/15/2015 15:24:10,false,prodege,1,31508822,CAN,AB,Calgary,136.159.160.253,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,GASTRIC ULCER,323-331,274,MISOPROSTOL,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 15:27:17,1738754584,9/15/2015 15:26:35,false,clixsense,1,32053717,GBR,,,51.174.76.80,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,misoprostol cimetidine GASTRIC ULCER,274-290-323-331,261-265-271-274-286-290-323,two doses of MISOPROSTOL and cimetidine gastric,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659527,9/15/2015 15:37:21,1738757568,9/15/2015 15:36:35,false,prodege,1,29350031,USA,SC,Columbia,74.243.223.246,323,274,,,336,285,GASTRIC ULCER,MISOPROSTOL,GASTRIC ULCER,323-331,274,MISOPROSTOL,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies.",323 331,274,323,274,336,285,-1,RO-may_prevent,820382,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double-blind placebo-controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double-blind comparisons of two doses of misoprostol and cimetidine in duodenal ulcer and gastric ulcer studies",gastric ulcer,misoprostol
788659528,9/15/2015 09:13:24,1738637131,9/15/2015 09:13:05,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,218,ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:14:30,1738637336,9/15/2015 09:14:01,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,218-249-256-267-228,ACYCLOVIR on zoster associated pain.,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:16:22,1738637658,9/15/2015 09:14:56,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster associated pain.",0-5-14-17-22-29-36-48-56-67-74-77-82-92-97-100-105-111-118-122-126-136-139-146-153-157-167-170-178-189-201-204-208-215-218-228-231-235-246-249-256-267,0-5-14-17-22-29-36-48-56-67-74-77-82-92-97-100-105-111-118-122-126-136-139-146-153-157-167-170-178-189-201-204-208-215-218-228-231-235-246-249-256-267,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.","Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:16:50,1738637746,9/15/2015 09:16:42,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,the treatment of HERPES ZOSTER was conducted to,122-126-136-139-146-153-157-167,218,ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:22:08,1738638631,9/15/2015 09:21:50,false,neodev,1,20306047,GBR,,,80.41.0.252,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,218,ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:33:17,1738641474,9/15/2015 09:33:02,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,218,ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:41:11,1738644174,9/15/2015 09:40:24,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,215-218,of ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:51:22,1738646990,9/15/2015 09:51:03,false,neodev,1,33758777,USA,,,38.95.108.251,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,218,ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:59:07,1738648906,9/15/2015 09:58:02,false,gifthunterclub,1,24043308,GBR,,,94.102.147.250,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,218,ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
788659528,9/15/2015 09:59:52,1738649120,9/15/2015 09:59:38,false,treasuretrooper,1,17956656,AUS,2,Jannali,14.200.59.55,139,218,,,152,227,HERPES ZOSTER,ACYCLOVIR,HERPES ZOSTER,139-146,218,ACYCLOVIR,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain.",139 146,218,139,218,152,227,-1,RO-may_prevent,820232,"Meta-analysis of four double-blind, randomized, placebo-controlled trials of oral acyclovir (800 mg five times daily) for the treatment of herpes zoster was conducted to provide definitive assessments of the effect of acyclovir on the resolution of zoster-associated pain",herpes zoster,acyclovir
